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General Introduction
Normal and malignant hematopoiesis
All blood cells originate from hematopoietic stem cells (1). Proliferation and differentiation lead to a 
diversity of cells with different morphology and function. When somewhere in the hematopoietic 
development an oncogenic mutation occurs this may lead to leukemia, malignant lymphoma or 
multiple myeloma. Leukemia is characterized by an aberrant production of abnormal blood cells. 
These leukemic cells spread into the human body, mainly the spleen, lymph nodes and other well 
vascularized regions. This may lead to lymphadenopathy, splenomegaly, hepatomegaly and 
chloromas. The enormous expansion of the malfunctioning leukemic cells displaces the normal cells 
which leads to immune system failure, infections, anemia and bleeding.
Chronic Myeloid Leukemia
The annual incidence of chronic myeloid leukemia (CML) is about 1.5 per 100.000 persons in most 
western countries. CML accounts for 15 percent of all cases of leukemia. The disease is characterised 
by several phases. The predominant feature of the chronic phase is hyperplasia of myeloid cells (2, 
3). These cells maintain the capacity to differentiate. This phase of the disease can be controlled 
easily. In the accelerated phase the abnormal cells gradually lose the ability of terminal differentiation. 
Eventually, about four years after diagnosis, the disease transforms into blast crisis in which the cells 
remain in the blast stage, accumulate rapidly and are resistant to chemotherapy (3-5). Current 
therapies of the disease are treatment with hydroxyurea or interferon alpha (6) and bone marrow 
transplantation (7). Most patients, however, do not have a suitable donor. In these cases an 
autologous bone marrow transplantation may be considered (8). For this treatment the leukemic cells 
have to be removed from the blood or bone marrow of the patient. Antisense oligonucleotides may be 
used for purging of the bone marrow (9-11). This thesis describes the nature and rationale for the use 
of these compounds.
ThePhiladelphiatranslocation
In over 95 % of patients with CML a characteristic chromosome is found. The so called Philadelphia 
(Ph) chromosome, results from a reciprocal translocation between chromosome 9 and 22 (12, 13). 
The genes that are involved are the c-abl gene on chromosome 9 and the bcr gene on chromosome 22
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(Figure 1). The translocation occurs in introns. In c-abl this is within a 200 KB intron between exon 
1b and 1a of the c-abl gene. In the bcr gene the breakpoints are clustered in a breakpoint cluster 
region (confusingly called bcr or M-bcr) of 5.8 KB. Breaks occur mainly between exon two and 
three or exon three and four. As a result of the translocation the bcr and c-abl genes are coupled. 
Because the breakpoints are located in introns, the same Bcr-Abl mRNA's are formed after splicing. 
Depending on the place of the breakpoint they are called a b2a2 or a b3a2 type of mRNA. In most 
patients only one type is found, but due to alternative splicing the b3a2 type is sometimes spliced to a 
b2a2 type resulting in the presence of both types of mRNA's. The reciprocal translocation can also 
occur and Abl-Bcr mRNA fusions have been detected (14). These however are not always expressed 
and their role in oncogenesis is doubtful.
In acute lymphoblastic leukemia (ALL) another type of the bcr-abl oncogene is found where the 
break occurs after exon 1 of the bcr gene. This type of mRNA is called the e1a2 type.
The Bcr-Abl mRNA is transcribed into an oncogenic fusion protein, the BCR-ABL protein. It has a 
size of 210 kDa and it possesses an enhanced tyrosine kinase activity (15-17). This enhanced tyrosine 
kinase activity is caused by activation of the normally inhibited tyrosine kinase activity of the c-abl 
proto-oncogene.
5  bcr (5.8 kb)
9
Figure 1: The Philadelphia translocation results from a reciprocal translocation of chromosome 9 and 22
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Figure 2: Two possible Bcr-Abl mRNA's can occur after splicing of the bcr-abl fusion gene found in patients with 
chronic myeloid leukemia.
c-ABL
The ABL protein has a size of 145 kDa. Alternative splicing of the first exon occurs. This leads to 
formation of two ABL proteins: Type Ia and type Ib (18) that are expressed in all tissues and cell lines 
tested (19). The exact differences in function of the two proteins is not known. The ABL proto­
oncogene is a non-receptor tyrosine kinase (20). It has several domains that are characteristic to 
tyrosine kinases. These domains are homologous to the c-src tyrosine kinase and are called src 
homology (SH) domains. The most important homology domain is the tyrosine kinase or SH1 
domain. The ABL also has a SH2 and a SH3 domain, that regulate the activity of the tyrosine kinase 
domain. Besides the src homology domains the ABL has a variable N-terminal domain (due to 
alternative splicing), a domain that has the ability to bind DNA (21) and a region that binds to actin 
fibres (22). The location and activity of the ABL is very complex and regulated by serine/threonine 
phosphorylation (23). The nuclear DNA binding capacity and the actin and cell membrane binding are 
combined into one protein that is able to switch between cytoplasm and nucleus. It has a function in 
regulation of transcription (24), of the cell cycle (23) and of signal transduction from cytoskelet to the 
nucleus (22). ABL is essential during the development since Abl null mutant mice are runted and die 
within 2 weeks after birth (25, 26).
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Figure 3: Functional domains within the BCR and ABL proteins
BCR
The BCR encodes a 160 kDa cytoplasmatic protein. The N terminal part of the protein contains a 
serine/threonine kinase (27) and an oligomerisation domain (28). A domain of homology to the Dbl 
proto-oncogene (29) and to pleckstrin (30) are located in the central part of the protein. The C- 
terminal part of the protein contains a GTPase activating protein (GAP) (31) activity domain that 
suggests a role in signal transduction.
Coupling o f BCR to ABL
The tyrosine kinase of the ABL protein is normally inhibited (22, 28, 32). The SH3 domain of the 
Abl is essential for this inactivation. Two possible mechanisms are proposed for this inactivation 
(Figure 4) (32). The first explanation is that a trans acting protein binds to the SH3 domain and can 
inhibit the tyrosine kinase activity and the second hypothesis is that a cis acting protein binds and 
inhibits the activity. The DNA binding element could be this cis acting element.
C-ABL
SH2 Tyr kinase ■NTS.-; ES
C-ABL I sH3 SH i Tyr kinase
|
G?fa ¡ dnA ■:NTSi
Figure 4: inactivation of the ABL protein tyrosine kinase
Activation of the ABL tyrosine kinase is induced by N-terminal fusion to another gene. The first 
fusions of the c-abl gene that were discovered were fusions to the gag protein of retroviruses. In the
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mouse virus A-MuLV this fusion causes a deletion of the SH3 domain and in the cat virus (HZ2) 
FeSV the c-terminal part (33, 34). Recently a gene called TEL was discovered that fuses to the c-abl 
gene in the t(9;12). This fusion causes activation of the ABL kinase (35).
The bcr-abl translocation results in activation of the ABL proto-oncogene. A model for activation of 
the ABL (22, 28) is presented in figure 5. The BCR part of the protein can form tetramers. This 
tetramer formation causes an intermolecular crossphosphorylation and it enhances the binding to F- 
actin. This F-actin binding is essential for the transforming capacity of the BCR-ABL (22).
BCR-ABL
tetramerization enhanced actin binding
cross phosphorylation
Figure 5: activation of the ABL protein tyrosine kinase.
BCR-ABL can transform Rat-1 and myeloid and lymphoid cells in vitro (36-38) and can cause 
leukemia in transgenic mice (39). BCR-ABL can make cells growth factor independent (38) or reduce 
the sensitivity to apoptosis (40-43). BCR-ABL can also affect the functions of adhesion molecules 
(44). It has been hypothized that CML cells, because of altered function of adhesion molecules, may 
migrate to alternative sites in the human body. Normally these cells would die, but due to the 
inhibition of apoptosis (40) by the bcr-abl oncogene product CML cells would be able to survive 
causing chronic myeloid leukemia.
Antisense oligonucleotides.
In 1978 Zamencik and Stephenson (45) first described the use of antisense molecules. This has 
resulted in a technology by which theoretically rational drug design has become possible. The 
antisense strategy uses the interaction of oligonucleotides that are complementary to (sense) mRNA or 
pre-mRNA to inhibit translation into protein. Theoretically oligonucleotides should be highly specific 
drugs because they use the sequence specific nature of the double helix formation.
Oligonucleotides are chemically synthesised, purified and desalted and finally added to the cells. They 
are internalised by the cells and finally can bind to the mRNA and may inhibit the protein formation. 
The inhibition is thought to occur by a blockade of ribosome reading and by a cytoplasmatic enzyme
12
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RNaseH. This enzyme can degrade the mRNA part of a DNA/RNA hybrid (figure 3). When the 
oligonucleotides are targeted to a splicing site on the pre-mRNA these can also inhibit splicing.
Bcr-Abl
RNase H cleavage
Figure 6: mechanism of antisense oligonucleotide mediated inhibition of protein expression
Efficacy of antisense oligonucleotides is limited by a number of factors. One of the most important 
factors is the stability in serum. Oligonucleotides are degraded in serum as described in Chapter 2 and 
3 of this thesis. To prevent this degradation serum may be omitted in the culture medium or nuclease 
resistant oligonucleotides can be used. Nucleases cleave the phosphodiester bond between the 
nucleotides and modification of this phosphodiester group results in an inhibition of the sensitivity to 
nucleases (46). The most commonly used modifications are the phosphorothioate compounds and the 
methylphosphonate compounds. The phosphorothioate oligonucleotides contain a sulphur atom 
instead of an oxygen and the methylphosphonates have a methyl group (Figure 7). These compounds 
are stable in serum but also have some disadvantages. Phosphorothioates can bind to proteins, have 
lower affinity for the target and have a reduced RNaseH triggering capacity (47). 
Methylphosphonates are insoluble and do not trigger RNaseH at all (48). After synthesis, both 
phosphorothioate and methylphosphonate oligonucleotides represent mixtures of two sterically 
different compounds of which only one is capable of binding to the complement.
Ribosome blockade / \
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Figure 7: Most commonly used modifications of antisense oligonucleotides.
Uptake is an important factor of consideration for the effectiveness of antisense oligonucleotides. 
Charged oligonucleotides bind to a putative receptor and are internalised partly by receptor mediated 
endocytosis and by pinocytosis (49) (chapter 2 and 3 of this thesis). Oligonucleotides are internalised 
very ineffectively and inhibit their own uptake (49, 50). Methylphosphonates can traverse the cell 
membrane because they are not charged (50). Only short methylphosphonates can be used because of 
the insolubility problem. Recently enhancement of uptake with liposomes (51) and streptolysin O 
(52) has been used that largely increases the effectiveness of antisense oligonucleotides.
When the oligonucleotides have entered the cytoplasm of the target cells the binding of the mRNA is 
important. As a result of the secondary structure not all sites on the mRNA are accessible for 
antisense oligonucleotides. Very often the translation start site on the mRNA is used as a target for 
antisense strategy (53) because of the potentially more accessible structure of the ribosome binding 
site. Also, the oligo binding could prevent the binding of the ribosomes. Theoretical models for the 
influence of the target sequence are very difficult to make (53).
The specificity of the oligonucleotides is a factor that influences their practical use. Frequently, in 
antisense experiments control oligonucleotides show similar activities. It is therefore important to test 
several different controls. Most researchers use the sense control, the complementary sequence. Also 
a scrambled control is used (54). A scrambled control the same base composition as the antisense 
oligonucleotide only in a different order. This is important because sometimes the breakdown product 
of the oligonucleotides induce effects. Apart from sequence related effects also the molecular structure
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of the antisense oligonucleotide can induce effects (55). The molecular structure can for instance bind 
protein or induce other unknown effects.
Antisense and Bcr-Abl
In this thesis oligonucleotides targeted to the Bcr-Abl fusion mRNA are used. Antisense 
oligonucleotides targeted to the breakpoint are designed not to bind to the normal Abl and Bcr mRNA 
and can therefore in theory specifically inhibit the expression of the BCR-ABL alone. The fusion 
mRNA's are excellent target controls for each other. A breakpoint specific oligonucleotide is expected 
to inhibit only one of the targeted mRNA's. Therefore one type of fusion mRNA can serve as a 
control for antisense oligonucleotide inhibition of the other type (56, 57).
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SCOPE OF THIS THESIS
The functions of the bcr-abl oncogene have been studied in cell lines and mouse model systems 
(38, 39, 42, 58). Through such experiments, several functions of the BCR-ABL protein could be 
studied. In addition to these studies it would be very useful to study the function of the bcr-abl 
oncogene in primary CML cells derived from patients by inhibiting its expression.
Because of conservation of breakpoints at the RNA level, CML is an excellent model for antisense 
inhibition of expression. Normal cells do not express the Bcr-Abl mRNA enabling a targeting of 
antisense oligonucleotides to this tumour specific marker.
The aim of this thesis was to explore the potentials of antisense oligonucleotides for specifically 
targeting and inhibition of protein translation of the Bcr-Abl mRNA. In this way we wished to study 
the function of the bcr-abl oncogene and to test the potentials of antisense oligonucleotides as 
purging agents in CML.
In chapter two of this thesis we describe how we studied the use of phosphorothioate antisense 
BCR-ABL oligonucleotides in cell lines. Stability, uptake, effect on Bcr-Abl mRNA and on the 
growth of CML and non CML cell lines is studied. Chapter 3 describes the specificity of 
phosphorothioate and phosphorothioate capped BCR-ABL oligonucleotides. By studying the BCR- 
ABL protein the mechanism of growth inhibition by antisense BCR-ABL oligonucleotides is 
evaluated. Determination of the specificity of oligonucleotides has been shown to be difficult and 
several types of controls are needed. Because of the importance of specificity, chapter 4 is a 
comment to an article dealing about specificity of BCR-ABL methylphosphonate oligonucleotides. 
Chapter 5 describes the use of capped BCR-ABL methylphosphonates. Their effect on BCR-ABL 
expressing cell lines and patient cells is studied as well as their effect on the BCR-ABL protein. 
Because of the non sequence specific effects of antisense oligonucleotides that were associated 
especially with the use of phosphorothioate and phosphodiester oligonucleotides we have tried to 
determine sequences in oligonucleotides that can be linked in some way to their activity. This is done 
by statistical computer analysis as described in chapter 6. Finally chapter 7 is a review, that links our 
findings on the mechanism of action of the BCR-ABL oligonucleotides to what others have 
discovered about this subject.
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ABSTRACT
BCR-ABL antisense oligonucleotides can specifically reduce colony formation of early hematopoietic 
progenitor cells from CML patients. Little is known about the mechanism of this inhibition.
We studied the inhibition of the bcr-abl oncogene using fluorescein labelled phosphorothioate 
oligonucleotides in the Philadelphia chromosome positive cell line BV173. Oligonucleotide stability, 
uptake, Bcr-Abl mRNA degradation, inhibition of cell proliferation and cell death were studied. The 
oligonucleotide uptake was directly dependent on the extracellular concentration and was constant 
over the first 18 hours of incubation. After that the uptake rate decreased. We detected a decrease in 
Bcr-Abl mRNA after 3 days of treatment with antisense oligonucleotides but much less in controls. 
The controls used in the experiments were the sense oligonucleotide, equimolar amounts of sense and 
antisense and an untreated control. Antisense oligonucleotides completely inhibited cell growth of 
BV173 cells and did not inhibit growth of HL-60 cells, whereas control oligonucleotides had no such 
effect on either cell line. An oligonucleotide specific for the other CML breakpoint was also effective 
in reducing cell growth of BV173. By the use of a DNA double staining technique to discriminate 
between necrotic and apoptotic cells we detected a large number of apoptotic cells in antisense treated 
BV173 cultures after 5 days of treatment as compared to controls. We conclude that antisense BCR- 
ABL oligonucleotides reduce Bcr-Abl mRNA expression in BV173 cells mainly in a sequence 
specific manner and induce apoptosis.
INTRODUCTION
Chronic myeloid leukemia (CML) is a myeloproliferative disorder originating from a transformed 
hematopoietic stem cell and resulting in an accumulation of myeloid cells and their progenitors (1, 2). 
CML usually progresses from a chronic disease to accelerated phase and blast crisis (2-4). In over 90
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% of CML patients the Philadelphia (Ph') chromosome is found. This chromosome is the result of a 
reciprocal translocation t(9;22) between the long arms of chromosomes 9 and 22 (5, 6). The c-abl 
proto-oncogene located on chromosome 9 is translocated to the breakpoint cluster region (bcr), 
located in the BCR gene on chromosome 22. The bcr-abl fusion gene encodes a 210 kD protein with 
enhanced tyrosine kinase activity (7-9). This translocation is the first or at least an early event in the 
oncogenesis of CML(10). Most of the breakpoints are located in a region that spans 5.8 kb in the bcr 
and over 200 kb in the c-abl gene (11). One of two possible Bcr-Abl mRNAs are transcribed from 
the fusion gene. In Bcr-Abl mRNA molecules exon b2 of the bcr is spliced to c-abl exon 2 (b2a2 
breakpoint) or exon b3 is coupled to the c-abl exon 2 (b3a2 breakpoint).
Against these mRNA breakpoints antisense oligonucleotides can be designed. Antisense 
oligonucleotides are short (15-30 nt) synthetic DNA molecules. They are actively internalised by cells 
and hybridise to their complementary mRNA. RNase H recognises hybrids of DNA and mRNA and 
cleaves the mRNA portion. Also ribosome blockage caused by RNA-oligo complexes reduces the 
expression of the gene. Antisense oligonucleotides have been found useful in reducing the expression 
of a large number of genes in a wide variety of cells (12, 13). Incubation of cells with antisense 
oligonucleotides complementary to the CML breakpoints on the mRNA reduced the clonogenic 
capacity of hematopoietic progenitors from the bone marrow of CML patients (14, 15), cells from 
healthy individuals however retained their clonogenic capacity. It might be possible to purge bone 
marrow from CML patients for autologous bone marrow transplantation with antisense 
oligonucleotides (13, 15, 16). Clinical trials are already planned (16).
To get insight in the mechanism of action and the cytotoxic effect of BCR-ABL antisense 
oligonucleotides on CML cells we studied the oligonucleotide uptake, mRNA degradation, inhibition 
of cell growth, and mechanism of cell death in the cell line BV173 in detail. This cell line has an 
undifferentiated morphology and contains the Philadelphia chromosome with a b2a2 type breakpoint 
(17). It is derived from patient with CML in lymphoid transformation.
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MATERIALS AND METHODS.
Cell lines
Human leukemic cell lines BV173 (CML lymphoid) (17), K562 (CML erythroblastic) (18) and HL- 
60 (promyelocytic) were cultured in RPMI 1640 medium (Flow Laboratories, Irvine, Scotland) 
supplemented with 10% heat inactivated (56°C, 30 min) Fetal Calf Serum (Hyclone), 2 mM L- 
glutamine , 50 IU/ml penicillin and 50 mg/ml streptomycin (Cellect®,ICN Flow) in a humidified 
incubator at 37°C with 5% CO2  in air.
Oligodeoxynucleotides
Oligodeoxynucleotides were synthesised on an Applied Biosystems DNA synthesiser model 391 
EP according to the manufacturers instructions. After deprotection in 25% ammonium hydroxide 
solution (Applied Biosystems) 8 hr at 55°C, oligonucleotides were purified by two ethanol 
precipitations and dissolved in diethylenepyrocarbonate (DEPC, Sigma) treated destilled water. 
Sequences of the oligonucleotides used are summarised in table 1.
Name Sequence (5'®3') T ■ *Location Gene Exon PCR template Fragment length
Bcr-abl breakpoint fragment cloning
aA21Bam AGAGGATCCTCACTGGGTCCAGCGAGAA 306-326 abl 3 K562 mRNA 348
B11Sal TCAGTCGACCTATGAGCGTGCAGAGTGGAGGG 3149-3171 bcr b2
Synthetic RNA template synthesis
aA21 TCACTGGGTCCAGCGAGAAGG 306-326 abl 3 pB3A2.3J 393
NM13-5 CAGCTATGACCATGATTACGCCAAG 797-821 BS
Competitive PCR
d(N)6 NNNNNN
BA5 CGGGAGCAGCAGAAGAAGTGT 3180-3200 bcr b2 pB3A2.3J RNA 269
BA3 GGGTCCAGCGAGAAGGTTTT 302-321 abl 3 BV173 mRNA 219
Antisense Oligonucleotides
Phosphodiester
C-aB2A2 GAAGGGCTTCTTCCTTAT 3295-3303 bcr b2
227-235 abl 2
Phosphorothioates
aB2A2.26M CGCTGAAGGGCTTCTTCCTTATTGAT 2391-3303 bcr b2
B2A2.26M ATCAATAAGGAAGAAGCCCTTCAGCG 227-239 abl 2
aB3A2.26M CGCTGAAGGGCTTTTGAACTCTGCTT 3366-3378 bcr b3
B3A2.26M AAGCAGAGTTCAAAAGCCCTTCAGCG 2391-3303 abl 2
* Positions correspond to: abl, human c-Abl mRNA genbank accession nr: X16416; bcr, human BCR mRNA genbank accession 
nr: Y00661; BS Bluescript KS +, genbank accession nr: VB0078
Table 1: Characteristics of oligonucleotides used in PCR and cell treatment.
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Phosphorothioate oligonucleotides
Phosphorothioate oligonucleotides used for treatment of cells were synthesised using tetraethyl 
thiuram disulfide (TETD, Applied Biosystems) as a sulphurisation agent during synthesis. After 
deprotection and ethanol precipitation the oligonucleotides were purified by HPLC on a reverse phase 
column (Aquapore RP-300, 7 mM 250 x 4.6, Applied Biosystems) using a linear gradient of 12-18 % 
acetonitrile over 40 minutes in 0.1 M triethyl ammonium acetate (TEAA, Merck) pH 7.0. They were 
lyophilised, desalted on a Sephadex G-25 column (NAP™-25, Pharmacia), dissolved in Iscoves 
Modified Dubeccos Medium (IMDM), sterilised using a Millex GV-IV 0.22 mM filter and stored at 
-80°C until use.
Breakdown of oligonucleotides
Thirty pmol of oligonucleotides C-aB2A2 and B2A2.26M (table 1) were labelled in a 20 ml volume 
with [g-32P] dATP (370 MBq/ml, 110 TBq/mMol, Amersham) and 20 units T4 polynucleotide 
kinase (Boehringer Mannheim) in 50 mM Tris (pH 7.5), 10 mM MgCl2, 5 mM DTT, 1mM 
spermidine for 1 hr at 37°C followed by enzyme inactivation 95°C, 10 min.
Labelled oligonucleotide (15 pmol) was added to 300 ml of culture medium (RPMI 10 % FCS) 
containing 10 mM of non labelled oligonucleotide. The medium was sterilised using a 0.22 mM filter 
(Millex GV4, Millipore) and incubated in a 100 ml volume in a 96 wells flat-bottomed microplate 
(Costar) in a humidified incubator at 37°C with 5% CO2 in air. At different time points 10 ml of the 
medium was frozen at -20°C. Analysis of oligonucleotide breakdown was done by diluting the 
samples 3 times in loading buffer (20 mM EDTA, 1 mg/ml xylene cyanol, 1 mg/ml bromophenolblue 
in formamide). After denaturation 3 min at 80°C, 3 ml of sample was loaded onto a 0.4 mm 20 % 
polyacrylamide gel containing 7 M ureum in 0.5 x TBE buffer (45 mM Tris, 45 mM boric acid, 1 mM 
EDTA). The gel was exposed to X-ray film (X-Omat S, Kodak) with two intensifying screens for 48 
hours at -80°C.
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Figure 1: Breakdown of 5' - 32P end labelled phosphorothioate B2A2.26M (26 mer, SE) and phosphodiester C- 
aB2A2 (18 mer, AS) after various times of incubation in RPMI 10 % FCS at concentration of 10 mM.
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Fluorescein labelled oligonucleotides
Fluorescein labelling was essentially the same as described by Spiller et al.(19). A 6-aminohexanol 
phosphate linker used for fluorescein attachment was coupled by the use of the phosphoramidite 
Aminolink 2 (Applied Biosystems) in normal synthesis. A fter HPLC purification (5)6- 
Carboxyfluorescein-N-hydroxysuccinimide ester (FLUOS, Boehringer Mannheim) dissolved in 
dimethylformamide (DMF) was added in a 25-fold molar excess to the oligonucleotides in 200 mM 
Na2 CO3 /NaHCO 3  buffer (pH 9.0) for 1 hr at room temperature with shaking. The conjugated 
oligonucleotide was directly desalted and unbound stain was removed on a Sephadex G-25 column 
(NAP-25™, Pharmacia). Purity and coupling efficiency was monitored by HPLC and by 
electrophoresis as described in the section "breakdown of oligonucleotides".
Incubation o f cells with antisense oligonucleotides
BV173 or HL-60 cells were seeded at a density of 1-3 x 105 cells/ml in RPMI 10% FCS with L- 
glutamine and antibiotics in 96 wells flat bottomed culture plates (Costar). HPLC purified and 
desalted oligonucleotides dissolved in IMDM were added to the wells at a final concentration of 1.25­
10 mM. Plates were incubated in a humidified incubator.
Cell cultures, cell counting and morphology.
Cells were seeded in triplicate wells at a concentration of 1 x 105 cells/ml in a 100 ml volume. 
Oligonucleotides were added to the cells up to a concentration of 10 mM. Cultures were placed in a 
humidified incubator at 37°C with 5% CO2 in air. Viable cell number was determined at day 6 after 
addition of oligonucleotides by trypan blue exclusion in a Burker haemocytometer. Cytospin 
preparations were made at day 5 after oligonucleotide addition. For morphological studies 
preparations were stained with May-Grunwald-Giemsa.
Isolations o f RNA from antisense treated cells
BV173 cells were plated in duplicate in a 500 ml volume at a density of 2 x 105 cells/ml in 24 wells 
flat bottom culture dishes (Costar) RPMI 10 % FCS, L-glutamine, penicillin and streptomycin. After 
3 days of incubation a sample of about 10,000 cells was taken from the cultures. Cells were spun
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down in an Eppendorf centrifuge (3000 rpm) and resuspended in 10 ml of the remaining culture 
medium.
RNA extractions were performed using the guanidinium thiocyanate acid phenol chloroform 
procedure (20) with small modifications. Briefly: 100 ml of guanidinium thiocyanate solution 
containing 100 mg/ml yeast tRNA (Boehringer Mannheim) as a carrier was added to the cells. After 
phenol/chloroform extraction and two isopropanol precipitations, two 75% ethanol washes of the 
RNA pellet were applied to obtain RNA free of substances inhibiting reverse transcriptase or Taq 
polymerase. RNA was dissolved in 50 ml of DEPC treated water for 10 min at 65°C and stored at 
-80°C.
Construction of internal standard vector pB3A2.3J
One mg of K562 RNA was reverse transcribed using oligonucleotide aA21Bam. cDNA synthesis 
and amplification were the same as described below in "competitive PCR" except for the use of 
competitor molecules. Amplification of bcr-abl cDNA was performed by addition of oligonucleotide 
B11Sal for 25 cycles. The fragment was digested with Sal I and Bam HI and ligated with T4 DNA 
ligase (New England Biolabs) into Sal I / Bam HI digested Bluescript KS + vector (Stratagene).
The pB3A2.3J vector was created from this vector by deleting a 25 bp fragment out of the bcr-abl 
insert. The deletion was introduced by digesting pB3A2 with Pst I and Hind III. These enzymes both 
cut in the bcr-abl insert. Pst I 3' overhanging end and Bam HI site were respectively removed and 
filled in using Klenow DNA polymerase (Gibco/BRL) as described (21). The blunt ended vector ends 
were ligated.
Synthesis o f internal standard RNA
Bcr-abl insert together with the T3 polymerase promoter sequences were amplified from pB3A2.3J 
to serve as a template for RNA synthesis. A sample of 0.01 mg of pB3A2.3J DNA was amplified in a 
100 ml volume in buffer containing 0.001 % gelatine, 50 mM KCl, 10 mM Tris-HCl (pH 8.4), 1,5 
mM MgCl2 , 12.5 mM of dATP dGTP, dCTP and dGTP , 500 pmol/ml of primers NM13-5 and 
a  A21 and 19 units Taq DNA polymerase. Samples were overlayed with 60 ml of mineral oil. 
Amplification was performed for 30 s at 94°C, 30 s at 58°C, and 90 s at 72°C for 30 cycles.
The PCR product was purified by phenol/chloroform extraction and ethanol precipitation. 20 pmol 
of PCR product served as a template in the RNA polymerase reaction. This reaction was performed in 
a total volume of 100 ml at 37°C in a solution containing 40 mM Tris-HCl (pH 7.5), 6 mM MgCl2, 2 
mM spermidine-HCl, 5 mM NaCl, 10mM DTT, 0.25 mM rATP, rUTP, rCTP, rGTP, 0.1 mg/ml
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BSA (Boehringer Mannheim), 200 units rRNase Inhibitor (Promega) and 400 units T3 RNA 
polymerase (Boehringer Mannheim). Remaining DNA template was digested by addition of 200 units 
RNase free DNaseI (Boehringer Mannheim) at 37°C for 15 min and extracted with 
phenol/chloroform. RNA was precipitated by addition of 0.1 volume of 5 M ammonium acetate (pH 
5.2) and 1.4 volumes of ethanol for 30 min at -20°C. The RNA pellet was dissolved in DEPC treated 
distilled water. Extraction and precipitation were repeated once and RNA was dissolved in 100 ml of 
DEPC treated water for 10 min at 65°C. RNA concentration was determined by measuring the 
absorbance of a diluted aliquot at 260 nm. Quality of the RNA sample was checked on a 6% 
denaturating polyacrylamide gel and staining with ethidium bromide. No degradation was observed. 
The RNA solution was stored at -80°C.
Competitive PCR
cDNA synthesis was performed in a total volume of 20 ml. To 17.5 ml of reverse transcriptase 
master mixture, that contained all reaction substances including the competitor RNA, 2.5 ml of RNA 
sample was added. The final concentrations in the solution were 50 mM Tris-HCl (pH 8.3), 75 mM 
KCl, 3mM M gCl2 , 10 mM DTT, 625mM of dATP, dGTP, dCTP and dGTP (Boehringer 
Mannheim), 2.5 mM of specific primer or 5.0 mM of random hexanucleotides, 2 x 105 molecules/ml 
synthetic pB3A2.3J RNA in the presence of 1000 units/ml rRNase inhibitor (RNasin, Promega) and 
10,000 units /ml of Moloney Murine Leukemia Virus reverse transcriptase (Gibco BRL). The 
reaction was carried out in a DNA thermal cycler 10 min at 20°C, 45 min at 42°C and 10 min at 95°C.
cDNA was amplified by addition of 80 ml of a master-mixture containing 0.001 % gelatine, 50 mM 
KCl, 10 mM Tris-HCl (pH 8.4), 1.5 mM MgCl2, 625 nM of upstream primer and if appropriate 625 
nM of downstream primer in the presence of 19 units/ml Taq DNA polymerase (Gibco BRL) and
1.85 MBq/ml [a - 32P] dCTP (370 MBq/ml, 110 TBq/mmol, Amersham). Samples were overlaid 
with 60ml of mineral oil (Sigma) and amplified in a DNA thermal cycler model (Perkin Elmer Cetus). 
Samples were denaturated for 5 min at 94°C. Amplification was 30 s at 94°C, 30 s at 58°C, and 90 s 
at 72°C for 50 cycles. After amplification a final extension of 10 min at 72°C was applied.
Electrophoresis and analysis o f radioactive PCR fragments.
PCR fragments were diluted 25 times in formamide dye (20 mM NaOH, 1 mg/ml bromophenol 
blue, 1 mg/ml xylene cyanol, 10 mM EDTA (pH 8.0) in formamide). Samples were denaturated for 5 
min at 95°C and snapcooled on ice. A sample of 3 ml was applied onto a denaturating 0.4 mm 6%
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polyacrylamide gel in 0.5 x TBE (45 mM Tris-borate, 1 mM EDTA pH 8.3). X-ray films (X-Omat S, 
Kodak) were exposed for 48 hours at -80°C in a cassette with two intensifying screens.
Bands on autoradiograms were scanned on a laser densitometer (Ultroscan XL, LKB). Band 
intensities were determined using Gelscan XL version 2.1 software. Relative band intensities of PCR 
products of synthetic and Bcr-Abl mRNAs of the calibration samples were plotted on a double 
logarithmic scale versus input RNA amount. Linear regression using this calibration curve was used 
to determine the amount of RNA in the samples with unknown Bcr-Abl mRNA amount from the 
relative band intensity.
Dot blot analysis o f Ribosomal RNA
An RNA sample of 5 ml, being one tenth of the total RNA isolate from 10,000 cells, was 
denaturated in 40 ml of 50 % formamide, 6.5 % formaldehyde, 1 x SSC (150 mM NaCl, 15 mM 
trisodium citrate, pH 7.2) for 15 min at 68°C and snapcooled on ice. After this, 200 ml of 20 x SSC 
was added and samples were loaded onto a Hybond N+ nylon membrane wetted with 10 x SSC in a 
dot blot apparatus (Bio-rad). After rinsing several times with 10 x SSC the membrane was dried and 
RNA was crosslinked to the filter using a UV crosslinker (Bio-rad) with energy of 50 mJ. 
Membranes were prehybridised using 10 ml of 0.1 M NaH2 P0 4 , 0.4 M Na2 HPO4 , 7% SDS, 1mM 
EDTA containing 0.1 mg/ml Herring sperm DNA at 65°C. The 28 S human ribosomal RNA probe (a 
5.2 Kb Eco Rl/Bgl II fragment) was labelled with [a-32P] dCTP using a T7 Quick-prime kit 
(Pharmacia) according the manufacturers instructions. Unincorporated label was removed on a 
Sephadex G-50 column. Incorporated radioactivity was determined by Cerenkov counting in a liquid 
scintillation counter (1214 RackBeta, LKB). To 10 ml of prehybridisation solution 1 x 107 cpm of 
the labelled probe was added at 65°C. After hybridisation (18 hr, 65°C) the membrane was washed in 
40 mM NaH2PO4/Na2HPO4 (pH 7.2), 1 % SDS for 3 times (15 min, 65°C). An X-ray film was 
exposed for 48 hours at -80°C in a cassette in the presence of two intensifying screens.
Flow cytometric analysis o f Oligonucleotide uptake
Cells were seeded in triplicate wells at a density of 2 x 105 cells/ml in a 100 ml volume. After 18 
hours FLUOS labelled oligonucleotides were added to the cells at concentrations ranging from 1.25 - 
10 mM. After various incubation times cells were washed with PBS and green fluorescence of 
FLUOS in the cells was determined using a Coulter Epics Elite (Coulter, Hialeah, FL) flow 
cytometer. The flow cytometer was equipped with a 40 mW argon ion laser running at 15 mW and 
green fluorescence was determined using a 550 nm dichroic mirror and a 525/30 nm band-pass filter.
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The flow cytometer was calibrated using DNA check Epics™ alignment fluorospheres (Epics division 
of Coulter, Hialeah, FL). Known amounts of FLUOS labelled oligonucleotides were bound 
completely to APS hypersyl hyperspheres 5 mm (Shandon Southern Products Ltd, Runcorn, UK). 
These spheres were used to quantify the exact amount of oligonucleotides in the cell according to the 
method of Spiller et al.(19) .
Analysis o f Cellular DNA content
Cellular DNA content was determined using a propidium iodide (PI)/Hoechst 33342 double 
labelling as described by Pollack et al. (22) with small modifications. Briefly: 3 x 105 cells/ml were 
seeded in a 100 ml volume into a 96 wells microtiterplate. Oligonucleotides were added to a final 
concentration of 10 mM to the cells. After 5 days of incubation cells from 3 wells were washed in 
glucose phosphate buffer and the cell pellet was labelled with 100 ml, 20 mg/ml PI at 4°C. Cells were 
fixed with 1.9 ml of 25% ethanol in PBS and stained with 50 ml 0.25 mM Hoechst 33342 on ice.
DNA content was analysed on the Coulter Epics Elite flow cytometer (Coulter, Hialeah, FL) 
equipped with a 40 mW, 488 nm argon ion laser running at 15 mW and in parallel a 5W, 351 nm 
water cooled argon ion laser (model 2020, Spectra Physics, Mountain View, CA, USA) with a power 
output of 100 mW. A high-pass filter of 610 nm for red fluorescence (propidium iodide), a band-pass 
filter of 415 nm for blue fluorescence (Hoechst 33342) and a dichroic mirror of 488 nm were used.
RESULTS
Breakdown o f oligonucleotides in the culture medium.
We tested the stability of the phosphorothioate oligonucleotides aB2A2.26M, B2A2.26M in 
culture medium compared to a normal phosphodiester C-aB2A2 oligonucleotide at a concentration of 
10 mM. The autoradiogram (Figure 1) shows that extensive breakdown of the phosphodiester C- 
aB2A2 occurred and after 3 days almost all oligonucleotide was degraded by exonuclease activity in 
the culture medium. The phosphorothioate oligonucleotide B2A2.26M is relatively stable, 
aB2A2.26M showed the same stability (data not shown). After 8 days in culture medium full length 
oligonucleotide could still be detected. Because of the relative stability of the phosphorothioate 
oligonucleotides a single dose of oligonucleotides for cell incubations over several days was used.
31
Antisense BCR-ABL oligonucleotides in CML.
Uptake o f FLUOS labelled BCR-ABL oligonucleotides in BV173 cells
In order to study the uptake of phosphorothioate BCR-ABL antisense oligonucleotides BV173 cells 
were incubated with FLUOS labelled phosphorothioates FLUOS-aB2A2.26M (antisense) and 
FLUOS-B2A2.26M (sense) oligonucleotides as a control.
A B
Figure 2: Intracellular distribution of FLUOS-aB2A2.26M in BV173 cells after 18 hours of incubation at 10 mM. A. 
FLUOS-aB2A2.26M fluorescence image B. Light microscopic image of A .
Figure 2A shows a picture of the uptake of the oligonucleotides in BV173 cells. Some cells 
showed very high fluorescence. These cells appeared to be dead cells as can be seen from light 
microscopic image (figure 2B) and trypan blue exclusion. FLUOS-antisense fluorescence in living 
cells is visible in intracellular vesicles, most of them located near the cell membrane. The actual 
cytoplasmatic concentration of the oligonucleotides is very low compared to the amount present in 
vesicles. A trace of free FLUOS in the oligonucleotide sample did not account for the green 
fluorescence in cells, because cells incubated with 10mM of free FLUOS showed a hardly visible 
fluorescence (data not shown).
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Figure 3. Oligonucleotide uptake determination by green fluorescence analysis of scatter gated and ungated BV173 
cells after incubation for 18 hours with 10 mM FLUOS-aB2A2.26M by flow cytometry. A: Forward scatter (FS) and 
right angle scatter (RAS) with gate A. B: Linear green fluorescence (GFL LIN) of cells from gate A. C. Green 
fluorescence of all cells and debris. Arrow marks dead cells. D. Green fluorescence of cells in gate A.
Figure 3 shows a flow cytometric analysis of BV173 cells at 18 hours after oligonucleotide 
addition. To exclude dead cells and clumps of cells in our analysis of oligonucleotide uptake a gate 
was placed based on forward and right angle scatter of the cells (figure 3A). All cells show green 
fluorescence indicating oligo uptake (figure 3C). Gated cells show a heterogeneous uptake (figure 3B 
& 3D). Some cells have internalised about 6 times as much oligonucleotide as others. Cells with low
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forward scatter and high right angle scatter (dead cells) have absorbed at least 100 times as much 
oligonucleotide as others (figure 3C, marked with arrow).
Time dependent uptake o f BCR-ABL oligonucleotides.
In order to quantify the uptake of the FLUOS labelled phosphorothioates we used a calibration 
curve of these oligonucleotides bound to APS-hypersil hyperspheres. This way we quantified time 
dependent uptake of FLUOS labelled FLUOS-aB2A2.26M (antisense) and FLUOS-B2A2.26M 
(sense) in BV173 cells.
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Figure 4: Time dependent and concentration dependent oligonucleotide uptake
A: Time dependent uptake of FLUOS labelled oligonucleotides in BV173 cells at 10 u \ I concentration determined by 
flow cytometry. ♦  FLUOS-aB2A2.26M (AS) -*■ FLUOS-B2A2.26M (SE).
B: Uptake of FLUOS labelled oligonucleotides in BV 173 cells at 18 hours after incubation dependent on the extracelluar 
concentration, determined by flow cytometry ♦  FLUOS-aB2A2.26M (AS) FLUOS-B2A2.26M (SE).
Figure 4A shows the results of flow cytometric analysis of time dependent uptake of FLUOS- 
aB2A2.26M and FLUOS-B2A2.26M in BV173 cells. The uptake of the oligonucleotides is linear 
and highest during the first 18 hours of incubation with the cells. Uptake characteristics of sense and 
antisense oligonucleotides were similar. After 18 hours of incubation uptake rates decreased as 
expected for receptor mediated uptake of phosphorothioate oligonucleotides (19, 23, 24).
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Concentration dependent uptake o f BCR-ABL antisense oligonucleotides and controls.
We studied the concentration dependent uptake of the oligonucleotides in the same way as the time 
dependent uptake. We measured the cellular uptake at 18 hours, because at this time the uptake is still 
linear (figure 4B).
Figure 4B shows the intracellular amount of oligonucleotide plotted against the extracellular 
concentration of oligonucleotide added to the medium. The figure shows a linear dependency of both 
the intracellular amount of sense and antisense oligo on the extracellular concentration in ranges up to 
10 mM. This shows that saturation of oligo uptake is not present at 18 hours of incubation and that 
the extracellular concentration directly affects the intracellular uptake.
BCR-ABL mRNA degradation by antisense oligonucleotides.
We investigated Bcr-Abl mRNA breakdown in antisense treated BV173 cells and controls to 
determine the specificity of antisense BCR-ABL oligonucleotides. In order to accurately quantify the 
amount of Bcr-Abl mRNA in the RNA isolates we used a competitive PCR method (25, 26). Cells 
were treated with 10 mM antisense BCR-ABL oligonucleotides. Controls used in the experiment were 
an untreated sample, the sense oligonucleotide and equimolar 10mM amounts of both sense and 
antisense oligonucleotides.
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Figure 5. Bcr-Abl mRNA amount in oligonucleotide treated and untreated BV173 cells after 3 days of incubation at
10 mM. Sample numbers in competitive PCR and Dot blot analysis correspond to each other.
A. Competitive PCR for quantitation of relative Bcr-Abl mRNA amount in total RNA isolated from treated cells. 2 x 
10 4 molecules of synthetic RNA (sRNA, 269 bp) used as an internal standard. Samples 1-8: calibration curve of 2 
fold serial dilutions of BV173 RNA. Samples 9-16: RNA samples from BV173 cells treated with oligonucleotides 
as indicated. "-" = negative control.
B. Dot blot analysis of ribosomal RNA of samples used in competitive PCR. Dot blot was screened with 5' human 28 
S ribosomal probe. Samples 9-16: RNA from BV173 cells treated with oligonucleotides as indicated. "-" = negative 
control. "+" = positive control.
The RNA isolated from antisense oligonucleotide treated cells and controls and serial dilutions of 
BV173 RNA were reverse transcribed into cDNA in the presence of 2 x 104 molecules of internal 
standard RNA. Figure 5A shows the autoradiogram of products from competitive PCR analysis. The 
relative amount of PCR product derived from Bcr-Abl mRNA compared to the PCR product derived 
from the internal standard RNA was used to quantify the Bcr-Abl mRNA in unknown samples. This 
was done by plotting the relative input concentration of Bcr-Abl mRNA in the calibration curve 
against ratios of relative densitometric units of scanned bands of synthetic and bcr-abl PCR products.
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Plotting ratios of band intensities versus input RNA in a double logarithmic way follows a precise 
linear relationship. Using the log-log relationship a band ratio of an unknown sample can be used to 
quantify the amount of Bcr-Abl mRNA in the sample by linear regression. Bcr-Abl mRNA amount 
determined by this competitive PCR was corrected for differences in the amount of total RNA isolated 
by the ribosomal RNA signal from the same samples as determined by dot blotting (Figure 5B).
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Figure 6. Relative Bcr-Abl mRNA amounts in BV173 cells after 3 days of incubation with 10 mM of 
oligonucleotides determined by competitive PCR (figure 5) and corrected for total mRNA by dot-blotting I  Antisense 
aB2A2.26M 5  Sense B2A2.26M 0  Antisense aB2A2.26M + Sense aB2A2.26M E j  Untreated
The Bcr-Abl mRNA amounts in oligonucleotide treated samples relative to untreated samples are 
depicted in figure 6. RNA from sense treated cells showed a 30 ± 16 % decrease in Bcr-Abl mRNA 
amount. In the total RNA from cells treated with a mixture of equimolar amounts of sense + antisense 
oligonucleotides Bcr-Abl mRNA expression was reduced by 12 ± 3 %. The decrease of Bcr-Abl 
mRNA amount in antisense treated cells was remarkably higher 69 ± 13 %.
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Effect o f BCR-ABL antisense oligonucleotides on cell growth of BV173 cells and HL-60 cells.
BV173 cells were seeded at a density of 1 x 105 cells/ml in the presence of 10 mM of 
oligonucleotides. After 6 days of incubation of BV173 cells with oligonucleotides, viable cell number 
was determined.
1
■  AS
0  AS-FLUOS
m se
AS + SE 
□  AS-FLUOS + SE 
n  Untreated
0
Figure 7. Cell number of BV173 cells after 6 days of incubation with non labelled and FLUOS-labelled 
oligonucleotides at 10 x^M concentration. I  Antisense aB2A2.26M FLUOS-Antisense aB2A2.26M 5  Sense 
aB2A2.26M Antisense aB2A2.26M+ Sense B2A2.26M 0  FLUOS-Antisense aB2A2.26M+ Sense B2A2.26M 
0  Untreated
Figure 7 shows a remarkable reduction in cell number of antisense treated cells compared to 
controls. Also sense and a mixture of equimolar amounts of 10 mM sense + antisense oligos caused a 
slight reduction in BV173 cell growth. FLUOS labelled oligonucleotides caused the same effect on 
cell growth of BV173 cells as unlabelled oligonucleotides. Apparently the FLUOS labelling had no 
effect on effectivity of these oligonucleotides.
To further examine non-specific toxicity we incubated both BV173 and HL-60 cells with antisense 
oligonucleotides and controls. Only in BV173 cells the antisense oligonucleotide was effective in
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reducing cell growth measured by cell counting on day 6 of incubation (figure 8). Antisense BCR- 
ABL oligonucleotides showed a slight decrease in cell number of HL-60 cells comparable to sense 
oligonucleotides and the sense + antisense control.
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ure 8. Relative cell number of BV173 and HL-60 cells after 6 days of incubation with 10 U.M oligonucleotides. 
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Analysis o f breakpoint specificity o f BCR-ABL antisense oligonucleotides.
To determine whether BCR-ABL antisense oligonucleotides were specific for the bcr-abl breakpoint 
we used 26 mer antisense BCR-ABL oligos directed against the b3a2 bcr-abl breakpoint and tested 
their activity on cell line BV173, containing the other b2a2 bcr-abl breakpoint. Figure 9 shows that 
the a  B3A2.26M oligonucleotide is nearly as effective in reducing cell growth of BV173 as 
aB2A2.26M. The B3A2.26M sense and the B3A2.26M sense + antisense was used as a control and 
did not reduce reduce cell growth significantly.
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Figure 9. Cell number of BV173 cells after 6 days of incubation with oligonucleotides complementary to both CML 
breakpoints aB2A2.26M and aB3A2.26M with complementary sense controls at 10 x^M concentration. I  Antisense 
5  Sense □  Antisense + sense 0  Untreated
Analysis o f the type o f cell death induced by BCR-ABL antisense oligonucleotides.
Cytospin preparations of BV173 cells treated with antisense oligonucleotides and controls were 
made and stained with May-Grunwald-Giemsa. The antisense treated sample showed a large number 
of cells with apoptotic morphology (figure 10B). Extensive cytoplasmatic vacuolation, chromatin 
condensation and development of protuberances at the cell surface can be seen. Untreated control cells 
(figure 10A) showed no such morphological characteristics.
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A
B
Figure 10. Cytospin preparations stained with May-Grunwald-Giemsa of BV173 cells after 5 days of incubation with 
10 mM of antisense aB2A2.26M oligonucleotide. A. Untreated BV173 cells. B. BV173 cells treated with aB2A2.26M
To further test if the treatment of BV173 cells with antisense BCR-ABL oligonucleotides caused
apoptosis or necrosis in these cells, we used an isotonic propidium iodide (PI) and Hoechst 33342
DNA double staining technique after 5 days of incubation (22, 27).
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Figure 11: DNA double staining for discrimination between living (marked B), necrotic (marked C) and apoptotic 
cells (marked D) by flow cytometry. After 5 days of incubation of BV173 cells with 10 mm oligonucleotides propidium 
iodide (PI) was used to stain dead cells. Hoechst 33342 stain was used to stain all cells after fixation. Reduced DNA 
staining ability of cells for both DNA stains indicates apoptosis. First column: Right angle scatter (RAS) versus 
forward scatter (FS). Second column: DNA double staining: PI versus Hoechst 33342. Third column: DNA histogram 
with Hoechst.
Figure 11 shows the flow cytometric analysis of cellular scatter and staining with PI and Hoechst. 
The first column of figures shows rigth angle scatter (RAS) versus forward scatter (FS) of untreated 
cells and cells treated with oligonucleotide. To exclude cellular debris and clumps of cells from
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analysis a gate was placed. (marked A). The second column shows the DNA double staining with PI 
versus Hoechst 33342 of gated cells. The third column shows the Hoechst DNA histogram of the 
gated cells; the DNA staining with Hoechst versus the number of cells. Because isotonic PI is used 
only those cells that do not have an intact cell membrane show hight PI staining (column 2, marked 
C). These cells show a normal staining after fixation with ethanol by Hoechst 33342 and can be 
characterised as necrotic cells. Cells marked B can be characterised as normal living cells by their low 
PI staining and normal Hoechst 33342 staining. Cells marked D have both low PI and Hoechst 33342 
staining. These cells are apoptotic cells, because apoptotic cells show a reduced staining ability to all 
known DNA stains most likely because of DNA condensation that occurs during the apoptosis 
process (27, 28).
of oligonucleotides determined by DNA double staining and flow cytometry. Oligonucleotides used were as indicated.
These data were used to quantify the percentage of living, apoptotic and necrotic cells (figure 12). 
Threshold of B, C and D was set based on the untreated control where all three populations were 
separate. None of the treated samples shows a higher proportion of cells with high PI staining
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(marked C) which means that necrosis is not the cause of cell death in antisense treated cell cultures. 
There was a difference in the number of apoptotic cells between antisense and control oligo treated 
cultures. About half of antisense treated cells were apoptotic (figure 12). Also controls showed a 
slight amount of apoptotic cells; 15 % in antisense + sense treated cells, 10 % in sense treated cells 
and 4 % in untreated controls. The DNA histogram (figure 11, column 3) of the samples also shows a 
very large amount of low Hoechst 33342 staining cells in antisense treated cells compared to controls. 
These apoptotic cells showed low forward scatter and high right angle scatter and were detected in 
large amounts in the antisense treated sample (figure 11, column 1). This typical scatter pattern is also 
one of the characteristics of apoptotic cells (27). These data indicate that in our test system in BV173 
cells, cell death by incubation with antisense BCR-ABL oligonucleotides is mainly caused by 
induction of apoptosis.
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DISCUSSION
Although BCR-ABL antisense oligonucleotides have shown to be effective in specifically reducing 
colony formation of early hematopoietic progenitor cells from CML patients, the mechanism of this 
inhibition is still largely unknown (13-15, 29). To obtain insight into the antisense mechanism and the 
effect of these oligonucleotides, we investigated the cellular uptake and breakdown characteristics of 
sense and antisense BCR-ABL phosphorothioate oligonucleotides, the effect on Bcr-Abl mRNA 
breakdown, cell growth and cell death in BV173 cells.
Phosphorothioate oligonucleotides were relatively stable to nuclease degradation in serum compared 
to unmodified oligonucleotides, as was shown before (30). In our system we still detected full length 
26 mer phosphorothioate oligonucleotide after 8 days of incubation in culture medium. About 50 % of 
the remaining oligo had a length of 25 nt and is probably also active in inhibiting bcr-abl expression. 
Phosphorothioate oligonucleotides are internalised into the cells by receptor mediated endocytosis 
(24). After incubation of cells with FLUOS labelled oligonucleotides the internalised oligonucleotides 
became visible inside vesicles in the cytoplasm which were located near to the cell membrane. The 
oligonucleotides inside these vesicles are not yet active since they are not available for hybridisation 
with the Bcr-Abl mRNA . The fluorescence of labelled oligonucleotides in the cytoplasm, apart from 
the vesicles, was very low. It is assumed that a small amount of oligonucleotides enters the 
cytoplasm from the vesicles (19, 29, 31) . The total amount of oligonucleotides in the cell is about 1 
attomol. The quantity of oligonucleotide available for hybridisation to the Bcr-Abl mRNA is only a 
fraction of this amount. Dead cells, as defined by cellular scatter on the flow cytometer and trypan 
blue exclusion, accumulated large amounts of oligonucleotide. This might lead to a reduction of 
effectivity of these oligonucleotides. In flow cytometric analysis these cells were gated out.
Using a concentration of 10 mM the uptake of BCR-ABL sense and antisense oligonucleotides 
showed a constant uptake rate during the first 18 hours of incubation. After this the uptake rate 
decreased. Measured at 18 hours of incubation and using concentrations of up to 10 mM, the 
intracellular amount of oligonucleotide appeared directly dependent on the concentration of the 
oligonucleotide in the culture medium. Concentration dependent uptake of sense and antisense 
oligonucleotides was generally the same although their sequence is different. Uptake of the 
oligonucleotides per cell is heterogeneous, some cells internalise about 6 times as much as others. 
Differences in cell size beween the individual BV173 cells could not account for this. The 
heterogeneous uptake could explain why not all cells respond to BCR-ABL antisense 
oligonucleotides. After 8 days of incubation with antisense oligonucleotides, living BV173 cells were 
still present in the cultures. This heterogeneous uptake could also be the reason that the reduction of 
colony formation of CML progenitor cells is not 100 per cent (14, 15). It is not known, how efficient
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and heterogeneous the cellular uptake in these progenitor cells is. This is the subject of ongoing 
experiments.
Our results indicate that BCR-ABL oligonucleotides act predominantly in a sequence specific 
manner although some non sequence specific effects were observed.
We have shown: first, a specific reduction of Bcr-Abl mRNA after 3 days of uptake in cells treated 
with b2a2 antisense oligonucleotides of 69 ± 13% compared to untreated controls. Sense oligo 
treatment caused a reduction of 30 ± 16% and the sense + antisense oligo treatment of 12 ± 3%. 
Second, the cell growth of antisense treated BV173 cells compared to untreated cells measured after 6 
days of incubation was totally inhibited and only slightly reduced in controls, although antisense 
oligonucleotides were not found to be completely breakpoint specific. Third, HL-60 cell growth was 
only slightly inhibited by BCR-ABL b2a2 antisense oligonucleotides and to the same extent as by 
control oligonucleotides. This inhibition was not complete as was found for BV173 cells. Fourth, cell 
death as measured by DNA staining and cell counting is much more evident in antisense treated 
BV173 cells than in cells treated with control oligonucleotides.
The low reduction of Bcr-Abl mRNA concentration, and of cell growth of BV173 and HL-60 and 
the slight induction of cell death in cells treated with control oligonucleotides has to be ascribed to non 
sequence specific effects that phosphorothioate oligonucleotides elicit (29, 32, 33). The sense + 
antisense oligonucleotide added in equimolar amounts provided a control to test for additional toxic 
substances in the oligonucleotide sample as well as for binding to proteins. Sense oligonucleotide can 
reduce the effect of antisense oligonucleotides on cells by competing with the Bcr-Abl mRNA for 
hybridisation. Effect on cell growth, Bcr-Abl mRNA expression and cell death caused by antisense 
oligonucleotides was reduced when sense oligonucleotide is added to the cells as well, while uptake 
of the oligonucleotides was not affected (data not shown).
We observed that the antisense b3a2 oligonucleotide aB3A2.26M was able to reduce cell growth of 
the b2a2 breakpoint containing cell line BV173. The sense B3A2.26M and the sense + antisense 
control only slightly reduced cell growth. It is likely that the 17 out of 26 nucleotides homology 
between the aB3A2.26M and aB2A2.26M is sufficient for the oligonucleotides to hybridise to both 
types of mRNA and reduce the expression of the bcr-abl gene. In both breakpoint oligonucleotides 
13 of the 17 identical nucleotides are complementary to sequences in the abl part of the Bcr-Abl 
mRNA. Because of that, it is likely that these BCR-ABL breakpoint oligonucleotides also hybridise 
with the normal c-Abl RNA. The effects seen in cell line BV173 however cannot be ascribed to down 
regulation of normal c-abl expression, because this cell line lacks the normal c-abl gene (34). 
W hether shorther phosphorothioate oligonucleotides show a better sequence and breakpoint 
specificity, as was demonstrated for unmodified BCR-ABL oligonucleotides (14), remains to be 
studied.
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BCR-ABL antisense oligonucleotides inhibited growth of BV173 cells completely. Also cell 
growth of the CML cell line EM-2 could be inhibited by an antisense BCR-ABL breakpoint 
oligonucleotide (35) and K562 cell growth was found to be inhibited by a BCR-ABL antisense RNA 
transcribed from a retrovirally transduced construct (36). This indicates that growth inhibition as a 
result of downregulation of BCR-ABL protein expression is a more general phenomenon.
We found that BCR-ABL antisense oligoncleotides induced programmed cell death in BV173 cells 
around the fifth day of incubation. The mechanism of this induction is not known. Most likely the 
BCR-ABL oncoprotein provides an internal stimulus which renders these cells independent of growth 
factors (37). By reducing this stimulus cells are returned to growth factor dependency. When growth 
factors are not sufficiently available, cells can undergo apoptosis (38, 39).
The bcl-2 proto-oncogene is found to play an important role in apoptosis. When expressed, it can 
protect cells from induction of apoptosis (40). Also expression of the BCL-2 protein in CML cells is 
found. In cells from 1 of 7 CML chronic phase patients investigated and all of 3 CML blast crisis 
patients, bcl-2 protein expression is high (41). By reducing the BCR-ABL protein expression by 
antisense oligonucleotides a reduction of the bcl-2 expression might be induced leading to an 
induction of apoptosis in these cells. Whether reduction of BCL-2 protein expression plays a role in 
induction of apoptosis in BV173 and CML cells treated with antisense BCR-ABL oligonucleotides 
remains to be proven.
As mentioned above heterogeneity in uptake of oligonucleotide may account for the escape of cells 
from treatment with antisense BCR-ABL oligonucleotides. Another mechanism could be the cell cycle 
dependent induction of apoptosis (27, 42). Possibly these cells are have not entered the cell cycle at 
the time point when apoptosis occurs. Also noncycling CML bone marrow progenitors might escape 
from transient inhibition with BCR-ABL antisense oligonucleotides in this way.
The bcr-abl oncogene might have a function in blockage of apoptosis. Apoposis could be a normal 
mechanism to remove deregulated cells. When apoptosis is blocked in these cells this could lead to 
accumulation of other aberrations, resulting into the accelerated phase in CML and eventually into 
blast crisis.
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Phosphorothioate BCR-ABL antisense oligonucleotides 
induce cell death, but fail to reduce cellular BCR-ABL 
protein levels.
Toon F.C.M. Smetsers, Louis T.F. van de Locht, Arie H.M. Pennings, Hans M.C. Wessels, Theo 
M. de Witte and Ewald J.B.M. Mensink.
ABSTRACT
The bcr-abl oncogene is a fusion gene resulting from a reciprocal translocation which forms the 
hallmark of chronic myeloid leukemia (CML). Antisense oligonucleotides complementary to the two 
possible mRNA breakpoints were found to inhibit cell growth of CML patient cells and cell lines, but 
doubt exists about their specificity. In order to test the specificity, phosphorothioate and 3' 
phosphorothioate capped antisense BCR-ABL oligonucleotides of different length were used. 
Stability, cellular uptake of oligonucleotides and effect on cell growth were studied in two CML cell 
lines, BV173 and LAMA-84. Phosphorothioate antisense BCR-ABL oligonucleotides were most 
stable, showed the highest uptake and induced cell death in BV173 but not in LAMA-84 cells. We 
selected the most effective antisense oligonucleotide for further analysis. The BV173 and LAMA-84 
cell lines do not express the normal C-ABL protein, we therefore used a C-ABL specific monoclonal 
antibody for the detection of p210BCR-ABL expression by flow cytometry. Dead cells found after 
treatment were gated out of analysis. Although BCR-ABL antisense oligonucleotides can induce 
apoptosis, no reduction of p210BCR-ABL levels could be detected in living cells after treatment with 
antisense oligonucleotides. We conclude that antisense mediated inhibition of translation of mRNA 
into p210BCR-ABL is not the mechanism responsible for the induction of apoptosis in cell line BV173.
INTRODUCTION
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by an accumulation 
of myeloid cells and their progenitors. In over 90 % of CML patients a characteristic Philadelphia 
chromosome (Ph') is found. The onset of the disease is thought to occur in the hematopoietic stem 
cell because the Ph' chromosome is present in most hematopoietic cell types. The Ph' chromosome is 
the outcome of a reciprocal translocation t(9;22) between the long arms of chromosomes 9 and 22 (1). 
The chromosomal regions involved in this translocation harbour the c-abl proto-oncogene located on
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chromosome 9 and the BCR gene on chromosome 22. As a result of the translocation a bcr-abl 
fusion gene is formed. This fusion gene encodes for a 210 kD protein with enhanced tyrosine kinase 
activity (2-4). Only two possible Bcr-Abl mRNAs occur. Exon b2 of the bcr (breakpoint cluster 
region of the BCR gene) can be spliced to c-abl exon 2 (b2a2 breakpoint) or exon b3 to the c-abl 
exon 2 (b3a2 breakpoint).
The breakpoint region on the hybrid mRNA molecules is thought to be a unique target for antisense 
oligonucleotides. Antisense oligonucleotides are short (15-30 nt) synthetic DNA molecules which are 
actively internalized by cells (5). It is thought that antisense oligonucleotides bind to their 
complementary mRNA and inhibit translation into protein. This is most likely to occur by a blockade 
of the ribosomal translation mechanism or by mRNA degradation by a cytoplasmatic enzyme RNase 
H, that recognizes RNA/DNA hybrid molecules (6, 7). Antisense oligonucleotides have been found 
useful in reducing the expression of a number of genes including the bcr-abl gene. Unmodified 18- 
mer antisense oligonucleotides targeted to the Bcr-Abl mRNA breakpoints reduced the clonogenic 
capacity of hematopoietic progenitors from the bone marrow of CML patients, but much less from 
normal hematopoietic progenitor cells (8-11). These 18-mer oligonucleotides inhibited the growth of 
several CML cell lines as well (12-14). Because these oligonucleotides are rapidly degraded by 
serum components, more stable 26 and 18-mer phosphorothioate modified oligonucleotides were 
tested in cell lines and normal CML cells(15-17). Phosphorothioate 26-mer oligonucleotides directed 
against the b2a2 breakpoint induced programmed cell death in the CML cell line BV173 expressing a 
b2a2 type Bcr-Abl mRNA, however B3A2 antisense oligonucleotides were also effective(17). Sense 
oligonucleotides showed only little effect on cell growth. When tested on cells from CML patients, 
26-mer and 18-mer antisense phosphorothioate oligonucleotides showed little specificity for the CML 
breakpoints (16). Because of this partial sequence specific effect we tested oligonucleotides with 
different length and chemical constitution. Since the rationale behind the antisense approach is based 
upon the inhibition of translation we tested the effects of the most effective antisense BCR-ABL 
oligonucleotides on p210BCR-ABL levels in the CML cell lines. To eliminate annoying effects on this 
analysis from the presence of dead cells, we chose to do this by flow cytometry in which only the 
living cells were analyzed. The tested cell lines BV173 and LAMA-84 do not express a normal C-
BCRABL protein. This enabled us to use a C-ABL specific monoclonal antibody to measure the p210
ABL expression by flow cytometry in these cells after treatment with BCR-ABL antisense 
oligonucleotides.
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MATERIALS AND METHODS.
Cell lines
Human leukaemic cell lines BV173 (CML lymphoid) (18), K562 (CML erythroblastic) (19) 
LAMA-84 (CML myeloid)(20), TOM-1 (ALL lymphoid), were cultured in RPMI 1640 medium 
(Flow Laboratories, Irvine, Scotland) supplemented with 10% heat inactivated (56° C, 30 min) Fetal 
Calf Serum (Hyclone, Logan, UT, USA), 2 mM L-glutamine , 50 IU/ml penicillin and 50 ^tg/ml 
streptomycin (Cellect®,ICN Flow, Irvine, UK) in a humidified incubator at 37° C with 5% CO2 in 
air.
Oligodeoxynucleotides
Oligodeoxynucleotides were synthesized on an Applied Biosystems DNA synthesizer model 391 
EP (Applied Biosystems, Foster City, CA, USA) according to the manufacturers instructions. After 
deprotection in 25% ammonium hydroxide solution (Applied Biosystems) 8 hr at 55°C, 
oligonucleotides were purified by two ethanol precipitations and dissolved in distilled water. 
Sequences of the oligonucleotides used are summarised in table 1, their location is shown in figure 1. 
Phosphorothioate (all-PS) and 3' phosphorothioate capped (cap-PS) oligonucleotides were 
synthesized using tetraethyl thiuram disulfide (TETD, Applied Biosystems) as a sulphurization agent 
during synthesis. After deprotection and ethanol precipitation the oligonucleotides were purified by 
HPLC and desalted as described (17). For fluorescein labeling a 6-aminohexanol phosphate linker 
was attached to the oligonucleotides by the use of Aminolink-2 (Applied Biosystems) in normal 
synthesis. A fter HPLC purification these oligonucleotides w ere coupled w ith (5)6- 
Carboxyfluorescein-N-hydroxysuccinimide ester (FLUOS) (Boehringer Mannheim, Mannheim, 
Germany) as described (17).
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❖
Name Sequence (5'—»3') Location Gene Exon Fragment length
Bcr-abl and c-Abl mRNA detection
Sense oligonucleotides
ALL-ei CGCATGTTCCGGGACAAAAGC 1677-1697 bcr e1
BA5 CGGGAGCAGCAGAAGAAGTGT 3180-3200 bcr b2
ABL-ia AGCTGGTGGGCTGCAAATC 167-185 abl 1a
ABL-ib GCTTGCCTGCCCTGCATTT 47-65 ablib 1b
Antisense oligonucleotide
BA3 GGGTCCAGCGAGAAGGTTTT 302-321 abl 2
Internal probe
a  A22 GGCTTCACTCAGACCCTGAGGCTC 259-282 abl b2
Beta-2- microglobulin mRNA detection
B2M5 CTCGCGCTACTCTCTCTTTCT 910-930 b2m1 1
B2M3 TGTCGGATTGATGAAACCCAG 198-218 b2m2/3 2
Antisense Oligonucleotides
OB2A2.16M AAGGGCTTCTTCCTTA 2396-3303 bcr b2
B2A2.16M TAAGGAAGAAGCCCTT 227-234 abl 2
OB3A2.16M AAGGGCTTTTGAACTC 3371-3378 bcr b3
B3A2.16M GAGTTCAAAAGCCCTT 227-234 abl 2
OB2A2.18M GAAGGGCTTCTTCCTTAT 2395-3303 bcr b2
B2A2.18M ATAAGGAAGAAGCCCTTC 227-235 abl 2
OB3A2.18M GAAGGGCTTTTGAACTCT 3370-3378 bcr b3
B3A2.18M AGAGTTCAAAAGCCCTTC 227-235 abl 2
OB2A2.26M CGCTGAAGGGCTTCTTCCTTATTGAT 2391-3303 bcr b2
B2A2.26M ATCAATAAGGAAGAAGCCCTTCAGCG 227-239 abl 2
OB3A2.26M CGCTGAAGGGCTTTTGAACTCTGCTT 3366-3378 bcr b3
B3A2.26M AAGCAGAGTTCAAAAGCCCTTCAGCG 227-239 abl 2
294
219/294
155
185
138
* Positions correspond to: abl, human c-Abl mRNA genbank accession nr: X16416; bcr. human Bcr mRNA genbank 
accession nr: Y00661; ab llb . human c-Abl mRNA with exon 1b genbank accession nr: M17310; b2m1. human 
beta-2-microglobulin gene exon 1 genbank accession nr M17986; b2m2/3. human beta-2 microglobulin gene 
exon 2 and 3 genbank accession nr M17987.________________________________________________________________
Table 1: Location, sequence and constitution of oligonucleotides used.
Monoclonal antibodies and antisera.
A hybridoma supernatant of the c-ABL monoclonal antibody 8E9 of the IgGI subclass (a gift from 
Dr. J.Y.J. Wang University of California at San Diego, La Jolla, CA, USA) was diluted twice for 
use. The CD-2 antibody TS2/18 of the IGgI subclass (21) was used as a control for 8E9 staining and 
also used in a twofold dilution. A polyclonal rabbit anti Ki-67 serum (Dako, Glostrup, Denmark) was
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diluted 20 times. The conjugates used were a polyclonal goat anti mouse IgGI conjugated with 
fluorescein isothiocyanate (FITC) (Southern Biotechnology Association, Birmingham, AL, USA) 
and was used in a 100 fold dilution. A polyclonal F(ab)2 goat anti rabbit conjugated with 
phycoerytherin (RPE) (Southern Biotechnology Association) was used at a 20 fold dilution.
Stability of oligonucleotides
Fifty picomoles of oligonucleotides were end labeled with [y-32P] dATP using T4 polynucleotide 
kinase (Boehringer Mannheim, Mannheim Germany) as described(17). Labeled oligonucleotide was 
added to 500 mil of culture medium (RPMI 10 % FCS) containing 10 miM of non labeled 
oligonucleotide. Samples of 10 mil were taken at different time periods and analyzed on a 20 % 
polyacrylamide gel containing 7 M ureum as described (17). The gel was exposed to a X-ray film (X- 
omat S, Kodak, San Diego, CA, USA) for 16 hours in a cassette with intensifying screens. 
Secondary structure of oligonucleotides was investigated using the oligonucleotide analysis software 
Oligo 4.0 (national Biosciences, Plymouth, MN, USA)
Flow cytometric analysis o f oligonucleotide uptake
Cells were seeded in triplicate wells at a density of 2 x 105 cells/ml in a 100 mil volume in a 96 well 
tissue cluster (Costar, Cambridge, MA, USA). After 18 hours FLUOS labeled oligonucleotides were 
added to the cells at concentrations of 10 mtM. After various incubation times cells were washed with 
phosphate buffered saline (PBS) and green FLUOS fluorescence of the cells was determined using a 
Coulter Epics Elite (Coulter, Hialeah, FL) flow cytometer as described (17). Known amounts of 
FLUOS labeled oligonucleotides bound to APS hypersyl hyperspheres 5 mtm (Shandon Southern 
Products Ltd, Runcorn, UK) were used to quantify the exact amount of oligonucleotides in the cell 
according to the method of Spiller et al (22) .
Confocal laserscanning microscopy.
Confocal laserscanning micropscopy was performed on a BioRad MRC-600 (BioRad, Hemael 
Hempstead, UK) connected to a Nikon Diaphot microscope (Nikon, Tokyo, Japan) equipped with a 
60 x objective (Pan-Apo, N.A. = 1.4). Excitation at 488 nm was obtained by directing the light of a 
15 mW Argon laser through an excitation filter (488 DF 10). To reduce bleaching of the fluorescent 
oligonucleotide, laser emission was attenuated to about 10% by introducing a neutral density filter in
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front of the laser. Fluorescent light was passed through a dichroic reflector (DR 510 LP) and a barrier 
filter (OG 515). Optical sections of approximately 1 mim were obtained by opening the confocal 
pinhole in front of the photon-multiplier tubes of 30%. Images were captured utilizing fast photon 
counting setup of the MRC-600. The diameter of the cells was estimated to be 7 miM. Images were 
obtained from a plane in the middle of the cells.
Incubation o f cells with antisense oligonucleotides or TPA and cell growth determination.
BV173 cells were seeded at a density of 1 x 105 cells/ml , LAMA-84 cells were seeded at a density 
of 0.5 x 105 cells/ml in RPMI 10% FCS with L-glutamine and antibiotics in 96 wells flat bottomed 
culture plates (Costar). Oligonucleotides were added to the wells. The 26-mer all PS oligonucleotides 
were added in a concentration of 10 m M, whereas 20 m M of all other oligonucleotides were used. If 
appropriate 12-O-Tetradecanoylphorbol 13-acetate (TPA) (Sigma, St. Louis, MO, USA) was added 
at a concentration of 10 nM. Plates were incubated in a humidified incubator at 37° C with 5% CO2 in 
air. For determination of p210BCR-ABL expression samples were taken after 3, 4 and 5 days of 
incubation. Viable cell number was determined on day 6 after addition of oligonucleotides by trypan 
blue exclusion in a Burker haemocytometer. Alternatively viable cell number was determined using 
flow cytometry. To the wells 10 mil of 50 times diluted viable dye calcein 1 mg/ml (Molecular Probes, 
Eugene, OR, USA) was added to the cells. After incubation 50 mil of cell suspension was transferred 
to a tube containing fluorescent beads (Immunocheck, Epics division of Coulter, Hialeah, FL) in 500 
mil PBS. These beads were used as a calibration for analysis on a Coulter Epics XL-MCL Flow 
cytometer(Coulter, Hialeah, FL). Filter setting was as described in the section "Analysis of cellular 
BCR-ABL protein levels by flow cytometry". All cells showing green fluorescence were considered 
viable cells. The viable cell number was determined by the relative amount of cells compared to 
beads.After 6 days of incubation viable cell number was determined by calcein staining and flow 
cytometry.
Isolation o f RNA from cell lines and reverse transcriptase PCR analysis.
RNA isolation of exponentially growing cell lines were performed by the Guanidinium 
Isothiocyanate method and purified over a CsCl gradient as described (23).
Synthesis of cDNA was performed in a 20mil volume in a solution containing 1 mig of RNA, 50 mM 
Tris-HCl (pH 8.3), 75 mM KCl, 3mM MgCl2, 10 mM DTT, 625|i M  of dATP, dGTP, dCTP and 
dGTP (Boehringer Mannheim, Mannheim, Germany), 5.0 | lM of random hexanucleotides, in the
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presence of 1000 units/ml RNase inhibitor (RNasin, Promega, Madison, WI, USA) and 10,000 units 
/ml of Moloney Murine Leukemia Virus reverse transcriptase (Gibco BRL, Life technologies, 
Gaithersburg, MD, USA). The reaction was carried out in a DNA thermal cycler model 480 (Perkin 
Elmer Cetus, Emeryville, USA) 10 min at 20° C, 45 min at 42° C and 10 min at 95° C.
Amplification of cDNA was performed by addition of 80 mil of a mixture containing 0.001 % 
gelatine, 50 mM KCl, 10 mM Tris-HCl (pH 8.4), 1.5 mM MgCl2, 625 nM of upstream primer and if 
appropriate 625 nM of downstream primer in the presence of 19 units/ml Taq DNA polymerase 
(Gibco BRL). Samples were overlaid with 60mil of mineral oil (Sigma) and amplified in a DNA 
thermal cycler model (Perkin Elmer Cetus, Norwalk, CT, USA). Samples were denaturated for 5 
min at 94° C. Amplification was 30 s at 94° C, 30 s at 58° C, and 90 s at 72° C for 30 cycles. 
Amplification was followed by a final extension for 10 min at 72°C.
Electrophoresis and Blotting o f PCR products
After amplification PCR products were separated on a 2% agarose gel. The separated PCR products 
were transferred to a Hybond™-N+ nylon membrane (Amersham, Buckinghamshire, England). The 
oligonucleotide a  A22 was 5' end-labeled with [y-32P]dATP using T4 kinase (Boehringer 
Mannheim). Unincorporated radioactivity was removed using a sephadex G-50 spin column. 
Membranes were screened using the radioactive labeled oligomer probe according to the instructions 
of the manufacturer. After this membranes were exposed to an X-ray film.
Analysis o f cellular BCR-ABL protein levels by flow cytometry
For analysis of BCR-ABL protein levels, cells were washed twice with PBS. After this cells were 
incubated with 100 mil of FACS® lysing solution (Becton Dickinson, San Jose, CA) for fixation and 
permeabilization for 1 hr at room temperature. Alternatively cells were fixed with 0.5 % 
Paraformaldehyde for 5 min at 4° C followed by permeabilization using 0.1 % Triton-X-100 also at 
4°C for 5 min. Cells were washed once with PBS and placed in 96 wells point bottom wells (Costar) 
and blocked for non specific binding with 50 mil of PBS containing 20 % pooled human serum for 15 
min at 37 ° C. Hybridoma supernatant (50 mil) and the polyclonal anti Ki-67 antibody were added and 
incubated for 30 min at 4° C. Cells were washed 3 times with cold PBS containing 0.5 % bovine 
serum albumin (BSA) (Organon Teknika, Boxtel, The Netherlands). After this cells were incubated 
with PBS 20 % human serum for 30 minutes at 4° C and incubated with the diluted FITC or RPE 
conjugates for 30 minutes at 4 ° C. Cells were washed twice with cold PBS 0.5% BSA and incubated
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with 20 mtg/ml propidium iodine (PI) in PBS for DNA staining at 4° C. Cells were then analyzed by 
flow cytometry.
For flow cytometric detection of the BCR-ABL protein, Ki-67 antigen and DNA, a 488 nm 40 mW 
argon ion laser running at 15 mW was used. Dichroic mirrors of 550 nm and 625 nm and band pass 
filters of 525/40 nm for green fluorescence and 575/30 nm for red fluorescence and a 610 nm long 
pass filter for PI fluorescence were used.
RESULTS
Detection o f the c-Abl and Bcr-Abl mRNAs in cell lines.
We tested the mRNA expression of the c-Abl and Bcr-Abl mRNAs in four cell lines by reverse 
transcriptase PCR (Figure 1).
ABL-1a
Normal c-abl 1aa2 1 a 2
ABL-1b _► a  A2*
BA3
Normal c-abl 1ba2 1b a2
ALL-e1 -► a  A22
BA3
ALL bcr-abl e1a2 1 e 1 a2
BA5 _►
a  A22 ^ -B A 3
CML bcr-abl b2a2 1 e l  I b2 a2
BA5 -►
aB2A2 ocA22 BA3
CML bcr-abl b3a2 Q e l  b2 1
aB3A2 aA22 BA3
IE
ie :
ie ;
i e :
i e :
Figure 1: Schematic representation of the c-Abl and Bcr-Abl mRNAs and the location of PCR and antisense 
oligonucleotides used. RNA was reverse transcribed with hexanucleotides. PCR analysis was used to detect the c-Abl 
and Bcr-Abl mRNA with oligonucleotide BA3 as antisense primer. Oligonucleotide aA22 was used as a probe for 
detection of the mRNAs.
The amount and quality of RNA was checked by a PCR for the beta-2-microglobulin and was 
approximately the same in the four cell lines (data not shown). Only cell line TOM-1 was positive in a 
PCR for detection of the e1a2 Bcr-Abl mRNA (Figure 2).
61
Antisense BCR-ABL oligonucleotides in CML.
b c r - a b l  
e1 &2
b c r - a b l  
b2a2/ b3a2
c - a b l  
1 aa2
c - a b l  
1 ba2
r -----------------------1 i------------------------- 1 1
T B K L - T B K L ' T B K L
i r
T B K L
Figure 2: Southern blot of a reverse transcriptase PCR analysis of the c-Abl and Bcr-Abl mRNAs in four cell lines. 
Southern blots were probed internally with an abl specific radioactively labeled oligonucleotide a A22. Primers used are 
as indicated in table 1 and figure 1. T: TOM-1 K: K562, L: LAMA-84, B: BV173, "-": Negative control.
Cell lines K562 and LAMA-84 expressed the b3a2 mRNA and BV173 the b2a2 type mRNA. Cell 
lines K562 and TOM-1 were both positive in a PCR for the detection of the normal c-ABL mRNAs. 
The c-Abl mRNA has two splicing variants (1a and 1b) that are detected with two different PCR 
reactions. Both types of c-Abl mRNA were found in these cell lines. Cell lines LAMA-84 and BV173 
showed no product after reverse transcriptase PCR for the normal c-Abl mRNAs. We therefore 
decided to use these cell lines for protein analysis using flow cytometry using a c-ABL specific 
monoclonal antibody.
Stability o f oligonucleotides in the culture medium.
We tested the stability of 5' labeled oligonucleotides at a concentration of 10 |iM  in RPMI containing 
10 % FCS. The autoradiogram (figure 3) shows that the unmodified phosphodiester oligonucleotide 
aB2A2.18M is rapidly degraded in the culture medium. An oligonucleotide with the same sequence 
containing two 3 ' phosphorothioate linkages (cap-PS) showed an enhanced stability in the culture 
medium and after 5 days still full length product could be detected. Although this oligonucleotide is 
more stable, it is not as stable as the full phosphorothioate modified (all-PS) oligonucleotide 
0CB2A2.26M, that only shows a slight breakdown. The same accounts for the 16-mer cap-PS 
oligonucleotides (Figure 3b). Minor phosphatase or 5' exonuclease activity is present in the culture 
medium since radioactivity seems to disappear from the aB2A 2.26M  band but no smaller 
oligonucleotide degradation products can be detected.
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Figure 3: A. Autoradiogram of separated 32P labeled unmodified (PO), phosphorothioate capped (PS CAP) and all 
phosphorothioate (PS) labeled oligonucleotides after incubation in RPMI 10 % FCS.
B. Autoradiogram of separated 32P labeled 16-mer oligonucleotides. The arrow marks breakdown products of the 
antisense oligonucleotide that are absent in the sense oligonucleotide.
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All-PS oligonucleotides were found to be more stable than cap-PS oligonucleotides. After gel 
analysis, these oligonucleotides show several breakdown products. Remarkably, the sense cap-PS 
oligonucleotide B2A2.16M lacks two of these breakdown products (figure 3b, marked by arrows) 
that are present in the antisense oligonucleotide aB2A2.16M. The absent bands on the autoradiogram 
indicate that the B2A2.16M oligonucleotide is in some way protected from degradation, possibly by 
the formation of a secondary structure or by protein binding. The presence of secondary structure was 
confirmed by computer analysis (data not shown)
Cellular levels o f FLUOS labeled BCR-ABL oligonucleotides.
In order to study the cellular accumulation of BCR-ABL oligonucleotides of different constitution 
and length in cell lines, we incubated BV173 and LAMA-84 cells with 10 |iM  of FLUOS labeled 
sense and antisense B2A2 oligonucleotides. Because it is difficult to strip the oligonucleotide from the 
cellular membrane (5) we determined the total of cell associated oligonucleotide.
At different time periods cellular fluorescence was measured by flow cytometry as described before 
(17). Confocal laserscanning microscopy showed that cellular fluorescence was indeed present inside 
the cells and not only at the cell membrane. The all-PS 26 mer oligonucleotides showed a vesicular 
fluorescence (Figure 4A, 4B), the cap-PS oligonucleotides showed a more diffuse cellular 
fluorescence (Figure 4C, 4D) with less vesicles present. Figure 5A shows the oligonucleotide uptake 
of sense and antisense all-PS oligonucleotides of 26-mer and 16-mer length in cell line BV173. While 
the uptake of antisense oligonucleotide aB2A2.16M showed reaches a maximum after 24 hours of 
incubation, this is not the case for the 26-mer oligonucleotides. LAMA-84 cells (Figure 5B) 
accumulate more oligonucleotide than BV173 possibly due to differences in cell size. Unlike in 
BV173 cells the 26-mer oligonucleotides are internalized better than the 16-mer oligonucleotides and 
the 26-mer sense B2A2.26M better than the antisense aB2A2.26M. Remarkably the cellular amount 
of the sense B2A2.16M showed no time dependency in both cell lines.
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Figure 4: A. Confocal laserscanning microsopic image of cell line BV173 after 18 hours of incubation with FLUOS 
labeled all-PS oligonucleotide OB2A2.26M.
B. Same as in A. for the light microscopic image.
C. Confocal laserscanning microsopic image of cell line BV173 after 18 hours of incubation with FLUOS labeled cap­
PS oligonucleotide aB2A2.18M. D. Same as in C. for the light microscopic image.
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When the cellular amount of 16-mer and 18-mer cap-PS oligonucleotides was compared with that of 
the all-PS oligonucleotides, they were found to internalize less effectively in BV173 and in LAMA-84 
cells (Figure 5C and 5D). The 18-mer capped oligonucleotides accumulate more efficiently than the 
16-mer cap-PS. A very poor uptake of the sense 16-mer cap-PS and all-PS oligonucleotide was 
observed. Because of this we investigated the cellular amount of the all-PS 16-mer antisense 
oligonucleotides targeted against the B2A2 as well as the B3A2 breakpoint after 18 hours of 
incubation with 10 |iM  of oligonucleotides (data not shown). No difference in the cellular amount of 
the aB2A2.16M compared to aB3A2.16M in cell line BV173 and LAMA-84 was observed. This 
indicates that the sense 16-mer B2A2.16M clearly shows different uptake kinetics compared to other 
oligonucleotides of the same length.
In general, uptake of PS-oligonucleotides is better than PS-capped oligonucleotides of the same 
length. Cellular uptake is length dependent. Sense 16-mers show a considerably reduced and no time 
dependent uptake.
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Figure 5. A. Cellular accumulation of FLUOS labeled all-PS oligonucleotides in cell line BV173.
B. The same as in A for LAMA-84.
C. Cellular accumulation of FLUOS labeled Cap-PS oligonucleotides compared to the aB2A2.26M all-PS 
oligonucleotide in cell line BV173.
D. The same as in C for LAMA-84.
All-PS oligonucleotides: T  aB2A2.26M, V B2A2.26M, *  aB2A2.16M, O B2A2.16.
Cap-PS oligonucleotides: +  aB2A2.18M, O B2A2.18M, *  aB2A2.16M, A B2A2.16M.
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Effect o f BCR-ABL antisense oligonucleotides on cell growth o f BV173 cells and LAMA-84 cells.
Figure 6 shows cell numbers of BV173 after 6 days of treatment with antisense BCR-ABL and 
control oligos. No effect on cell growth of LAMA-84 cells after treatment with any of the 
oligonucleotides was observed (data not shown). Cell growth of BV173 was dramatically reduced 
after addition of the all-PS aB2A2.26M. As discussed before the antisense oligonucleotide targeted 
against the B3A2 breakpoint aB3A2.26M also inhibited cell growth in these cells (17). The control 
26-mer all-PS sense oligonucleotides had little effect on cell growth of BV173. The 16-mer all-PS 
ocB2A2.16M showed growth inhibition, while the antisense oligonucleotide targeted against the 
B3A2 breakpoint did not. Incubation with both 16-mer sense control oligonucleotides showed a 
drastic growth inhibition. Of the cap-PS oligonucleotides the aB2A2.18M showed poor inhibition of 
cell growth of BV173 while all other control oligonucleotides of the same length had no effect. Cap­
PS 16-mer oligonucleotides did not induce a cell growth reduction of cell line BV173.
We conclude that some of the all-PS oligonucleotides tested are effective in reducing cell growth of 
BV173 whereas cap-PS are not. The effectivity depends on the sequence and length of the 
oligonucleotide. Sense 16-mer oligonucleotides also reduce growth of BV173. The all-PS 
ocB2A2.26M is the most effective antisense oligo.
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Figure 6. Cell number of cell line BV173 after 6 days of incubation with different BCR-ABL antisense 
oligonucleotides and controls determined by flow cytometry.
BCR-ABL protein levels after antisense treatment.
In order to determine whether the cytotoxic effect of BCR-ABL antisense oligos was caused by a 
decrease in BCR-ABL protein expression we determined p210BCR-ABL expression using flow 
cytometry. The effect of antisense on the levels of p210BCR-ABL was also analyzed in LAMA-84 cells. 
Because the antisense 26-mer all-PS oligonucleotides were most effective, whereas the 26 mer sense
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controls were not, we selected these oligonucleotides for protein studies. Measurements of expression 
of p210BCR-ABL after antisense treatment were complicated in BV173 because of induction of apoptosis 
(17). Apoptotic cells could be found after 4 days of incubation with antisense oligonucleotides and 
were identified by their low DNA staining ability. We analyzed cells stained for the p210BCR-ABL 
protein in combination with the DNA stain propidium iodine(PI). Figure 7 shows a dual parameter 
flow cytometric analysis for p210BCR-ABL and DNA of BV173 cells after 5 days of treatment with 26- 
mer all-PS BCR-ABL oligonucleotides. The p210BCR-ABL accumulates gradually as cells pass trough S 
phase and is highest in the G2/M phase of the cell cycle. Cells with low PI staining, i.e. the apoptotic 
cells also show a low staining for the p210BCR-ABL. Because these cells are not viable, the 
determination of BCR-ABL protein levels in these cells is not reliable.
After treatment with all 26-mer all-PS oligonucleotides, no decrease of p210BCR-ABL levels could be 
found in the cells with normal PI staining. Also no difference in expression during different phases of 
the cell cycle could be found. To exclude staining artefacts caused by improper fixation we used a 
control antibody specific for the Ki-67 antigen. Cells that were not properly fixed showed a very low 
staining for the Ki-67 antigen, while dead cells showed an extremely high fluorescence signal after 
staining (data not shown). Only cells with a normal signal for the Ki-67 antigen were analyzed. The 
experiment was repeated at least 3 times at different time periods after incubation. A decrease in levels 
of cellular p210BCR-ABL was never observed.
Uritrttited «B2A220M B2A22WI
DMA ƒ O lA  ƒ OJA
Figure 7. Dual parameter flow cytometric analysis of BCR-ABL protein expression versus DNA content in BV173 
cells after 5 days of incubation with 26-mer phosphorothioate oligonucleotides. Arrow marks apoptotic cells.
Because TPA was known to decrease BCR-ABL protein expression in K562 cells (24) we analyzed
BCRBV173 cells and LAMA-84 cells after 3 days of treatment with TPA as a positive control for p210 '
ABL decrease. TPA induced cell death in both cell lines. Figure 8A shows flow cytometric analysis of
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p210BCR'ABL expression of BV173 cells with normal Ki-67 staining after 5 days of incubation with 
oligonucleotides and after 3 days of treatment with TPA. Treatment of TPA resulted in a decrease of 
p210BCR-ABL levels in these cells. The same effect of TPA was observed in LAMA-84 (Figure 8B).
TPA a B2A2.26M
B2A2.26M a B3A2.26M
B3A2.26M
A
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TPA a B2A2.26M
B2A2.26M a B3A2.26M
B3A2.26M
B
Figure 8. A. Flow cytometric analysis of BCR-ABL protein expression in BV173 cells by staining with the 8E9 
monoclonal antibody after 5 days of treatment with 26-mer phosphorothioate oligonucleotides and after 3 days with 
TPA. Cells were gated on scatter and normal Ki-67 expression.......CD-2 MoAb negative control.----- Untreated
control------Oligonucleotide or TPA treated.
B. The same as in A for LAMA-84 cells.
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DISCUSSION
Antisense BCR-ABL oligonucleotides have been shown to reduce the colony formation and cell 
growth of CML cell lines. The observation that 26-mer and 18-mer phosphorothioates complementary 
to both types bcr-abl breakpoints inhibit cell growth of cells from CML patients and CML cell line 
BV173 independent of breakpoint type (16, 17) raised questions about the sequence specificity of 
these oligonucleotides. To address this issue we used phosphorothioate oligonucleotides and 3' 
phosphorothioate capped oligonucleotides of different length and tested their ability to inhibit 
translation of the p210BCR-ABL Corresponding sense oligonucleotides were used as controls. Cell lines 
BV173 and LAMA-84 used in this study express Bcr-Abl but not c-Abl mRNA. The absence of 
normal C-ABL protein enabled us to use a C-ABL specific monoclonal antibody for detection of 
p210BCR-ABL expression by flow cytometry. Therefore, these cell lines provided an excellent model for 
studies on the p210BCR-ABL expression.
Stability, cellular accumulation and localization and effect on cell growth of all-PS and cap-PS BCR- 
ABL antisense and sense oligonucleotides complementary to both Bcr-Abl mRNA breakpoints were 
tested. Phosphorothioate 26 and 16-mer antisense oligonucleotides were most stable, accumulated 
better in the cells than phosphorothioate capped oligonucleotides and inhibited the growth of BV173 
but not of LAMA-84. The 26-mer PS antisense oligonucleotides showed no specificity for either 
breakpoint while 16-mer antisense oligonucleotides did. Unlike the sense 26-m er PS 
oligonucleotides, both sense 16-mer PS oligonucleotides showed strong growth inhibition of cell line 
BV173 as well. Their degradation pattern is different and their cellular accumulation is low and shows 
no time dependency compared to the corresponding antisense oligonucleotides. It is therefore not 
likely that a sequence specific cellular mechanism is engaged in cell death induced by these 
oligonucleotides.
The 26-mer phosphorothioate antisense oligonucleotides were the most cytotoxic. Corresponding 
control oligonucleotides showed no growth inhibition. We selected these oligonucleotides for 
determination of their effect on p210BCR-ABL evels and to test the rationale of antisense inhibition of 
translation. To discriminate between the BCR-ABL protein levels in dead and living cells, we used a 
flow cytometric detection. Staining of DNA with PI and the usage of the Ki-67 monoclonal antibody 
allowed us to gate out apoptotic cells. We observed that in all-PS antisense 26-mer treated cells the 
levels of the BCR-ABL protein did not decrease in the remaining non apoptotic cells. As expected 
(24), we could detect a decrease of p210BCR-ABL levels in LAMA-84 and BV173 cells 3 days after 
treatment with TPA. These data show that a decrease in p210BCR-ABL levels indeed can be detected by 
the flow cytometric method used. A decrease of p210BCR-ABL levels is not necessarily linked to
74
Chapter 3: BCR-ABL antisense and protein expression.
immediate cell death. In cell line BA/F3bcr-abl cell death could already be detected after 12 hours of 
treatment with unmodified BCR-ABL antisense oligonucleotides (12). Considering the half-life of the 
p210BCR-ABL, which is over 24 hours (25), and the kinetics of oligonucleotide accumulation it is also 
not likely that a decrease of p210BCR-ABL in this cell line was responsible for the effect.
One could think of several explanations for the inhibition of cell growth found after antisense BCR- 
ABL oligonucleotide incubation without the expected decrease in levels of p210BCR-ABL.
First, a slight decrease in p210BCR-ABLlevels could induce immediate cell death, thereby not allowing 
detection of cells with low p210BCR-ABL. This explanation is not likely, because TPA reduced 
p210BCR-ABL levels in BV173 and LAMA-84 cells, that did not (yet) die of apoptosis. Also LAMA-84 
cells, that do not die after BCR-ABL antisense treatment, do not show a protein decrease, indicating 
that at least in this cell line it is clear that no protein decrease exists after antisense BCR-ABL 
treatment. Furthermore, because the half life of the p210BCR-ABL is very long it is also not likely that, if 
even a minor protein decrease exists, it could not be detected.
A second explanation for the observed growth inhibition of BV173 cells is a non sequence specific 
toxic effect induced by the phosphorothioate oligonucleotides. Non sequence specific effects mediated 
by binding of growth factors, induction of transcription factors or by oligonucleotide degradation 
products have been described (26-28). Possibly, the all-PS 16 mer sense oligonucleotides used in this 
study induce cell death by one of these mechanisms. We demonstrated sequence dependent effects of 
the antisense 26-mer and 16-mer phosphorothioate oligonucleotides on cell growth of cell line 
BV173. It is however possible that only the antisense oligonucleotides and not the control 
oligonucleotides bind a protein or produce toxic degradation products thereby inducing apoptosis. 
Recently it was found that oligonucleotides containing the sequence GGC can bind to the p210BCR-ABL 
thereby inhibiting its autophosphorylation(29). The antisense oligonucleotides used in this study also 
contain the sequence GGC while the sense oligonucleotides do not. This therefore can be an 
explanation for the effect. The oligonucleotide aB3A2.16M does not reduce cell growth of BV173 
while aB2A2.16M does. Both oligonucleotides contain the GGC motif. This indicates that the GGC 
mediated p210BCR-ABL function inhibition is not the only cause of growth inhibition of cell line 
BV173. More data from carefully controlled antisense experiments are needed to determine to what 
extent the antisense effect is mediated by protein binding.
A third and entirely hypothetical explanation for the growth inhibition of BV173 cells is that the 
presence of mRNA/oligonucleotide hybrids as such act as a signal for the onset of an apoptotic 
pathway. Unlike most CML cell lines, BV173 contains a wild type p53 gene (30), that is known to be 
involved in some mechanisms of apoptosis induction . The p53 protein preferentially binds to free 
single stranded DNA ends and promotes renaturation (31). It may therefore have a function in
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antisense mediated cytotoxicity. Cell line LAMA-84 contains a mutant p53 gene and could therefore 
be less sensitive. We are currently testing the involvement of p53 in antisense mediated cytotoxicity 
using transfection studies. Whatever the direct mechanism of action of antisense oligonucleotides, the 
cellular background in which the experiments are performed is important. In our hands, BV173 is the 
most sensitive cell line for a BCR-ABL antisense approach. It could therefore be susceptible to 
induction of apoptosis by other mechanisms not induced by p210BCR-ABL decrease. Although sequence 
dependent effects of antisense BCR-ABL oligonucleotides are found in cell line BV173, our 
experiments on p210BCR-ABL levels indicate that these are not a result of the proposed antisense 
mediated inhibition of translation of Bcr-Abl mRNA.
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Specificity of BCR-ABL antisense oligonucleotides..
Toon F.C.M. Smetsers and Ewald J.B.M. Mensink.
To the editor:
Recently in a very interesting publication in Blood it was shown that antisense treatment of 
Philadelphia-positive cell lines resulted in growth inhibition of chronic myelogenous leukemia (CML) 
cells. Liposomes containing methylphosphonate oligodeoxynucleotides complementary to specific 
regions of the Bcr-Abl mRNA were used. The investigators claim that growth inhibition resulted 
from selective inhibition of the expression of the p210BCR-ABL protein. A Western blot was screened 
with the 8E9 monoclonal antibody. This antibody is specific to the SH2 domain of the c-abl protein 
(1) and detects the p210BCR-ABL as well as the p145C-ABL The investigators show a decrease of the 
p210BCR-ABL expression relative to the p145C-ABL expression and conclude that the antisense strategy 
results in selective inhibition of the expression of p210BCR-ABL . the cell lines used were BV173 and 
K562. Both showed the same phenomenon (Figs 4 and 5 in Tari et al. (2)).
However the presence of the p145C-ABL in cell line BV173 is surprising because this cell line lacks 
the normal chromosome 9 (3) and, as a result of that, does not express the normal c-ABL protein. 
Dikstein et al used Western blotting with the same monoclonal antibody and indeed demonstrated that 
BV173 is c-ABL negative. Absence of c-Abl mRNA in a reverse transcriptase-polymerase chain 
reaction assay was also confirmed (4, 5).
The rationale behind antisense studies is that antisense oligos are effective because they inhibit 
translation of the mRNA to which they are targeted. The specificity of antisense oligonucleotides is 
still a controversial issue (6). We fully agree with Tari et al. (2)that protein studies are the best way to 
determine the effectiveness of an antisense approach in CML. In fact, we think that this is crucial.
How can Tari et al find that there is a selective decrease of p210BCR-ABL relative to p145C-ABL in 
BV173 when the cell line is p145C-ABL negative? What does this mean for the experiments performed 
in K562 and the specificity of the BCR-ABL antisense oligonucleotides in general. Using the same 
monoclonal antibody in flow cytometric analysis of BV173 after BCR-ABL antisense 
phosphorothioate treatment in which only viable cells were analysed, we observed a growth 
inhibitory effect but no decrease in cellular p210BCR-ABLlevels (5).
We would like these questions to be addressed. If the observation by Tari et al (2) holds, it may well 
be that BCR-ABL methylphosphonates are the best alternative antisense approach in CML. This 
would be an important contribution to this field of research.
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RESPONSE
G. Lopez-Berestein, A. Tari and A. Deisseroth.
We thank Drs Smetsers and Mensink for their very kind comments on our work published in the 
July 15, 1994 issue of Blood (1) In our report, we studied the effect of liposomal-MPs (MPs, 
methylphosphonate antisense BCR-ABL oligonucleotides) on the growth inhibition of CML cell 
lines. Exposure of K562 and BV173 cells to L-MPs targeted to the breakpoint junction of the Bcr- 
Abl mRNA inhibited specifically the growth of the CML cells and was associated with a decrease in 
the level of p210BCR-ABL protein. This effect was specific and selective and did not affect the transcript 
of the nonrearranged gene.
In response to the question posed by Drs Smetsers and Mensink regarding how we find that 
there is a selective decrease of p210BCR-ABL relative to p145C-ABL in BV173 when the cell line is 
p145C-ABL negative, we point out that the clones cited by them were negative, whereas others have 
found clones that are positive (2, 3). This variability in the relative expression of single-copy genes 
has been commonly obtained in established cell lines maintained in long-term culture.
They also ask what this means for experiments performed in K562 and the specificity of the BCR- 
ABL antisense oligonucleotides in general. In our experiments, we found the antiproliferative effect 
of the antisense oligonucleotides to be specific for the junctional sequence. These L-MPs are 
homologous to the mRNA transcript of bcr-abl but not the nonrearranged abl allele. The clear 
implication is that we observed a sequence specificity downregulation of the p210BCR-ABLprotein 
product that led to the inhibition of cell growth.
They also remark that, using the same monoclonal antibody in a flow cytometric analysis of 
BV173 cells after BCR-ABL antisense phosphorothioate treatment in which only viable cells were 
analysed, they observed a growth inhibitory effect but no decrease in cellular p210BCR-ABL levels. 
This is a common problem with antisense oligonucleotides. In many cases, the antiproliferative 
activity generated by antisense may be related to unexpected homologies with other transcripts.
Once again, we than Drs Smetsers and Mensink for raising these important questions.
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An antisense BCR-ABL phosphodiester tailed 
methylphosphonate oligonucleotide reduces the growth of 
chronic myeloid leukemia patient cells by a non antisense 
mechanism.
Toon F.C.M. Smetsers, Ellen H.P. Linders, Louis T.F. van de Locht, Theo M. de Witte and Ewald 
J.B.M. Mensink.
SUMMARY
The specificity of antisense oligonucleotides targeted to the mRNA breakpoint region of the bcr-abl 
oncogene found in leukemic cells from patients with chronic myeloid leukemia remains controversial. 
Especially phosphorothioate antisense oligonucleotides can induce non sequence specific effects 
caused by protein binding. Methylphosphonates due to a lack of charge show less non specific effects 
but are insoluble and therefore need to be packed into liposomes. For this reason we designed and 
tested a methylphosponate oligonucleotide with a 3' soluble phosphodiester tail attached to it. Growth 
of CML cell lines BV173, KCL-22 and cells of all of the four CML patients tested was inhibited to 
about 30% after treatment with the b2a2 type antisense BCR-ABL oligonucleotide. Control 
oligonucleotides did not inhibit cell growth of these cell lines. Also the growth of control CD34+ cells 
of two healthy donors and several control cell lines was not affected. Growth reduction of other 
leukemic cells as tested in four samples from acute myeloid leukemia patients was only moderate or 
absent. To study the mechanism of inhibition we investigated the effect of the oligonucleotides on the 
expression of the BCR-ABL and the cell death regulating proteins BAX, BCL-2 and p53. In a 
subpopulation of the treated cells the BCR-ABL protein was decreased. In these cells also actin was 
found decreased, indicating a non specific protein degradation. No evidence was found for 
involvement of p53 or of BAX/BCL-2 in the pathway towards programmed cell death. Growth 
reduction occurred by a blockade in the S phase of the cell cycle and cell death. We conclude that the 
antisense methylphosphonate BCR-ABL oligonucleotide tested is an inhibitor of the growth of CML 
cells and works in a non antisense manner.
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INTRODUCTION
Chronic myeloid leukemia (CML) is a myeloproliferative disorder originating in a hematopoietic 
stem cell. It is characterised by an accumulation of myeloid cells and their progenitors in the bone 
marrow. The presence of Philadelphia chromosome is the hallmark of 95% of clinical cases of CML. 
A reciprocal translocation t(9;22) between the long arms of chromosomes 9 and 22 (1) is responsible 
for the formation of this characteristic chromosome. As a result of the translocation the bcr gene and 
the c-abl gene are coupled and abcr-abl fusion gene is formed. This fusion gene is translated into a 
210 kDa protein that shows enhanced tyrosine kinase activity (2-4).
Because the breakpoints are conserved at mRNA level, they are a suitable target for an antisense 
approach using oligonucleotides. Antisense oligonucleotides are short (15-30 nt) synthetic DNA 
molecules that are designed to bind to their complementary mRNA and inhibit translation into protein. 
Ribosomal blockade and RNA degradation by a cytoplasmatic enzyme RNase H are thought to be the 
mechanisms responsible for this (5, 6).
A variety of antisense oligonucleotides targeted to the Bcr-Abl mRNA have been used, in most cases 
directed to the bcr-abl breakpoint. Unmodified antisense oligonucleotides were shown to reduce the 
growth of CML cell lines (7-9) and leukemic cells from CML patients (10-13). Components in serum 
can cause extensive degradation of unmodified oligonucleotides and thereby reduce their activity. 
Predominantly 3' exonuclease activity is responsible for the degrading effect (14). Modifications of 
the phosphodiester bond significantly increase stability in serum. Phosphorothioate oligonucleotides 
are much more stable in serum and are effective in reducing the growth of CML cell lines (15-17), 
but non sequence specific effects occur (16, 18, 19). This is probably caused by binding to proteins 
as a result of the negative charge of the oligonucleotides. Antisense phosphorothioates were shown to 
bind to protein (for review see ref (20)). The uncharged methylphosphonates were claimed to reduce 
cell growth by specific antisense effects (21). Liposomal delivery was necessary because the 
oligonucleotides are not soluble in aqueous solutions. In this study we used methylphosphonate 
oligonucleotides targeted to the Bcr-Abl mRNA breakpoint junctions. We tried to overcome liposomal 
delivery by adding a charged 3' phosphodiester tail to the oligonucleotides to make them soluble in 
culture medium. Effects of these oligonucleotides on the in vitro growth of CML, AML and normal 
cells were tested. The mechanism of growth inhibition was studied. The involvement of the p53 
protein in induction of cell death, especially generated by DNA damage was shown before (22). Also 
the relation between p53 and the BAX/BCL-2 regulated mechanism of programmed cell death was 
demonstrated (23, 24). To find evidence for the involvement of these regulatory systems in antisense 
generated cell death we measured the expression of the p53, BAX and BCL-2 at the protein level after 
antisense treatment.
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MATERIAL AND METHODS
oligonucleotides
Antisense oligonucleotides were synthesised and purified by the Eurogentec corporation 
(Eurogentec, Seraing, Belgium). They were dissolved in sterile IMDM, sterilised by filtration through 
a 0.22 mim spin filter (Costar, Cambridge, MA, USA). After concentration determination on a 
spectrophotometer the oligonucleotides were added to the cells in a concentration of 10 i^M.
The sequence of the oligonucleotides is as follows: 
aB2A2.21MET :5'- CTGAAGGGCTTCTTCCTTATT-3'
B2A2.21MET : 5'- AATAAGGAAGAAGCCCTTCAG-3' 
aB3A2.24MET : 5 - GGGCTTTTGAACTCTGCTTAAATC-3'.
Bold characters represent methylphosphonate linkages, plain characters represent normal 
phosphodiester linkages.
Cell lines and patient cells.
CML cell lines BV173 (25), K562 (26), LAMA-84 (27), KCL-22 (28) and KYO1 (29) as well as 
non CML cell lines Jurkat (30), HL-60 (31) and DOHH2 (32) were cultured in RPMI 1640 medium 
(Life technologies LTD, Paisley, Scotland) supplemented with 10% heat inactivated (56° C, 30 min) 
Foetal Calf Serum (Integro, Zaandam, The Netherlands), 2 mM L-glutamine , 50 IU/ml penicillin and 
50 H-g/ml streptomycin (Cellect®,ICN Flow, Irvine, UK) in a humidified incubator at 37° C with 5% 
CO2 in air. Nucleated cells of 15 ml bone marrow or peripheral blood from CML and bone marrow 
from AML patients were isolated and cryopreserved in the same way as CD34+ cells only the 
immunomagnetic bead selection was omitted. Cells were rapidly thawed in a 37° C water bath and 
suspended in ice cold IMDM by dropwise addition. Cells were washed once and resuspended in 
medium as described in the section "cell growth determination".
CD34+ cell selection
Bone marrow was aspirated from normal bone marrow donors after informed consent. Nucleated 
cells were isolated from the aspirate by Ficoll (Sigma) 1.077 g/ml density centrifugation. After 
washing twice in buffer, interphase cells were incubated for 45 min at 4° C with anti-CD34 BI3C5 that 
were directly coated onto M450 immunomagnetic beads (Dynal, Oslo, Norway)(cell/bead =2/1, in 1
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ml buffer). The rosetted cells were isolated by magnetic separation with 8 washing steps. To remove 
the beads the cells were diluted with Detach-a-Bead (Dynal, 10ml/100ml buffer) for 60 min at room 
temperature. The cells were removed in 3 washing steps with a magnet and resuspended in Iscove's 
medium (Flow Laboratories, Irvine, Scotland) with 10% (v/v) Fetal Bovine Serum (FBS, Hyclone, 
Logan, Utah, USA) and 15 U/ml preservative free heparin at a concentration of about 2 x 105 
cells/ml. This cell suspension was diluted twice with medium containing 20% DMSO (v/v) on ice. 
The cells were cryopreserved (Kryo 10, PlanerBiomed, Sunbury, Middlesex, UK) in 2 ml freezing 
tubes and stored at -198° C.
Antibodies
The following antibodies were used for flow cytometry as well as immunoblotting. Polyclonal 
rabbit antisera used were: anti actin (Zymed laboratories Inc, San Francisco, CA, USA), anti Ki-67 
(Dako, Glostrup, Denmark) and anti BAX P-19 (Santa Cruz Biotechnology, Santa Cruz, California, 
USA). The mouse monoclonal antibodies of the IgGI subclass were: anti CD2 TS2/18, anti BCL-2 
clone 124 (Dako) anti c-ABL 8E9 (a gift from Dr. J.Y.J. Wang University of California at San Diego, 
La Jolla, CA, USA) and anti CD34+ anti-HPCA-2 (Becton Dickenson, San Jose, CA, USA), directly 
conjugated to phycoerytherin. The mouse monoclonal antibody anti P53 DO-7 (Dako) is of the IgG2b 
isotype. Horseradish peroxidase conjugated goat anti mouse IgG1 or IgG2b (Southern Biotechnology 
Association Inc., Birmingham, AL, USA) and peroxidase conjugated goat anti rabbit (Jackson 
Immuno Research, West Grove, USA) were used as secondary antibodies in immunoblotting and 
used in 3000 fold dilution. The conjugates used for flow cytometry were a polyclonal goat anti 
mouse IgG1 conjugated with fluorescein isothiocyanate (FITC) (Southern Biotechnology 
Association, Birmingham, AL, USA) and was used in a 100 fold dilution. A polyclonal F(ab)2 goat 
anti rabbit conjugated with phycoerytherin (RPE) (Southern Biotechnology Association) was used at 
a 20 fold dilution.
SDS PAGE and immunoblotting.
Cells were washed once with phosphate buffered saline (PBS) containing 50 t^M Na3 V0 4  as a 
phosphatase inhibitor and resuspended at a concentration of 2 x 107 cells/ml in PBS containing 
Na3 V0 4 . Cells were boiled after addition of 2 x SDS sample buffer. One t^l of these extracts was 
applied to a 4 - 15 % gradient polyacrylamid gel (Phast System™, Pharmacia, Upsulla, Sweden). 
After electrophoresis the samples were blotted by diffusion for 1 hr at 60 ° C onto a 0.45 t^m nitro­
cellulose membrane (Schleicher & Schuell, Dassel, Germany) in blotting buffer (25 mM Tris, 192
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mM Glycine pH 8.3, 20 % methanol). Blocking buffer for immunological detection was prepared by 
heating 0.5 % NIP 552 blocking reagent (Amersham, Buckinghamshire, England) for 1 hr at 65° C. 
Blocking buffer was cleared by centrifugation and tween-20 was added to a final concentration of
0.05%. The membrane was blocked for 1 hr at room temperature (RT) in blocking buffer. The first 
antiserum was added to a final concentration of 2 ^ig/ml. The membrane was washed three times in 
PBS containing 0.05 % tween-20 and incubated for 1 hr at room temperature in 3000 fold diluted 
secondary antibody in blocking buffer. After 5 washes with PBS containing 0.05% tween-20, blots 
were developed using the ECL detection system (Amersham) and exposed to an X-ray film.
Cell Growth determination.
Cells plated at a density of 2 x 105 cells/ml in 96 wells flat bottom culture plates (Costar) in Iscove's 
modified Dubecco's medium (IMDM, Life technologies. Paisley, Scotland) containing 2 mM L- 
glutamine , 50 IU/ml penicillin and 50 ^tg/ml streptomycin, 2.5 % pooled human serum, and the 
recombinant growth factors 50 ng/^tl IL-3 (Sandoz, Pharma, Basel, Switzerland), 20 ng/ml G-CSF 
(Amgen, Thousand Oaks, CA, USA) and 20 ng/ml GM-CSF (Sandoz) in a humidified incubator at 
37° C with 5% CO2 in air.
Viable cell number was determined using flow cytometry (19, 33). To the wells 10 t^l of 50 times 
diluted viable dye calcein 1 mg/ml (Molecular Probes, Eugene, OR, USA) was added. After 15 
minutes incubation at room temperature 50 t^l of cell suspension was transferred to a tube containing 
fluorescent beads (Immunocheck, Epics division of Coulter, Hialeah, FL) in 500 t^l PBS. These 
beads were used as a calibration for analysis on a Coulter Epics XL-MCL Flow cytometer (Coulter, 
Hialeah, FL). All cells showing green fluorescence were considered viable cells. The viable cell 
number was determined by the relative amount of cells compared to beads.
Characterization of cells.
Bcr-Abl breakpoint type was determined by reverse transcriptase PCR as described before (19) . 
For flow cytometric analysis of protein expression, labelled cells were analysed on a Coulter Epics 
Flow cytometer (Coulter, Hialeah, FL, USA). A 40 mW Argon ion laser running at 15 mW with an 
emission of 488 nm was used. Dichroic mirrors of 550 nm and 625 nm and band pass filters of 
525/40, 575/30 and a long pass filter of 610 nm was used. A gate in forward scatter versus right 
angle scatter light scatter diagram was used to exclude dead dells and debris. Measurement of area 
versus peak intensities of PI fluorescence signal were used to exclude clumps of cells in DNA 
analysis. To standardise for fluorescence intensity green and red fluorescent beads (Calibrite, B&D,
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San Jose, Ca) were used. For cell cycle analysis cells were stained by addition of hypertonic 
propidium iodine solution to the cell pellet. This solution consisted of 1% (w/v) Sodium Citrate, 0.1 
mg/ml RNase A (Sigma), 0.1% Triton X-100 and 20 mig/ml Propidium Iodine (PI, Sigma). After 15 
min staining at 4° C red fluorescence was determined using flow cytometry.
RESULTS
Solubility o f tailed oligonucleotides.
Antisense methylphosphonate oligonucleotides of 15 nucleotide and longer are not soluble in 
aquaeous solutions. We modified the oligonucleotides described by Tari et al.(21). The 
oligonucleotides described by Tari et al. were dissolved in DMSO and packed in liposomes. The 
oligonucleotides used here contain an additional 5 nucleotide long phosphodiester tail at the 3' end of 
the oligonucleotide and could be dissolved in culture medium.
Effect on cell growth
The effect of the partial methylphosponate oligonucleotides on cell growth of several CML and non 
CML cell lines was determined in medium containing 10 % FCS at an oligonucleotide concentration 
of 10 miM. Figure 1A shows cell number of these cell lines after 6 days in culture. Sense control 
oligonucleotide B2A2.21MET showed no reduction of cell growth of any of the tested cell lines, even 
a small growth stimulation could be observed in cell lines DOHH2, HL-60 and KCL-22. Treatment 
with antisense oligonucleotide aB2A2.21MET resulted in a decrease in cell number of cell lines 
BV173 and also of KCL-22 to respectively 12% and 56% relative to the untreated control. Other cell 
lines were not affected. Oligonucleotide ocB3A2.24MET failed to inhibit the growth of any of the cell 
lines tested. The effect on BV173 was most prominent and was concentration dependent (data not 
shown). BV173 and KCL-22 are both cell lines with a B2A2 type breakpoint. The growth of these 
cell lines is inhibited by an antisense oligonucleotide targeted to this breakpoint. Cell line KYO1 also 
expresses a Bcr-Abl mRNA containing this breakpoint, but its growth is not affected by the 
oligonucleotide.
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Figure 1. A. Relative cell number of cell lines after 6 days of treatment with 10 of oligonucleotides B. Relative 
cell number of cells of CML patients and purified normal CD34+ cells after 6 days of treatment with 10 ^M of 
oligonucleotides. C. Relative cell number of cells of AML patients. =  Untreated 2  aB3A2.24MET UH 
B2A2.21MET I  aB2A2.21MET.
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Cells Name Sample % CD 34 Sex Breakpoint Remaining cells SD
Cell Lines BV173 10.4 B2A2 11.7 0.5
LAMA-84 0 B3A2 94.5 7.8
DOHH2 0 - 121.3 5.5
HL-60 0 - 116.5 3.5
K562 0 B3A2 106.3 3.5
KCL22 0 B2A2 56.2 6.3
JURKAT 0 - 84.2 4.6
KYO1 0 B2A2 119.8 1.4
CML samples WI BM Blast Crisis 38.5 M B3A2 19.6 2.8
WO BM 9 M B2A2 31.5 4.3
BO PB Blast Crisis 7.1 F B2A2 23.4 5.3
LA PB CP1 10.8 F B2A2 28.0 1.4
AML samples KO AML M5b 87.7 M - 75.8 1.3
LI AML M3 84.6 F - 73.7 1.9
HO AML M2 20 F - 103.4 11.0
SC AML M4e 15.9 M - 67.5 3.9
Normal CD34+ GE BM CD34+ >90 M - 103.0 3.5
PR BM CD34+ >90 F - 84.9 11.4
Table 1. Cell lines and patient cells characterization and sensitivity to treatment with aB2A2.21MET. %CD34: 
percentage of CD34+ cells in the sample determined by flow cytometry. Breakpoint: Bcr-Abl type mRNA expression 
determined by reverse transcriptase p C r. Remaining cells: percentage of cells remaining after treatment with 
oB2A2.21mEt relative to the untreated control.
Because the behaviour of CML cell lines in culture can be different from primary CML cells ( 3 4 ) we 
also tested cells from CML patients. CML patient cells were selected based on expression of the Bcr- 
Abl mRNA, presence of more than 5% CD34+ cells and in vitro growth of cells (Table 1). The four 
CML patient cells tested all showed a 20-30% reduced growth, relative to the untreated control, when 
treated with aB2A2.21MET (Figure 1B). Also sample WI containing CML cells expressing the other 
B3A2 type Bcr-Abl mRNA was affected, indicating that the aB2A2.21MET oligonucleotide 
inhibition is not breakpoint specific. Control cell line BV173 was drastically inhibited by 
aB2A2.21MET. The normal CD34+ cells were not inhibited at all by aB2A2.21MET. This 
oligonucleotide only showed a decrease of growth to about 70 % in three out of the four randomly 
chosen AML patient cells (Figure 1C). Oligonucleotide aB3A2.24MET showed similar effects but 
less drastic than aB2A2.21MET. Sense control oligonucleotide B2A2.21MET did not induce an 
effect on the growth of any of the tested cells.
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Effect on protein expression.
We used a flow cytometric assay to investigate whether the cell growth reduction by the tailed 
methylphosphonate oligonucleotide is caused by an antisense mediated reduction of the expression of 
the p210BCR-ABL protein as described before (19). Figure 2 shows flow cytometric analysis of BV173 
cell samples after 5 days of treatment with aB2A2.21MET and complementary sense oligonucleotide 
B2A2.21MET in medium containing 10% FCS. First expression of Bcr-Abl together with actin was 
determined (Figure 2, upper panel). Only in the antisense aB2A2.21MET treated cells a negative cell 
population with low expression of p210BCR-ABL could be detected. These cells however also had a low 
expression of actin. There were no cells expressing low amounts of only actin or only p210BCR"ABL\ 
This indicates that cells simultaneously express lower amounts of actin and p210BCR-ABL. A similar 
effect was observed in cell line KCL-22 only less, about 10% p210BCR-ABLnegative cells were present 
(Data not shown). Cell line KYO-1 and K562 showed no BCR-ABL negative cells after treatment 
(Data not shown).
We also tested the expression of BCR-ABL with respect to DNA staining in cell line BV173 
(Figure 2, lower panel). A population of p210BCR-ABL negative cells can be detected only in cells 
treated with antisense aB2A2.21MET. Cells with a low DNA staining are apoptotic cells. These cells 
all show a low p210BCR-ABL staining. Some cells with a normal DNA staining express normal 
p210BCR-ABL amounts, while others have a low p210BCR-ABL amount. There are no cells with low 
DNA staining that express normal p210BCR-ABL levels.
We analysed effect on protein expression also using an immunoblotting technique (figure 3). 
Cellular extract of BV173 and KCL-22 cells after 5 days of incubation with oligonucleotides were 
analysed using immunoblotting. Cellular extract of K562 after 2 days of treatment with Herbimycin A 
was used as a control for decrease in p210BCR-ABL expression. Indeed after immunoblotting and 
screening with the anti-abl antibody 8E9 the relative expression of p210BCR-ABL with respect to p145C- 
ABL was reduced in the Herbimycin A treated K562 cells. This however was not the case in antisense 
treated KCL-22 cells. In BV173 the relative expression could not be determined because this cell line 
does not express the normal p145C-ABL.
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BCR-ABLFigure 2. Flow cytometric analysis of expression p210 in cell line BV173 after 5 days of treatment with
oligonucleotides. AS : aB2A2.21MET SE: B2A2.21MET. NT^notüeated. Upper panel: expression of p210BCR 
relative to Actin expression. Lower panel: expression p210 relative to DNA.
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Figure 3. Immunoblot assay of cellular extracts of cell line BV173 and KCL-22 after 5 days of treatment with 
oligonucleotides and K562 after 2 days of treatment with Herbimycin A. AS: OB2A2.21MET SE: B2A2.21MET. NT: 
not treated. Herb A: Herbimycin A treatment. mut: mutant protein.
Effect on cell cycle.
Growth inhibition often occurs by a blockade of the cell cycle. To provide information on the type of 
growth inhibition induced by antisense aB2A2.21MET oligonucleotide treatment we investigated the 
effect on the cell cycle. Cell lines BV173, KCL22 and K562 were incubated with the 
oligonucleotides. After 5 days of incubation, effects on cell cycle were determined using a staining of 
the DNA with propidium iodine and flow cytometric analysis (figure 4). The DNA histograms of cell 
lines BV173 and KCL22 treated with aB2A2.21MET both showed more cells in the S-Phase of the 
cell cycle than untreated cells. The DNA histogram of cells treated with control oligonucleotides 
B2A2.21MET and ocB3A2.24MET was the same as of the untreated cells. In cell line BV173 also 
cells staining low for PI were detected, indicating the presence of apoptotic cells. The DNA histogram 
of ocB2A2.21MET and the control oligonucleotides treated K562 was identical.
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Figure 4. Analysis of DNA content in cell lines after 5 days of treatment with 10 |jM oligonucleotides.
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Mechanism of programmed cell death.
Cell line BV173 is the most sensitive cell line for treatment with aB2A2.21MET. It is also the only 
CML cell line tested here expressing a wild type p53 protein. We therefore tested if a p53 and BAX 
mediated mechanism is involved in cell death observed in this cell line after treatment with 
0CB2A2.21MET. We did this by immunoblotting of cell extracts of samples containing apoptotic cells 
after 5 days of treatment with oligonucleotides (figure 3). Although the expression is low, in extracts 
of cell line BV173 two bands of the wild type p53 protein could be detected, probably representing 
the two different phosphorylated forms of the protein (35). KCL-22 shows a much smaller protein, 
but the expression is very high relative to the expression in BV173. This is the result of a mutation 
that probably resultis in a truncated and much more stable protein (36). No induction of the 
expression of the p53 protein after treatment with aB2A2.21MET and the sense control 
oligonucleotide was observed. We also did not observe an induction of BAX protein expression after 
incubation with aB2A2.21MET, even a slight decrease of BAX expression could be detected in 
aB2A2.21MET treated BV173 cells. Because the ratio of BAX/BCL2 protein seems important in the 
regulation of cell death (37, 38) we also determined the BCL-2 protein expression on the same blot. 
The BCL-2 protein expression remained unchanged in all samples treated.
DISCUSSION
Non sequence specific effects are associated with the use of antisense phosphorothioate 
oligonucleotides for targeting the Bcr-Abl mRNA junction (16, 18, 19). These non sequence specific 
effects of phophorothioate oligonucleotides are most likely a result of protein binding as a result of 
their charge. Methylphosphonate oligonucleotides are uncharged compounds. They were claimed to 
specifically inhibit the expression of the p210BCR-ABL protein in CML cell lines (21), although some 
doubt on the specificty exists (39). The uncharged methylphosphonates seem to be a good alternative 
for targeting the Bcr-Abl mRNA junction (17). Liposomal delivery however is necessary because the 
oligonucleotides are not soluble in aqueous solutions. In this study we used a normal phosphodiester 
tail attached to methylphosphonate oligonucleotides that were targeted to both Bcr-Abl breakpoint 
junctions. These hybrid oligonucleotides are soluble in culture medium and can be added to the cells 
in culture medium without the use of liposomes. As shown earlier, the phosphodiester tail is highly 
sensitive to nuclease degradation (17). In our antisense experiments we defined an oligo to be 
effective and specific when growth reduction occurred after incubation whereas the corresponding 
sense oligonucleotide did not show growth reduction. When added to the cells the aB2A2.21.MET
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oligonucleotide reduces the cell growth of CML cell lines BV173 and KCL-22 and of all four CML 
patients tested. Control cell lines and CD34+ cells of healthy donors were not affected. Growth of 
cells of AML patients was not or only slightly reduced. The sense control oligonucleotide 
B2A2.21.MET had no effect on growth of any of the cell lines tested, CML and AML patient cells 
and normal CD34+ cells. The antisense oligonucleotide aB3A2.24M had no effect on any of the cell 
lines tested, showed a minor reduction of the cell growth of the CML patient cells and did not affect 
growth of CD34+ cells and AML cells. aB2A2.21MET is a specific inhibitor of the growth of CML 
cells but does not show breakpoint specificity since cells of one CML patient (WI) carrying a B3A2 
type Bcr-Abl mRNA junction are also inhibited by the oligonucleotide. The growth of cell line KYO-
1, also expressing the complementary B2A2 type mRNA is not inhibited by this oligonucleotide. The 
effect observed in BV173 and KCL-22 could therefore be caused by a non specific effect.
In case of a true antisense mechanism leading to inhibition of translation, we expect the expression 
of the targeted protein to be decreased, whereas the expression of other proteins is not affected. To 
test if inhibition of translation of the p210BCR-ABL protein is responsible for the growth inhibitory 
effect of the antisense oligonucleotide aB2A2.21MET we tested the expression of this protein by 
flow cytometry and immunoblotting. Flow cytometric analysis showed that a p210BCR-ABL expression 
is decreased in a number of treated BV173 and KCL-22 cells but the expression of the housekeeping 
gene actin is also decreased in the same population. This indicates that a non specific protein decrease 
is going on in a population of the treated cells. Protein decrease occurs before the cells show DNA 
condensation and go into apoptosis. Also immunoblotting showed that in cell line KCL-22, that is 
growth inhibited, there is no specific protein decrease of p210BCR-ABL compared to the normal p145C-
ABL protein expression.
Cell line BV173 is the most sensitive cell line to treatment with the a  B 2A 2.21M ET 
methylphosphonate oligonucleotide. It is also the only CML cell line tested that expresses a wild type 
p53 (36). The p53 protein plays a crucial role in the induction of cell death, especially generated by 
DNA damage (22). Since p53 can detect single stranded DNA ends (40) it could well be that addition 
of antisense oligonucleotides to cells activates a p53 response. One mechanism by which p53 
regulates programmed cell death is by a direct positive effect on the expression of BAX protein and a 
negative effect on the BCL-2 potein (23, 24). For these reasons we investigated the expression of 
p53, BCL-2 and BAX in antisense treated cells. No evidence for p53 and BAX/BCL-2 mediated cell 
death however could be found, since the expression of the Bax and p53 protein was not increased in 
treated cells. p53 is also known to stop the cell cycle in late G1 phase (41). This however is not the 
case for the BV173 and KCL-22 cells treated with aB2A2.21MET. Cells that are growth inhibited 
show a higher percentage of the cells in the S-Phase of the cell cycle. Since there are less cells present 
it is likely that the cells are frozen in S-phase. As a consequence, involvement of a p53 mediated cell
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death mechanism seems unlikely. This could be an advantage because many CML patient cells, 
especially in blast crisis show loss of function or mutation of the p53 protein. This reduces the 
sensitivity for radiation treatment or certain types of cytostatics.
Oligonucleotide aB2A2.21MET is a specific inhibitor of the growth of CML cells. An antisense 
mechanism however is not responsible for this growth inhibition. Many differences exist of the tailed 
oligonculeotide compared to liposomal packed full methylphosphonates with respect to the growth 
inhibition (21). Full methylphosphonate oligonucleotides were able to reduce the growth of cell line 
K562, while tailed oligonucleotides are ineffective in growth reduction of K562. The untailed 
oligonucleotides show a specificity for the two breakpoint types whereas the oligonucleotide 
a  B2A2.21MET does not. The use of liposomes however is likely to target the oligonucleotides 
directly to the cytoplasm. This can increase the specificity of the oligonucleotides in an antisense 
mediated effect. It is however possible that the effects observed by these liposome encapsulated 
oligonucleotides are a mixture of antisense and non antisense mediated effects on the cells. The use of 
the tailed oligonucleotide a  B2A2.21MET has the advantage above the liposome encapsulated 
oligonucleotide that it is more easy to prepare and it reduces the growth of both breakpoint types of 
CML cells.
There are also differences between phosphorothioate BCR-ABL antisense oligonucleotides and 
these methylphosphonate oligonucleotides in the treatment of cell lines. The effect of 
methylphosphonates is not dependent on cell density while the effect induced by phosphorothioates is 
(data not shown). It was shown that cell line KCL-22 is not sensitive to treatment with 
phosphorothioates (18), while methylphosphonates can reduce the growth of this cell line. Both types 
of oligonucleotides however are not specific for the two Bcr-Abl breakpoints and both are involved in 
a non antisense effect (16, 18, 19). After treatment with methylphosphonate aB2A2.21MET a 
p210BCR-ABL and actin negative cell population can be observed. This is not observed after treatment 
with phosphorothioate antisense BCR-ABL oligonucleotides.
Phosphorothioate and methylphoshonates oligonucleotides of the aB2A2 breakpoint type both 
show activity and are also more effective than aB3A2 oligonucleotides. It was suggested that the 
b3a2 mRNA is less accessible to the antisense oligonucleotides (42). Since no protein decrease exists 
it is also possible that hybridisation to another mRNA occurs. CML cells might be more sensitive to 
inhibition of this putative mRNA and the oligonucleotides could therefore not be available for 
hybridisation to the Bcr-Abl mRNA.
Whatever the mechanism of growth reduction is, the oligonucleotide aB2A2.21MET specifically 
reduces the growth of CML cells and seems a potential cytostatic drug for purging of CML bone 
marrow.
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Bias in nucleotide composition of antisense 
oligonucleotides.
Toon F.C.M. Smetsers, Jan B.M. Boezeman and Ewald J.B.M. Mensink.
ABSTRACT
In this study we investigated if specific sequence motifs occur with a higher frequency in antisense 
oligonucleotides than can be expected on the basis of the mRNA composition to get an impression on 
the importance of these motifs for antisense effects. Computer analysis of 206 antisense 
oligonucleotides extracted from literature and from sequence databases, all targeted against human 
mRNA was performed. We compared the sequence composition of these oligonucleotides with the 
average of 100 equally large and randomly selected sequences from sequence databases and of their 
target mRNA's. We found that the frequency of sequence motifs containing GG, CCC, CC, GAC 
and CG is significantly higher and TT and TCC is significantly lower in antisense oligonucleotide 
sequences than in the randomly selected mRNA sequences. We conclude that there is a bias in the 
nucleotide composition of antisense oligonucleotides.
Some of these biased sequence motifs have been reported to induce non antisense effects mediated 
by protein binding. Further analysis of the biological function of these motifs is necessary to 
investigate if they should be avoided or incorporated in future design of therapeutic effective 
oligonucleotides.
INTRODUCTION
Antisense oligonucleotides have frequently and successfully been used in a number of biological 
models in an attempt to modulate gene expression. If translation of the mRNA is inhibited, reduction 
of the expression of the corresponding protein should be observed. Recent publications however 
show that in some cases the antisense effect is not caused by an antisense mediated inhibition of 
translation of mRNA. A number of specific motifs of two (1), three (2, 3) four nucleotides (4, 5) or 
polynucleotides (6-8) present in antisense oligonucleotides were found to be responsible for non 
sequence specific effects. In most cases these nucleotide motifs induce a biological effect that is 
caused by protein binding (9, 10). Both normal and phosphorothioate oligonucleotides are charged 
compounds that can bind proteins. In this study we analysed the composition of antisense 
oligonucleotides to investigate if particular nucleotide sequence motifs are preferentially used and to
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get an impression of the importance of certain sequence stretches in the effects induced by antisense 
oligonucleotides.
MATERIALS AND METHODS
Sequence analysis was performed using the Genetics Computer Group (GCG) software running 
on a Challenge L ultrix computer (Silicon Graphics Systems) at the CAOS/CAMM Center Nijmegen 
The Netherlands. For calculation a program called Compositor was used. Random selection of 
sequences and calculation of frequencies was performed using the program Compositor. This was 
written using Hypercard 2.1 (Apple Computer inc. Cupertino, CA).
Selection of oligonucleotide sequences.
Phosphodiester and phosphorothioate antisense oligonucleotides were selected from literature until 
November 1994 based on their effectivity. No selection was made on the type of effect, all antisense 
oligonucleotides claimed to induce an effect by the authors were used. Only oligonucleotides targeted 
against human mRNA sequences were selected. Also antisense oligonucleotides from the 
GENESEQN patented sequence database were used. After this selection we checked the antisense 
sequences for doubles. Of antisense oligonucleotides with corresponding sequence but with a length 
difference, only the smallest effective antisense oligonucleotide was used. Of sets of oligonucleotides 
that had only one or two bases difference, one of the oligonucleotides was used. After these 
selections we ended up with 100 oligonucleotides from literature and 106 from the sequence 
databases (see appendix)
Selection of mRNA sequences.
The Sequence Retrieval System (SRS version 3.1) present in the GCG software package was used 
for several sequence selections from the sequence databases, the European Molecular Biology 
Laboratory EMBL (version 40: 21 October 1994) and the EBMLNEW (version 40: 16 November 
1994). We constructed six separate databases. One of total mRNA, two separate databases containing 
relevant human mRNA target sequences that contained the complete coding sequence (CDS), the 
keywords used were: human not virus complete CDS. The mRNA's containing the complete CDS 
were saved. A database, called -50/END CDS, was created from 1522 mRNA's using a region from 
-50, with respect to the initiation codon up to the translation stop codon. Because many antisense 
oligonucleotides are directed against the translation start region we analysed this region in more detail
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by selecting two areas around the translation start. The subsequent databases were called -10/30 
CDS, containing 2102 sequences from -10 to 30 and +4/30 CDS, containing 2789 sequences from 
+4 to 30 with respect to the initiation codon. Some antisense oligonucleotides are targeted against 
mRNA splice sites. We therefore selected regions containing 5' and 3' splice sites of human RNA's 
and DNA's. Keywords used in this selection were: Human Exon not virus. 11014 sequences were 
found. The first and the last 9 nucleotides of the exons were selected and exported. The databases 
were called 9nt 5'exon (9404 sequences) and 9nt 3'exon (9436 sequences) respectively. We used 
the SRS system to select for the mRNA's complementary to the investigated antisense 
oligonucleotides. This selection was done by name. We also used the program FASTA to look for 
complementary sequences. Not for all antisense oligonucleotides the complementary sequence could 
be found. Therefore only the available 178 sequences were used.
RESULTS
Because antisense oligonucleotides are often targeted to the initiation codon we compared the 
trinucleotide frequency in this region (-10/30 CDS) with the trinucleotide frequency from the whole 
coding mRNA sequence (-50/END CDS) (data not shown). Some trinucleotides (ATG, TGG and to 
a lesser extent GCC and GGC) were more frequently found in the translation start region (-10/30 
CDS) than in the total mRNA (-50/END CDS). This is not surprising since the translation initiation 
region contains a consensus sequence that is necessary for ribosome initiation. This so called Kozak 
sequence is composed of (GCC)GCCAGCCATGG (the initiation codon is underlined) (11). To 
avoid a bias by preference for these trinucleotides we excluded nucleotides up to 4 in the initiation 
region of the mRNA's (+4/30 CDS). We repeated the sequence trinucleotide comparison (data not 
shown) and the higher frequency of the trinucleotides was nearly lost. To compare the nucleotide 
composition of antisense oligonucleotides with human mRNA's we removed all nucleotides up to +4 
from the selected antisense oligonucleotides. The average length of the remaining oligonucleotides 
was 17.2 nucleotides. To compare the composition of these oligonucleotides with that of normal 
mRNA's the Compositor program randomly selected 206 sequences out of the total mRNA's (­
50/END CDS). This number equals the number of antisense oligonucleotides we extracted from the 
sequence databases and literature. From each mRNA the program randomly selected a region with a 
length of 17 nucleotides. From 100 drawings of 206 sequences we determined the frequency of 
mono, di, tri and tetranucleotides. From these frequencies we determined the average and standard 
deviation. The same random selection and frequency analysis was performed on the 176 target 
mRNA sequences, for this in all 100 drawings the same 176 target mRNA's were used. We 
compared the frequency of mono, di, tri and tetranucleotides of the antisense oligonucleotides, both
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with (AS +KOZAK) and without the Kozak sequences (AS -KOZAK), with the average frequency 
of the random selections. Because the mRNA sequences are complementary to the sequences of 
antisense oligonucleotides we used the reverse complement of the mRNA sequences in all analyses. 
The sequence motifs in antisense oligonucleotides whose frequency exceeded 3 or more standard 
deviations (SD) from that in random sequences (table 1) were analysed in more detail. It appears that 
the frequency distribution of the tested sequences relatively equals the statistical normal distribution 
(data not shown). Because of the large number of drawings, we used the statistical normal 
distribution for determination of the significance of the frequency differences. Only nucleotide motifs 
found to be significantly different (3 SD or more) are depicted in table 1. The frequency of the 
sequences containing the motifs GG, CCC, CC, GAC and CG is significantly higher in antisense 
oligonucleotides than in the randomly selected sequences (Table 1). The frequency of the sequences 
containing TT and TCC is much lower in antisense oligonucleotides. Generally the same differences 
were found when the frequency of these sequences were compared with the frequency in their own 
complementary mRNA targets (Table 1).
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Sequence Frequency (% of total)
CDS + SD Target ± SD Oligo + ] Oligo - \
Difference (x SD) Significance (p value)
+ ] - ] Oligo + ] Oligo - ]
GG 7 8 6 8 0 5 8 1 8 6 1 0 0 6 5 4 9 6 4 9 9 9 2 5 3 0 6 5 3 5 4 1 0 . 0 0 1 0 7 0 . 0 0 0 2 0 0 1
GGC 2 2 1 1 0 2 6 4 2 3 0 1 0 2 8 3 3 4 7 0 3 1 0 3 4 7 6 6 3 3 7 6 0 . 0 0 0 0 0 0 9 6 8 0 . 0 0 0 3 7 5 8
GGG 2 0 6 0 0 3 6 9 2 7 1 2 0 4 1 7 3 2 7 6 3 4 2 3 3 2 9 9 3 6 9 7 0 . 0 0 0 5 0 0 9 0 . 0 0 0 1 1 2 1
CGG 1 1 7 9 0 1 9 9 1 2 6 0 0 2 2 9 1 8 8 8 1 9 1 9 3 5 5 7 3 7 1 5 0 . 0 0 0 1 8 5 4 0 . 0 0 0 1 7 8 5
GAGG 0 5 8 5 0 134 0 6 9 4 0 1 8 0 1 0 6 2 1 0 6 2 3 5 5 6 3 5 6 2 0 . 0 0 0 1 8 5 4 0 . 0 0 0 1 8 5 4
CCGG 0 3 4 8 0 105 0 3 8 0 0 1 2 6 0 7 3 7 0 7 5 4 3 7 0 5 3 8 6 4 0 . 0 0 0 1 0 3 6 0 . 0 0 0 0 5 6 6 9
GCCC 0 5 4 7 0 144 0 5 9 6 0 1 5 9 1 2 6 8 1 1 3 1 5 0 1 7 4 0 6 3 <0 . 0 0 0 0 0 0 3 0 1 9 0 . 0 0 0 0 2 5 6 1
CCCG 0 3 1 9 0 1 0 7 0 3 8 3 0 1 0 6 0 8 2 6 0 9 6 0 4 7 2 7 5 9 7 5 0 . 0 0 0 0 0 1 1 2 3 < 0 0 0 0 0 0 0 3 0 1 9
CCCT 0 3 9 1 0 1 2 1 0 5 1 2 0 1 6 0 0 7 9 6 0 8 5 7 3 3 3 6 3 8 3 5 0 . 0 0 0 4 5 0 1 0 . 0 0 0 0 6 4 0 7
ACCC 0 2 4 3 0 102 0 2 3 3 0 1 0 0 0 7 9 6 0 9 2 5 5 4 4 1 6 7 1 2 <0 . 0 0 0 0 0 0 3 0 1 9  <0 0 0 0 0 0 0 3 0 1 9
AGCC 0 5 5 4 0 1 4 1 0 4 5 2 0 1 22 1 0 3 2 1 0 6 2 3 3 9 7 3 6 1 1 0 . 0 0 0 3 4 9 5 0 . 0 0 0 1 5 9 1
CCGG 0 3 4 8 0 105 0 3 8 0 0 1 2 6 0 7 3 7 0 7 5 4 3 7 0 5 3 8 6 4 0 . 0 0 0 1 0 3 6 0 . 0 0 0 0 5 6 6 9
GACC 0 2 7 3 0 0 8 0 0 3 2 4 0 1 1 7 0 7 0 8 0 7 5 4 5 4 0 4 5 9 7 8 <0 . 0 0 0 0 0 0 3 0 1 9  <0 0 0 0 0 0 0 3 0 1 9
GGAC 0 3 3 6 0 1 0 3 0 3 7 3 0 1 2 8 0 6 7 8 0 6 5 1 3 3 3 6 3 0 7 1 0 . 0 0 0 4 1 8 9 0 . 0 0 1 1 0 7
AGAC 0 2 8 5 0 0 9 4 0 3 0 5 0 1 0 6 0 5 6 0 0 6 1 7 2 9 2 4 3 5 2 6 0 . 0 0 1 8 0 7 0 . 0 0 0 2 0 7 8
GACC 0 2 7 3 0 0 8 0 0 3 2 4 0 1 1 7 0 7 0 8 0 7 5 4 5 4 0 4 5 9 7 8 <0 . 0 0 0 0 0 0 3 0 1 9  <0 0 0 0 0 0 0 3 0 1 9
GACG 0 1 7 1 0 0 7 5 0 1 6 6 0 0 8 6 0 5 0 1 0 4 1 1 4 4 1 7 3 2 1 3 0 . 0 0 0 0 0 4 9 3 5 0 . 0 0 0 6 6 3 7
CG 3 6 3 0 0 3 8 9 3 6 1 6 0 3 8 6 4 6 9 3 4 8 2 8 2 7 3 2 3 0 7 7 0 . 0 0 3 1 6 7 0 . 0 0 1 0 7
CGG 1 1 7 9 0 1 9 9 1 2 6 0 0 2 2 9 1 8 8 8 1 9 1 9 3 5 5 7 3 7 1 5 0 . 0 0 0 1 8 5 4 0 . 0 0 0 1 7 8 5
CCCG 0 3 1 9 0 1 0 7 0 3 8 3 0 1 0 6 0 8 2 6 0 9 6 0 4 7 2 7 5 9 7 5 0 . 0 0 0 0 0 1 1 2 3 < 0 0 0 0 0 0 0 3 0 1 9
CCGG 0 3 4 8 0 105 0 3 8 0 0 1 2 6 0 7 3 7 0 7 5 4 3 7 0 5 3 8 6 4 0 . 0 0 0 1 0 3 6 0 . 0 0 0 0 5 6 6 9
GACG 0 1 7 1 0 0 7 5 0 1 6 6 0 0 8 6 0 5 0 1 0 4 1 1 4 4 1 7 3 2 1 3 0 . 0 0 0 0 0 4 9 3 5 0 . 0 0 0 6 6 3 7
CCGG 0 3 4 8 0 105 0 3 8 0 0 1 2 6 0 7 3 7 0 7 5 4 3 7 0 5 3 8 6 4 0 . 0 0 0 1 0 3 6 0 . 0 0 0 0 5 6 6 9
T 25 3 5 2 0 8 2 5 24 6 1 0 0 9 4 3 23 0 5 0  22 5 1 7 - 2 7 9 2 - 3 4 3 8 0 . 0 0 2 6 3 5 0 . 0 0 0 3 0 1 8
TT 6 9 0 2 0 5 5 1 6 8 9 0 0 6 2 8 5 0 0 8 5 1 8 7 - 3 4 3 9 - 3 1 1 3 0 . 0 0 0 3 0 1 8 0 . 0 0 0 9 3 5 4
TTC 2 2 3 0 0 2 2 8 2 0 2 9 0 2 8 4 1 6 1 0 1 5 9 9 - 2 7 2 6 - 2 7 7 3 0 . 0 0 3 1 6 7 0 . 0 0 2 8 9
ATTC 0 3 6 3 0 0 9 4 0 3 5 0 0 1 3 3 0 0 8 8 0 0 6 9 - 2 9 1 5 - 3 1 2 6 0 . 0 0 1 8 0 7 0 . 0 0 0 3 9 6 7 6
CTTG 0 6 5 2 0 1 3 1 0 5 8 0 0 1 4 1 0 2 6 5 0 2 4 0 - 2 9 5 7 - 3 152 0 . 0 0 1 8 6 6 0 . 0 0 8 1 6 4
TCCA 0 8 2 9 0 1 5 6 0 6 8 5 0 1 55 0 1 7 7 0 2 0 6 - 4 175 - 3 9 9 2 0 . 0 0 0 0 1 5 9 1 0 . 0 0 0 3 3 0 4
GTCC 0 5 1 4 0 135 0 5 0 7 0 1 6 6 0 1 4 7 0 1 3 7 - 2 7 2 4 - 2 8 0 1 0 . 0 0 3 2 6 4 0 . 0 0 1 9 8 8
TCAT 0 6 2 6 0 1 2 8 0 4 7 1 0 1 4 6 0 2 9 5 0 2 0 6 - 2 5 9 0 - 3 2 8 9 0 . 0 0 4 9 4 0 . 0 0 0 5 1 9
TATA 0 1 6 1 0 0 7 8 0 2 0 4 0 1 1 9 0 4 1 3 0 4 8 0 3 2 2 1 4 0 7 5 0 . 0 0 0 6 4 1 0 . 0 0 0 0 2 3 5 1
Table 1. Frequency of nucleotide motifs in antisense oligonucleotides compared to human mRNA's 
and complementary target mRNA's. For mRNA sequences the reversecomplemented sequence was used.
CDS: mRNA selections of coding sequences of human mRNA's. Target: selections of the complementary target 
sequences of the investigated antisense oligonucleotides. +K/-K: Antisense oligonucleotides with Kozak sequence or 
with Kozak sequences removed respectively.
112
Chapter 6: Bias in antisense oligonucleotide composition.
DISCUSSION.
The aim of antisense strategy is to inhibit the translation of the targeted mRNA into protein. An 
antisense strategy is defined to be effective when the antisense oligonucleotide induces a biological 
effect whereas control oligonucleotides do not. In several studies the expression of the protein was 
not studied. Recently several reports demonstrated that many putative antisense effects are not only 
caused by an antisense mediated inhibition of translation (2, 4, 12, 13).
We analysed the composition of antisense oligonucleotides to investigate if some nucleotide 
sequence motifs are over represented or under represented, to get an impression of the function of 
sequence stretches in antisense oligonucleotides and the effect they cause. We found that sequence 
motifs containing GG, CCC, CC, GAC and CG occur more frequently in antisense oligonucleotides 
than in coding regions of human mRNA's. These differences are not due to the presence of the 
Kozak sequence, because this was omitted. This bias was also not caused by a relative frequent use 
of the intron/exon boundary as a target for antisense oligonucleotides because the investigated intron 
and exon boundaries (9nt 3' exon and 9nt 5' exon, data not shown) do not show a higher frequency 
for these motifs. Also, comparison to the corresponding mRNA sequences showed that antisense 
oligonucleotides show higher frequencies for these sequence motifs than their mRNA targets. The 
sequence bias as observed in antisense oligonucleotides therefore cannot be explained by the presence 
of a sequence bias in the target mRNA molecules.
The sequences GG, GGG and GGC in antisense oligonucleotides are the most important since 
they are present at a frequency of respectively 9.9 %, 3.4 % and 3.1% in antisense oligonucleotides. 
If a nucleotide motif is important for efficacy of antisense function in general, it is expected to be 
present at a high frequency in the sequence database of effective antisense oligonucleotides. Also the 
sequence CG is present at a higher percentage in antisense oligonucleotides than in mRNA's (4.7 %). 
Motifs of two and three C's and the sequence GAC are found more often in antisense 
oligonucleotides than in their mRNA counterparts. The percentage of occurrence of these sequences 
in antisense oligos is low, but one can speculate that in a 15-20 mer antisense oligonucleotide there is 
still a reasonable chance of occurrence of a sequence motif with a low frequency of about 1%. For 
example we counted that the sequence GACG, with an overall frequency of occurrence of 0.41%, is 
present in 10 % of the studied 206 antisense oligonucleotides. This illustrates that sequences 
occurring at a low frequency can still be of importance.
The biased sequence motifs have a higher G or C percentage. This results in a higher melting 
temperature of RNA/DNA hybrids. Not all tri and tetranucleotides investigated with a high G or C 
percentage were found significantly more often in the reverse complement of antisense
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oligonucleotides (not shown), but only the ones depicted in table 1. An example is the motif GTCC 
that was found significantly less often in the reverse complement of antisense oligonucleotides than in 
mRNA's (table 1). This indicates that the higher G or C content in biological effective antisense 
oligonucleotides is not solely based, if based at all, upon the concomitant higher melting temperature.
As a prerequisite, sense oligonucleotides most often used as a control for the effects of the 
antisense oligonucleotide are ineffective in the published studies. In this study the frequency of the 
reverse complement of the antisense sequences represents the frequency of the ineffective sense 
oligonucleotide sequences. Surprisingly also the biased sequence stretches are found with a higher 
frequency in sense oligonucleotides. An example is the sequence CG that is the same in the sense and 
the antisense oligonucleotide and therefore has the same frequency in both of them. These sequences 
are therefore not solely responsible for non antisense effects observed in some studies.
It is likely that the identified sequence motifs have biological significance. This can be by 
enhancing antisense or non antisense functions. Involvement of stretches in non antisense 
mechanisms was already demonstrated for the sequence GGC in antisense oligonucleotides. This 
sequence motif is responsible for binding the p210BCR-ABL tyrosine kinase protein and reduction of its 
activity in vitro and in vivo (2, 14) . Our finding that this sequence is present at a higher frequency in 
antisense oligonucleotides suggests that more antisense oligonucleotides induce effects that are 
caused by inhibition of tyrosine kinases. Another sequence found to have a biological significance is 
the sequence CG (2). It was recently shown that this sequence induces B-cell proliferation due to a 
mitogenic stimulus. This sequence is also found relatively more often in antisense oligonucleotides 
than in their mRNA counterparts. Also motifs of two or three G's can induce biological effects (3, 4) 
and are found more frequently in antisense oligonucleotides (GG and GGG in table 1). For the 
sequence GAC, also present at a higher frequency in antisense oligonucleotides, no biological 
significance has been reported yet. Also no biological effect was reported of the sequences TT and 
TCC, that are found less often in the reverse complement antisense oligonucleotides.
As some of the biased sequence motifs were shown to exert biological effects, one could speculate 
that antisense oligonucleotides were therefore selected for having these sequences. Not all biological 
significant sequence motifs however occur at a higher frequency in antisense oligonucleotides. The G 
quartet, known to be effective in HIV inhibition (5, 15) and found in c-myc and c-myb antisense 
oligonucleotides (4) is found with equal frequency in antisense oligonucleotides relative to mRNA's 
(not shown).
Most effects observed in literature of antisense studies probably are caused by a mixture of true 
antisense and other effects. The sequences as identified in this study are important for antisense 
effectivity mediated by non antisense as well as antisense mechanisms, for example by increasing 
uptake or changing cellular localization.
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We conclude that there is a bias in the sequence composition of antisense oligonucleotides 
compared to human mRNA's and their complementary mRNA sequences. Biased sequence motifs 
probably play a role in effectivity of the oligonucleotides. This can be by enhancing antisense or non 
antisense mechanisms or factors like uptake and localisation. Non antisense involvement of some 
sequences stretches was already determined for some of them (1, 2, 4). Determining the function of 
the sequence motifs is important for the design of therapeutically effective DNA oligonucleotides in 
future.
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NOTE:
The Compositor software, a table with mono, di, tri, and tetra nucleotide frequency distribution of 
antisense oligonucleotides and mRNA's, a table of the 206 selected antisense oligonucleotides can be 
obtained by sending e-mail request : "compositor" to t.smetsers@chl.azn.nl. Only a Macintosh 
version is available. The tables are given in the appendix section of this thesis.
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INTRODUCTION
Chronic myeloid leukemia (CML) is a disorder of hemopoietic stem cells characterised by anemia, 
extreme peripheral blood granulocytosis with immature granulocyte forms, basophilia, 
thrombocytosis and splenomegaly. Currently the only ‘curative’ therapy is allogeneic bone marrow 
transplantation and without this intervention the disease is invariably fatal (1). About 95% of patients 
with CML, and about 10% of patients with acute lymphoblastic leukemia, have the Philadelphia 
chromosome (2) which represents part of a reciprocal translocation between chromosomes 9 and 22 
(3) (figure 1). This t(9;22) (q34;q11) translocation results in the juxtaposition of sequences of the abl 
gene, located on chromosome 9, to sequences of the BCR gene on chromosome 22 giving rise to a 
new bcr-abl chimeric gene at the genomic level (see figure 2). In a proportion of cases the 
complementary ABL-BCR chimeric gene, located on chromosome 9, is also expressed (4) although 
the corresponding protein has been difficult to consistently demonstrate. One of two Bcr-Abl mRNA 
transcripts of approximately 8.5 kb is found in most patients, either b2a2 or b3a2, depending on 
whether or not exon b3 of the bcr gene is spliced out. Recently other possible transcripts, probably of 
less pathogenic importance, have also been identified (5).
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Figure 1. The Philadelphia chromosome. The (9;22) (q34;q11) reciprocal translocation results in the 
juxtaposition of sequences of the abl gene, located on chromosome 9, to sequences of the bcr gene on chromosome 22 
giving rise to a new bcr-abl chimeric gene at the genomic level. ABL-BCR is also expressed in a proportion of patients 
but does not seem to be relevant to the pathogenesis of CML.
Bcr-abl encodes a p210BCR-ABL tyrosine kinase protein (compared to the normal ABL-encoded 
protein of molecular weight 145Kda (6) which appears to be at the confluence of a number of signal 
transduction pathways (figure 3) and can form a complex with GRB-2/SOS proteins (7) possibly 
resulting in up-regulation of the RAS signalling pathway (8). This has been demonstrated in some 
p210BCR-ABL transformed myeloid cell lines (9). The p210BCR-ABL protein is able to confer growth 
factor independence on previously factor dependent cell lines (10)and mouse models have provided 
evidence that BCR-ABL is a sine qua non for CML (11, 12). It seems likely that activation of this 
kinase is the first step in the oncogenesis of CML (13). The minority of cases of acute lymphoblastic 
leukemia (ALL) that are Ph-positive express a p190 chimeric BCR-ABL protein. ALL has received 
far less attention than CML in the context of antisense research and this review will largely 
concentrate on CML. The ubiquitous nature of BCR-ABL in CML makes this disease arguably the 
most useful paradigm for molecular genetic intervention in a malignant disease, a fact clearly reflected 
by the number of groups that have become involved in investigating Bcr-Abl as a potential target for
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antisense oligonucleotides and ribozymes. Because of the multiplicity of intronic breakpoints at the 
genomic level and the non-favorable nucleoside composition of genomic junctional sequences that 
have been characterised the authors are not aware of any triple helix antisense strategies being 
employed in the context of Bcr-Abl. The vast majority of experiments have employed 
oligonucleotides designed to anneal to Bcr-Abl mRNA in the cytoplasm.
Normal genes
ABL b f  Ia i  aß all
- I I--------" -------- 1 = 1 --------— □— Q—C H U — □------------------------------ 1 I-
BCR e  ^  b1 b 2 ^ B  ^  b4 b5 e23
— il----------B— B — B — E 2 — E— /i------------ E 2 3 --------------
BCR-ABL mRNAs
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b2a2 BK................ I
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Figure 2. BCR-ABL. Due to alternative splicing during transcription one of two Bcr-Abl mRNA transcripts is 
found in most patients, either B2A2 or B3A2 depending on whether or not exon B3 of the bcr gene is spliced out. e1a2 
is found in a small proportion of patients with acute lymphoblastic leukemia. Recently other inconsistent alternative 
chimeric mRNA transcripts have been defined in CML. Arrows indicate the sites of breakpoints; black bars under the 
B2A2 and B3A2 transcripts schematically indicate unique junctional sequences that have been targeted by antisense 
oligonucleotides.
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RELEVANCE OF BCR-ABL AS A TARGET
BCR-ABL is clearly not the only genetic requirement for producing the terminally malignant 
condition that patients with CML develop. It is therefore fundamentally important to consider the 
relevance of Bcr-Abl as an antisense target. In itself the acquisition of bcr-abl and the development of 
chronic phase CML may arguably be considered not to be a fatal occurrence. Although not 
consistently identified it seems likely that there are secondary genetic abnormalities that are acquired 
secondary to bcr-abl that are responsible for the fatal nature of CML. Furthermore during disease 
progression leukemic cells may survive independently of BCR-ABL as indicated by patients whose 
leukemic cells have lost BCR-ABL expression (14, 15). Although there is some evidence that BCR- 
ABL may prevent apoptosis in CML cells (16, 17), in a manner analogous to BCL2 in follicular 
lymphoma, there is also a suggestion that the most primitive leukemic progenitors may not express 
p210BCR-ABL (16). So whilst there is still some uncertainty surrounding these issues it seems likely 
that if BCR-ABL antisense were to be effective at all in a therapeutic context it would probably have 
to be employed in the chronic phase of the disease.
FACTORS THAT INFLUENCE BCR-ABL EFFECTIVENESS 
Half life and degradation
Because the eventual aim of using antisense BCR-ABL oligonucleotides is to treat CML cells in vivo 
or ex vivo, experiments usually use serum which unfortunately possesses considerable nuclease 
activity. This predominantly 3' exonuclease activity (18) can degrade oligonucleotides, reducing their 
half life and effectiveness. A number of workers have addressed this problem in different ways often 
by adapting culture conditions. By selecting serum batches with low nuclease activity or using 
thoroughly heat inactivated fetal calf (19) or human serum (20) oligomer degradation can be 
prevented or significantly reduced. Because human cells grow better in human serum, allowing the 
quantity in the culture to be reduced, it has been used in a large number of experiments including the 
first BCR-ABL antisense experiments (21). Fetal calf serum generally also contains a higher amount 
of nuclease activity than human serum (20).
Oligonucleotides can also be modified in order to enhance nuclease resistance. In many experiments 
phosphorothioate (22-29) or methylphosphonate (30-32) oligonucleotides have been used. These 
modified oligonucleotides in general seem to be more active than naturally-occurring phosphodiester
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oligonucleotides however significant non-sequence specific effects have been observed with some of 
these analogues (27-29, 33). Because phosphodiester and phosphorothioate oligonucleotides are 
polyanions they can bind proteins and in certain circumstances induce non-specific effects (34).. 
Methylphosphonates, which lack this charge, can circumvent some of these problems but are less 
soluble and therefore need to be packaged (30) or be used for only some of the internucleoside 
linkages in a given oligomer (31). The culture conditions and backbone modifications employed by 
various group are summarized in table 1.
Target sequence position within the RNA
An important, and yet difficult to define, factor influencing the effectiveness of oligonucleotides is the 
optimum position in the mRNA of the gene of interest that should be targeted for potential antisense 
inhibition. Most antisense oligonucleotides are designed to bind to the AUG translation start site of 
the mRNA; RNA structure is probably more open in this region as ribosomes also gravitate to this 
area. An oligomer targeted to this site may also be able to inhibit translation by preventing the binding 
of ribosomes. However the translation start site does not always seem to be the best position (35) and 
a theoretical prediction of the best target site is still very difficult. In order to target a unique region of 
the bcr-abl gene there is only one choice i.e. to design an oligomer that is antiparallel to junctional 
sequences represented by the two common breakpoints of the Bcr-Abl mRNA found in CML thus not 
exploiting two of the potential advantages mentioned above in relation to the AUG site. Although 
there are computer predictions of Bcr-Abl mRNA secondary structure there are few if any substantive 
data that allow useful predictions of how accessible certain mRNA regions are. Some in vitro data 
suggest that there is a difference in accessibility of the two mRNA breakpoints (31); the b3a2 
Breakpoint seems less accessible than the b2a2 breakpoint possibly indicating the importance of 
choosing the correct target region. Furthermore junctional sequences are only formed after splicing as 
this region is precisely at a splice site. Therefore only mRNA and not pre-mRNA can in theory be 
targeted. This may be disadvantageous as it has been demonstrated that oligonucleotides, once in the 
cytoplasm, largely migrate to the nucleus of the cell (36, 37).
BCR and ABL are expressed as well as BCR-ABL in CML cells, although not in some cell lines (4). 
Some experiments have also targeted antisense oligonucleotides at the translation initiation sites of 
these normal genes (17, 25, 38-41) , which can occasionally cause some confusion. The BCR 
translation start site has been explored as a target by some groups (17, 25, 38, 40) and similar effects 
to those observed with breakpoint BCR-ABL antisense oligonucleotides have been seen.
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Not only target site but oligomer length is important if unwanted effects are to be minimized. There is 
of course significant homology between BCR-ABL antisense oligomers and the normal bcr and abl 
genes. If an oligomer is too long it may anneal to normal cellular mRNAs (29, 42). The design of 
effective BCR-ABL antisense oligonucleotides is therefore constrained by target position and 
oligomer size.
Protein
The p210BCR-ABL protein has a long half life of over 24 hours (43) which may be a considerable 
disadvantage when using antisense oligonucleotides. Theoretically therefore, assuming that the cells 
do not divide, it would take about three days to reduce the BCR-ABL protein to about 10% if 
translation is completely blocked over the whole of this period. Therefore conceptually high doses of 
oligonucleotides may be needed over a long period of time to accomplish this effect.
Uptake
Oligomer uptake is a critical issue in all areas of antisense research and since BCR-ABL antisense 
oligonucleotides are probably only effective in the cytoplasm where they bind the spliced RNA 
optimizing uptake into the correct intracellular compartment is particularly important. Some studies 
have determined the total amount and location of BCR-ABL oligonucleotide within cells (26, 27, 44). 
Phosphorothioate oligonucleotides appear to be better internalized than unmodified oligonucleotides 
and longer oligomers better than shorter. The amount actually in the cell is only a small part, about 1 
% in concentration, of the concentration of extracellular oligonucleotide (27, 44-46) . Liposomes 
(30), electroporation (40) or the use of the chemical permeabilization agent streptolysin-O (31, 47) 
can enhance the uptake of BCR-ABL oligonucleotides and target them to appropriate intracellular 
compartments necessitating a smaller quantity of oligomer for a significant effect to be achieved. 
While many types of cells appear to internalize BCR-ABL oligonucleotides by the passive 
mechanisms such as fluid phase pinocytosis (26) uptake enhancement by artificial mechanisms is 
seldom 100% (47). This is a clearly a disadvantage when used for treatment of leukemia or any other 
malignancy, in that ideally all leukemic cells need to be targeted. Enhancing uptake may well be a way 
to enhance specific effects and prevent concentration-dependent non-sequence specific effects of 
antisense BCR-ABL oligonucleotides.
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AN OVERVIEW OF PUBLISHED BCR-ABL ANTISENSE DATA 
Phosphodiesters
Szcylik et al in 1991 produced the seminal BCR-ABL antisense paper, published in Science, which 
reported the apparently specific growth inhibition of leukemic cell lines from CML blast crisis patients 
using phosphodiester antisense oligonucleotides against both Bcr-Abl breakpoints (21). 
Oligonucleotides reduced the colony formation of CML blast crisis cells expressing the 
complementary mRNA and not of the alternative Bcr-Abl mRNA type. Furthermore colony formation 
of normal cells was not inhibited and mismatched control oligonucleotides had no effect. These 
observations, determining the reduction of the colony formation (CFU-GM) of CML patient cells, 
were confirmed in other papers and by other groups (48-50) although not universally (20, 28, 51) 
(table 1). The specificity of the effect was confirmed by BCR-ABL RT-PCR on remaining colonies. 
This is not necessarily an indication of a specific effect on Bcr-Abl mRNA but may be a result of 
elimination of leukemic colonies by whatever mechanism. The experiments are difficult to perform 
because specific culture conditions are required to prevent degradation of the oligonucleotides (20, 
24).
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18 mer Phosphodiester BCR-ABL antisense oligonucleotides
Author_____ Journal_______________________ Target____________________________________Experiments
Szylick Science 1991 CML-BC, normal MNC CFU-GM colony/mRNA expression
Skorski Folia Histochemica 1991 CML-BC, CML-CP CFU-GM, mRNA colony PCR
Skorski J. Clin Invest 1993 CML-BC, MNC, BV173 CFU-GM, mRNA colony PCR
Mice engraftment, combination mafosfamide
Mahon Lancet 1993 CML-CP, CML-AP, NBM CFU-GM
Okabe Leukem. Lymphoma 1993 MC3, K562, HL-60 In vitro growth
Snyder Blood 1993 EM-2 pTyr assay after immunoprecipit 
mRNA PCR
Thomas Leukemia Res. 1994 K562, BV173 In vitro growth, Capping
Bedi Blood 1994 BaF3p210, CML granulocytes Viability, Apoptosis
Mahon Leukem. Lymphoma 1995 CML-CP, Non CML CFU-GM, cell cycle analysis
Bedi Blood 1995 BaF3-p210, FDC-P1-p210 
IL-3 dependent transfected cell lines
Protein inhibition after immunoblot/precipitation 
Apoptosis induction, Resistance cytostatics 
Radiation sensitivity
Vaerman Blood 1995 BV173, K562, KCL-22 
KYO-1, LAMA-84, K562, HL-60
In vitro growth, Mutation analysis
Giles Blood 1995 LAMA-84, KYO-1 streptolysin O mRNA in vitro cleavage 
mRNA PCR
Clark Leukemia and Lymphoma 1995 bcr-abl RNA mRNA in vitro cleavage
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Phosphorothioate BCR-ABL oligonucleotides
Author Journal Target Length Experiments
De Fabritiis Bone Marrow Transp. 1993 BV173, NBM CFU-GM 26 In vitro growth, Dosage
Kirkland Lancet 1993 CML-CP 18, 26 CFU-GM
Skorski PNAS 1994 BV173 26 In vitro growth, SCID mice survival 
p210 immunoblot, mRNA detection
Smetsers Leukemia 1994 BV173, HL-60 26 In vitro growth, mRNA PCR 
apoptosis, uptake
Skorski J. Exp. Med. 1994 CML-CP, CML-BC, BV173 
HL-60, NB4
16 p210 immunoblot, In vitro growth 
ras activation
OBrien Leukemia 1994 BV173, LAMA84, KYO1 
KCL-22, K562, HL-60 
Ri1, Sc1
16, 18, 26 In vitro growth, Mutation analysis
Smetsers Leukemia 1995 BV173, LAMA84 16, 26 In vitro growth, uptake 
Apoptosis/ IF flow cytometry
Maekawa Int J. Cancer 1995 BV173 16, 18, 26 Cell growth, Apoptosis 
IF microscopy, mRNA PCR
Giles Blood 1995 LAMA84, KYO-1 streptolysin O 18 mRNA in vitro cleavage 
mRNA PCR
Methylphosphonate BCR-ABL antisense oligonucleotides
Author Journal Target MP Experiments
Tari Blood K562, BV173 liposomes Full Viability, Cell viablility 
Immunoblot p210
Giles Blood 1995 KYO-1 streptolysin O Capped mRNA in vitro cleavage, cap length 
mRNA PCR
Giles Antisense Res. Dev. 1995 bcr-abl RNA, KYO1 Capped mRNA in vitro cleavage 
In vivo RNase H activity
Clark Leukemia and Lymphoma 1995 bcr-abl RNA Capped mRNA in vitro cleavage 
uptake
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BCR antisense oligonucleotides
Author Journal Target Length Experiments
Taj Leukemia and Lymphoma 1990 K562, HL-60 electroporation PO IF microscopy, p210 pTyr assay 
Cell viability
Okabe Leukemia and Lymphoma 1993 FDC-P2 transfected p210 PO In vitro cell growth
McGahon Blood 1994 K562, HL-60 PS IF microscopy, p210 immunoblot 
Resistance cytostatics/ Apoptosis
Bergan Nucleic Acids Res. 1994 p210 protein from K562 PS/PO Inhibition of p210 autophosphorylation
Bergan Antisense Res. Dev. 1995 p210 protein from K562 
K562 after electroporation
PS capped Inhibition of p210 phosphorylation in vivo 
K562 colony formation
Table 1: experiments with BCR-ABL and BCR oligonucleotides divided by comparable groups.
Cell lines provided a way to test the specificity and mechanism of action of these oligonucleotides. In 
some studies the IL-3-dependent cell lines BaF3 and FDC-P1 were made IL-3 independent with a 
retroviral p210BCR-ABL construct (16, 52). Transfected cells without IL-3 survive, but after incubation 
with BCR-ABL antisense oligonucleotides they die rapidly by apoptosis. Nonsense oligonucleotide 
controls showed no such effects. This indicates that BCR-ABL antisense oligonucleotides 
downregulate the p210BCR-ABL protein and make the cells dependent again on IL-3 and hence in the 
absence of IL-3 the cells die. The amount of BCR-ABL protein after antisense treatment was studied 
with an immunoprecipitation immunoblotting technique in these cell lines and seemed to be reduced 
by treatment with antisense oligonucleotides (52). Since a construct is used the mRNA is not spliced 
at the point of the BCR-ABL breakpoints. It is therefore a useful, but not ideal, representation of the 
mechanisms in patient cells. In addition only the b3a2 type breakpoint was studied and no b2a2 or 
other target control was used.
Other experiments have been performed using cell lines from CML patients (20, 24, 50, 53, 54) in 
which somewhat conflicting data have been generated. For instance K562 is sometimes inhibited by 
BCR-ABL antisense oligonucleotides (54) and sometimes not at all (20, 24). This discrepancy may 
well be due to culture conditions and could also reflect variable quality in synthesized oligomers.
Using many CML cell lines it has been demonstrated that the inhibitory activity of for example a 
BCR-ABL b2a2 phosphodiester oligonucleotide may not only be related to the complementarity to 
BCR-ABL mRNA but is due to sequence motifs present in the oligonucleotides (20). Sequence 
modification analysis of a number of oligonucleotides indicated that a TAT sequence at the 3' end of 
the oligonucleotide was responsible for growth inhibition. Only one mutation of the A in this
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sequence to a C completely abolished the effect seen on cell lines and introduction of this sequence in 
a non-BCR-ABL antisense oligonucleotide induced toxic effects on both CML cell lines and normal 
cells. The b3a2 oligonucleotide does not contain this TAT sequence and therefore the effects induced 
by this oligonucleotide therefore cannot be explained by the TAT sequence.
When the specificity of phosphodiester oligonucleotides was studied in vitro however they were 
found to be able to cleave Bcr-Abl mRNA in the presence of RNaseH (31, 44) and breakpoint 
specificity could be observed. When introduced into CML cell lines using streptolysin O breakpoint 
specificity can still be observed and the complementary mRNA is reduced while the alternative 
junctional breakpoint mRNA is left unchanged (31). It would seem therefore that specific effects may 
be achieved with phosphodiesters but that demonstration of such effects is very dependent on 
experimental context.
Phosphorothioates
The earliest and probably most frequently used BCR-ABL phosphorothioate oligonucleotides were 
26 nucleotides long (table 2). These oligomers significantly inhibit the proliferation of the CML cell 
line BV173 in vitro (22, 26-29, 55, 56). These molecules were also potent in vivo in a BV173/SCID 
mouse model of CML (22). In these studies oligonucleotides were injected intravenously 7 days 
following the inoculation of leukemia cells. Antisense phosphorothioates reduced the growth of the 
cell line in SCID mice whereas control oligonucleotides did not. The BCR-ABL protein, as monitored 
by an immunoblotting technique, was reduced after 60 hrs of treatment .
26 mer oligonucleotides appeared to have little effect on normal bone marrow (55). On patient- 
derived CML-CP cells the oligonucleotides induced inhibitory effects on colony formation (CFU- 
GM), but the oligonucleotides were not specific for their complementary Bcr-Abl breakpoint type and 
in addition effects on normal bone marrow were seen (28). Although the sense controls were 
generally less inhibitory (often not statistically significant) the absence of breakpoint specificity cast 
some doubt on the specificity of phosphorothioate antisense BCR-ABL oligonucleotides in general. 
Further analyses were therefore conducted by other groups. In one study, treatment of BV173 cells 
treated with 26 mer antisense oligonucleotides underwent apoptosis (26) but b3a2 antisense 
oligomers were as inhibitory as b2a2 antisense oligomers on this b2a2-expressing cell line. The use 
of sense and antisense oligomers together served as a toxicity control; sense oligonucleotide is able to 
completely block the cell death-inducing activity of the antisense oligonucleotide. Bcr-Abl mRNA 
was evaluated by quantitative RT-PCR but was only mildly reduced by antisense treatment (26).
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Antisense BCR-ABL oligonucleotide Sequences
18 mer Antisense Mismatch Sense
B2A2 GAAGGGCTTCTTCCTTAT GAACGGCATCTACGTTAT ATAAGGAAGAAGCCCTTC
B3A2 GAAGGGCTTTTGAACTCT GAAGTGCTGTTGAACTCT AGAGTTCAAAAGCCCTTC
Vaerman mismatch GAAGGGCTTCTTCCTTCT ATAAGGAAGAAGCCCTAT 
Obrien SE-AS hybrid___________________ GAAGGGCTTAGAGTTCAA___________________
26 mer
B2A2 CGCTGAAGGGCTTCTTCCTTATTGAT ATCAATAAGGAAGAAGCCCTTCAGCG
B3A2 CGCTGAAGGGCTTTTGAACTCTGCTT AAGCAGAGTTCAAAAGCCCTTCAGCG
16 mer
B2A2 AAGGGCTTCTTCCTTA TAAGGAAGAAGCCCTT
B3A2 AAGGGCTTTTGAACTC GAGTTCAAAAGCCCTT
Ineffective oligonucleotides are depicted in italic
Table 2: Sequence of most commonly used antisense BCR-ABL oligonucleotides
Because of the lack of specificity of 26 mers shorter oligonucleotides were tested for breakpoint 
specificity (27, 29, 56, 57). 18 mer antisense oligonucleotides reduced the cell growth of BV173 but 
still in a breakpoint-non specific manner (29). 16 mer antisense oligonucleotides proved to be specific 
for the b2a2 Bcr-Abl mRNA breakpoint type of cell line BV173 (27, 29, 56, 57) but the 16 mer sense 
oligonucleotides used as a control reduced proliferation of BV173 even more than the antisense 
oligonucleotides (27, 29, 56).
Cross reactivity was studied by frame-shifting oligonucleotides around the breakpoint (29) to 
examine whether partial homology with the normal BCR or ABL genes was responsible. Shifted 
oligonucleotides were also inhibitory but no clear pattern emerged. A combined b3 sense a2 antisense 
oligonucleotide was less inhibitory than the b2a2 and b3a2 antisense oligonucleotides but still had 
significant inhibitory effects. It therefore seems unlikely that the non-specific effects observed were 
due to cross reactivity of the ABL part of the oligonucleotide, but more were probably induced by a 
sequence motif within the oligonucleotide itself.
In other studies flow cytometry has been used to quantify the p210BCR-ABL protein in BV173 and 
LAMA84 cells after treatment with antisense BCR-ABL oligonucleotides (27). Cell death could be 
detected but the amount of p210BCR-ABL in the remaining viable cells was not reduced. In dead cells 
p210BCR-ABL levels were considerably reduced probably due to protein degradation or leakage 
following cell death. Taken together the analyses of the different shifted oligonucleotide sequences
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and the protein analyses indicate that it is unlikely that phosphorothioate antisense oligonucleotides 
induce growth inhibition of CML cells by an antisense mechanism and a reduction of the p210BCR- 
ABL.
Antisense BCR oligonucleotides
In one of the earliest CML antisense experiments electroporation of phosphodiester anti BCR 
oligonucleotides reduced the growth of cell line K562 (40). Antisense phosphorothioate BCR 
oligonucleotides have in general produced similar effects to BCR-ABL oligonucleotides and have 
been shown to induce apoptosis in K562 and reduce resistance to cytostatics (17). Anti BCR 
phosphorothioates have also been shown to inhibit the autophosphorylation of the p210BCR-ABL 
protein in vitro (25, 58), an effect induced by binding of the oligonucleotides near to the phosphate 
acceptor site. Interestingly other oligonucleotides with sequences unrelated to BCR or BCR-ABL 
could also inhibit autophosphorylation, an effect which appears to be correlated with the presence of 
GGC sequence motifs in the test oligomers. Even an oligonucleotide containing only seven GGC 
sequences inhibited autophosphorylation.
Electroporation of these oligomers in K562 demonstrated that inhibition of autophosphorylation does 
not always correlate with inhibition of tyrosine kinase activity in vivo but inhibition of 
phosphotyrosine content is correlated with reduced colony formation in vitro. The conclusion from 
these experiments is that BCR oligonucleotides can inhibit the phosphotyrosine content of K562 cells 
without necessarily changing the amount of p210BCR-ABL. Again it seems likely that BCR 
oligonucleotides do not induce growth inhibitory effects predominantly by an antisense mechanism. It 
is of course possible that more than one mechanism may be involved.
Methylphosphonate and chimeric oligonucleotides
To prevent non-sequence specific effects of antisense oligonucleotides induced by protein binding the 
non-charged methylphosphonates have been extensively evaluated. Methylphosphonates are non­
ionic and therefore less soluble than other commonly available analogues and in addition RNase H, 
the cellular enzyme responsible for mRNA cleavage, is not induced by methylphosphonates (59). To 
address the insolubility and RNase H issues Tidd and colleagues constructed chimeric oligomers such 
that the central part of the oligonucleotide was left unmodified (or thioated) whilst the 3' and the 5' 
part were synthesised as methylphosphonates. The length of the central portion was varied and the 
effect of the oligonucleotides on the cleavage of the Bcr-Abl mRNA in vivo and in vitro were studied 
(18, 31, 32, 60-62). The optimal structure comprised 9 central phosphodiester linkages and 4
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methylphosphonate linkages at both ends. After transient permeabilization of the cells with 
streptolysin O (31, 32, 47, 63) such hybrid oligonucleotides can cleave BCR-ABL mRNA in the 
presence of RNase H with impressive specificity.
The use of liposomes has been evaluated by the MD Anderson group in order to circumvent some of 
the solubility problems of all-methylphosphonate oligomers (30). Liposomes packed with 
methylphosphonates in DMSO can reduce cell growth of cell line K562 and BV173 in a breakpoint 
specific manner and at a low concentration (1|iM). p210BCR-ABL protein was also specifically reduced 
compared to p145ABL. It is curious to note that in these experiments the BV173 cell line also 
expressed p145ABL although many publications state that this cell line is ABL negative (33).
Generally it can be concluded that chimeric oligomers comprising of methylphosphonate and/or 
phosphorothioate/phosphodiester linkages are amongst the most specific and effective antisense 
molecules although results from basic cell-free in vitro test systems cannot always be extrapolated to 
cellular systems and in vivo models. The rules of the game are still somewhat difficult to fathom.
Ribozymes
BCR-ABL directed ribozymes have been employed with apparently good results so far (53, 64-67), 
but being RNA these molecules tend to be more difficult to handle and have not been as widely 
adopted as DNA oligomers.
MEASURING THE EFFECTS OF BCR-ABL ANTISENSE
Early BCR-ABL antisense publications, and some current papers, have made the assumption that an 
antisense oligomer will do what it is intended to do. This makes the reliable interpretation of many 
published studies very difficult, if not impossible, since it is now very clear that certain 
oligonucleotides can affect cellular processes by means other than ‘classical antisense’ (68). The end 
points most commonly evaluated have been the analysis of i) Bcr-Abl mRNA by either Northern 
blotting or reverse transcriptase-polymerase chain reaction (RT-PCR) ii) p210BCR-ABL protein product 
iii) biological effect - usually by morphology or proliferation assay. All these methods are legitimate if 
used in the correct context but often data have been derived from these analyses using only one 
control oligomer; firm conclusions could therefore not be drawn (69). Furthermore there are 
individual problems with these analytical methods.
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mRNA
Specificity of action on mRNA is the first requirement for antisense oligonucleotides to be specific 
effectors. Studies on Bcr-Abl mRNA downregulation or cleavage provide limited evidence of the 
specificity of antisense oligonucleotides on their intended target message (31, 32) but since only a 
relatively short-lived interaction is involved it is not always clear that p210BCR-ABL production will 
necessarily be affected. Short-lived target RNA species such as Bcr-Abl that are expressed at a 
relatively low level have often been compared with p actin mRNA whose constitutive expression is at 
much higher levels. It is entirely possible that an antisense oligomer may disrupt, in a non-specific 
manner, several RNA species that are expressed at low level whilst still permitting significant 
expression of p actin. A directly comparable RNA species should therefore be evaluated - for example 
Abl for comparing with Bcr-Abl (70). To complicate matters it may not always be necessary for the 
target mRNA to be degraded for an antisense molecule to be effective; oligonucleotides may also 
block the translation of mRNA into protein by steric hindrance and therefore measurement of mRNA 
may assess only part of the effect. Another compounding factor is that on occasion RNA, but not 
protein, levels can be affected with significant biological effects (27) emphasising the need for both 
analyses. Finally cell death is a complicating factor in Bcr-Abl mRNA studies; during cell death 
mRNA degradation occurs making mRNA quantification in dead or dying cells less reliable.
BCR-ABL p210
Previously published data would indicate that the best way to study antisense specificity is to look at 
the antisense mechanism itself and protein studies arguably serve as the best way to provide insight 
into whether antisense oligonucleotides do what they are designed to do - downregulate the protein 
product of the target gene. BCR-ABL has provided an excellent model for studying specificity by 
virtue of the existence of two breakpoints junctions which provides an internal ‘target control’. If 
there are oligonucleotide sequence-related effects these should be apparent because a specific BCR- 
ABL breakpoint oligonucleotide should be able to downregulate the protein translated from the 
complementary breakpoint mRNA and not from the alternative breakpoint mRNA.
BCR-ABL protein studies can be performed by flow cytometry (27) in ABL-negative cell lines, or 
using immunoblotting techniques (22, 30). Flow cytometry studies have the advantage that small 
subpopulations of cells can be detected and that dead cells can be separated from living cells. Using 
this technique it can be determined whether downregulation of the BCR-ABL protein is induced 
before the induction of cell death. Immunoblotting compares the content of the normal ABL protein
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with that of the p210BCR-ABL protein using the same antibody (30), ABL serving as an internal 
control. Frequently the cell line BV173 (71), which lacks the expression of the normal ABL protein, 
has been used as a control. This makes protein studies less reliable when an immunoblotting 
technique is used since the internal control is lost (22).
As with mRNA studies a complicating factor is that cell death is often induced by treatment with 
antisense BCR-ABL oligonucleotides as a result of which non-specific protein degradation occurs. 
There are no reports of p210BCR-ABL protein inhibition after treatment with antisense BCR-ABL 
oligonucleotides without the inhibition of cell growth and/or induction of cell death. Possibly the ideal 
system would be to use transfected cell lines that express, but are independent of, p210BCR-ABL. This 
would allow the antisense mechanism to be studied without the complicating factor of cell death 
induction.
Biological endpoints
Besides determination of the antisense mechanism by direct means biological effects can be assessed 
in antisense experiments but great care must be taken in drawing conclusions from biological 
endpoints and usually they provide circumstantial evidence only. They can be particularly useful 
however in the initial assessment of non-specific toxicities (20, 29).
Many BCR-ABL antisense studies have assessed the reduction of colony formation (CFU-GM, 
BFU-E) or the growth or death of CML cell lines or transfected cell lines. To draw any reasonable 
conclusions in this context many controls are needed, preferably including a target control, for 
instance both the b2a2 and b3a2 breakpoint mRNA. It is important that on both targets there is an 
effect with the appropriate oligomer, but that the observed effects do not occur with the control 
combination of antisense and alternative BCR-ABL junction target. Ideally two additional controls 
should be used: a mismatched and a sense control for instance. Practical constraints, not least of 
which is cost, often limit the number of controls that can be employed but in general terms the more 
controls, the more credible the experiment.
Whatever cells and/or control oligomers are used it is ultimately necessary is to show that any 
growth-inhibitory effect is induced by a specific down regulation of the p210BCR-ABL protein which, 
because of the frequent induction of cell death, is often very difficult to demonstrate.
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PROBLEMS WITH CURRENTLY AVAILABLE OLIGOMER CHEMISTRIES
The non-specific interactions of oligomers have already been alluded to and new observations are 
constantly being described. Many non-specific effects have been described with phosphorothioate 
oligomers; however their problems, compared to other oligomer chemistries, may be somewhat 
exaggerated by virtue of widespread availability. A number of groups have observed non-specific 
effects (72, 73) and some workers have attributed the degree of non-specific protein binding directly 
to the phosphorothioate component of the oligo (74). Sometimes the effects may be non-antisense but 
sequence specific (75) and the polyanionic structure of these molecules may in part explain some of 
the non-specific effects observed (76, 77). BCR-ABL experiments have not been exempt from these 
non-specific effects (29).
Interestingly a number of biological effects have been ascribed to certain sequence motifs within 
oligomers (78). For example a simple CpG motif has been found to modulate immune function. 
When injected intraperitoneally phosphorothioates containing the CpG motif can stimulate a dramatic 
increase in immunoglobulin secretion within 24 hours and increased expression of activation markers 
such as MHC class II (79). The same motif can also induce interferon production and NK cell 
activation (80).
A 3’ TAT motif, irrespective of the remaining oligomer sequence, has been found to be inhibitory in 
CML cell lines (20) and Bergan and colleagues have determined that GGC motifs within what were 
originally thought to be BCR-ABL antisense oligomers directly inhibit the tyrosine kinase activity of 
the p210BCR-ABL protein by an aptameric interaction (58). (An aptamer is an oligonucleotide that binds 
to a specific protein, rather than another nucleic acid molecule, presumably by virtue of its tertiary 
structure - aptus is the Latin for ‘to fit’). Curiously the effects of motifs such as the well known G 
quartet may be dependent on flanking sequences (81) but as yet the rules governing this effect have 
not been elucidated.
NEWER METHODS FOR ASSESSING SPECIFICITY.
Newer test systems have been developed recently which provide more compelling evidence of 
antisense effects, particularly in the context of BCR-ABL. Protein assays and RT-PCR will continue 
to be useful but reverse ligase-mediated PCR (RL-PCR) (82)has recently been applied to antisense 
research and has extended the ability to analyse RNA degradation products. RT-PCR in combination 
with RL-PCR (figure 4) provides compelling evidence that a target RNA molecule has been cleaved at
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a specific site and is a useful method for assessing oligomer specificity (32). In vitro transcription 
systems (31) can also provide valuable data on cleavage specificity before moving into cellular assays 
but findings are not always consistent between such basic in vitro systems and more complex cellular 
assays. Recently retroviral vectors have been constructed which comprise of a cDNA sequence that 
encodes an mRNA species containing sequences homologous to the BCR-ABL breakpoint junction 
upstream of a reporter construct e.g. chloramphenicol acetyl transferase or luciferase. Oligomer 
treatment of cells transfected with such constructs can facilitate the definition of specific antisense 
effectors and the system can be readily adapted to any target sequence (83).
A
Target mRNA 5
No cleav^e
+ Linker
No product
Specific cleavage
+ Linker
mRNA
RT
cDNA
PCR (nested)
Specific PCR 
product
3’
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to target gene product
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specific amplification 
product of correct size
Figure 4. Reverse ligase-mediated polymerase chain reaction.
A. The RL-PCR procedure will generate a PCR product of predicted length when the initial target mRNA species has 
been cleaved in the expected location. If no cleavage or non-specific cleavage has occurred, either no RL-PCR 
product or products of unexpected size respectively will be generated.
B. In conjunction with reverse transcriptase polymerase chain reaction (RT-PCR) corroborative data can be generated to
determine the specificity of a given antisense oligomer. In this schematic example the specific antisense oligomer 
has cleaved its target mRNA resulting in the disappearance of the RT-PCR band and a specific cleavage product of 
appropriate size has been generated in the RL-PCR reaction.
CLINICAL TRIALS USING BCR-ABL ANTISENSE
Although MYB antisense has been used to purge autologous stem cells from CML patients prior to 
autografting (84, 85) there has been only one clinical trial using BCR-ABL-directed antisense 
oligonucleotides. In Rome 8 patients with advance phase CML (7 accelerated phase, 1 second chronic 
phase) have been treated with a 26mer phosphorothioate oligomer directed symmetrically at the BCR- 
ABL junction in a study conducted in collaboration with Lynx Therapeutics (Hayward, CA). In this 
study, in a similar manner to the MYB study, autologous stem cells were purged in vitro before 
subsequent return to the patient as an autograft (86) The purging procedure did not appear to have an 
adverse effect on engraftment (87). 30-100% of cells were Ph-negative following the purging 
procedure and in 2 patients complete Ph-negativity was achieved post-autograft albeit transiently. 2 
further patients achieved a major cytogenetic response which again was transient. 6 patients received 
interferon post-autograft and it is not possible at present to make any meaningful comment about the 
impact of this procedure upon survival.
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DOES BCR-ABL ANTISENSE HAVE A FUTURE?
BCR-ABL antisense research has undoubtedly had a somewhat chequered history. Workers in this 
field have faced the considerable hurdles of obtaining pure oligomers of a chemistry and sequence 
that does not cause non-specific effects, of trying to get these large molecules into cells and of 
generating convincing data that demonstrate sequence specific cleavage of Bcr-Abl mRNA and 
reduction in its p210BCR-ABL protein product. To date success in producing favorable and reproducible 
experimental data has been limited - should we give up?
At this stage we believe not. As a technology, antisense must still be considered to be in its infancy 
and it is probably too early to consign our endeavours with BCR-ABL to the historical scrap heap. 
BCR-ABL arguably remains the most attractive molecular genetic defect in human cancer for which to 
develop new genetic therapies and to give up on it at this stage would seem premature. Although it 
would seem that all-phosphodiester and all-phosphorothioate oligomers are unlikely to be fruitful 
BCR-ABL antisense effectors newer approaches have been developed and innovation continues. 
New DNA and RNA analogues may be developed that could overcome some of the problems of 
specificity, efficiency and perhaps uptake that have been encountered with ‘1st generation’ oligomers. 
2’O-methylribose (88), C5 propyne (89), ap anomeric (90) phosphoramidate (91) and formacetal 
(92) oligonucleotides seem promising. The methylphosphonate/phosphodiester or phosphorothioate 
chimeric oligonucleotide structures appear to be some of the most impressive BCR-ABL antisense 
effectors yet in terms of their specificity of action (93, 94) and this may well be an area from which 
further encouraging results may come. Biotech companies are busy producing a considerable number 
of new DNA and RNA analogues and there are in excess of 30 now available - prospects seem good 
for a better oligomer chemistry.
The ‘unwanted’ side effects of so-called antisense could be exploited in the area of aptamer 
development. The finding that certain oligonucleotides bind with high affinity to some proteins by 
virtue of certain sequence motifs within the oligomer (95) is being actively investigated by a number 
of research groups although the nature of the sequence motifs that direct this sequence-dependent, but 
not sequence-specific, binding is not currently well understood. It is likely that oligomer secondary 
and tertiary structures are important factors but to date most studies of aptameric effects have been 
largely empirical in their design. For example, by repeated selection and PCR amplification of an 
oligonucleotide library, Gilead Sciences Inc. (Foster City, CA) have developed a 15-mer 
oligonucleotide aptamer (5’-GGTTGGTGTGGTTGG-3’) which binds specifically to and inhibits 
thrombin (96). This intriguing oligomer has been shown by solution NMR studies to adopt a compact
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and symmetrical structure consisting of two guanine tetrads and three loops. The throne-like structure 
binds with high affinity to thrombin and in animal models exhibits anticoagulant activity with a rapid 
onset and short half life. The clinical application is immediately apparent.
NexStar (Boulder, CO) have been developing their proprietary ‘Selex’ technology using similar
principles. In this system a ‘target’ protein of interest is bound to a column and large number (1011­
1310 ) of oligomers of random sequence, in this case usually modified RNA species, are run through 
the column repeatedly. The final stage is to elute and sequence the oligomer(s) with highest affinity 
and hone down the candidates until a single oligomer of defined sequence and high protein-binding 
affinity is derived. This process is laborious and time consuming and there are a considerable number 
of technical variables that have to be optimised such as oligomer length, stability and purity and the 
number of randomers that are put into the system. In addition there is no guarantee that the aptamer 
will bind to a functionally important site on the target protein. However although this technology is 
still in its infancy impressive results have been obtained in targeting cell surface molecules such as the 
selectins and various growth factor receptors such as EGF and PDGF.
Newer technical approaches such as surface plasma resonance and evanescent wave technology 
should make the selection of aptamers quicker and more efficient and may facilitate the development 
of ‘nucleic acid therapeutics’. Whilst extracellular/cell surface proteins are clearly the most obvious 
targets of aptamer strategies in the immediate future it is possible that intracellular proteins could also 
be targeted and the technology already exists for generating the required quantities of the purified 
proteins involved in signal transduction, and in particular BCR-ABL (7) using baculovirus systems. 
If this approach proved effective there are numerous signal transduction proteins that could potentially 
be targeted given the complex nature of the interactions of p210BCR-ABL (figure 3).
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BCR-ABLFigure 3. The role of p210 in signal transduction.
Recently there has been a refreshing realisation in the antisense community that rather than trying to 
play down or frankly ignore difficulties with antisense, the careful definition and evaluation of these 
problems can allow important new break-throughs - some quite unexpected (97, 98). With this more 
realistic view of what can be expected from antisense, ribozyme and aptamer technology as applied to 
BCR-ABL one can be fairly optimistic that a useful experimental and therapeutic niche can be found 
for these intriguing nucleic acid molecules.
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Concluding Remarks
Concluding Remarks
Studies on the mechanisms of antisense BCR-ABL oligonucleotides have resulted in a change of 
attitude in the antisense field. They have led to a reinterpretation of the old studies that coupled cell 
death induced by antisense oligonucleotides to the function of the BCR-ABL protein in CML and 
resulted in guidelines for the experimental design of future antisense experiments in general. The 
studies also contributed to the design of newer high affinity antisense molecules that lack the non­
sequence specific effects of the older charged molecules. A new intriguing stategy has evolved from 
the previous studies. This strategy uses the formerly non specific binding capacity of antisense 
oligomers for the production of a new type of drugs called aptamers.
The two aims of this thesis were to study the function of the BCR-ABL protein and to evaluate the 
possibility of bone marrow purging using antisense oligonucleotides. It is clear that the function of 
the BCR-ABL protein cannot be studied reliably using antisense oligonucleotides because of 
additional effects. Bone marrow purging might be possible using these compounds but additional 
research for this is required.
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Summary
Summary
The aim of the study described in this thesis was to evaluate the function of the BCR-ABL protein by 
inhibition of its expression using antisense oligonucleotides. Also the possibility of the use of 
antisense oligonucleotides for purging of the bone marrow of patients with CML was studied. 
Antisense oligonucleotides were designed to bind to a target mRNA and to inhibit the expression of 
the targeted protein. Antisense oligonucleotides complementary to the Bcr-Abl mRNA were used in 
the investigations described in this thesis. The chimeric BCR-ABL protein is expressed in leukemic 
cells of patients with Chronic Myeloid Leukemia (CML).
In chapter 2 we describe how phosphorothioate BCR-ABL antisense oligonucleotide behave when 
they are added to a leukemic cell line (BV173). Breakdown, uptake and the effect of these molecules 
on the Bcr-Abl mRNA expression and cell growth were studied. Antisense BCR-ABL 
oligonucleotides induced programmed cell death in the CML cell line BV173. Control 
oligonucleotides and a non-CML cell line showed much less of this effect. The oligonucleotides were 
not specific for one of the two Bcr-Abl mRNA breakpoints. The effect of these oligonucleotides on 
the reduction of the amount of Bcr-Abl mRNA was also limited.
In chapter 3 the mechanism and specificity of the oligonucleotides was studied. We studied in detail 
whether an antisense mechanism (an inhibition of protein translation by the antisense hybrid) is 
responsable for the progammed cell death induced by antisense BCR-ABL phosphorothioate 
oligonucleotides. This did not appear to be the case. Antisense BCR-ABL oligonucleotides induced 
cell death, but reduction of the expression of the BCR-ABL protein could not be detected. The 
observed phenomenon was sequence dependent, since antisense oligonucleotides caused cell death, 
while control oligonucleotides did not. The effect of length on the growth inhibitory effect was also 
studied. Short oligonucleotides (16 nucleotides) showed a breakpoint-specific effect. Because the 
effect of these oligonucleotides was not antisense mediated, another mechanism was responsible for 
the observed effects. Protein binding by modified negatively charged phosphorothioate 
oligonucleotides could be one of these mechanisms.
In chapter 4 and 5 other non-charged antisense BCR-ABL oligonucleotide methylphosphonates 
were used. These oligonucleotides also induced cell death, while other oligonucleotides did not. The 
expression of the BCR-ABL protein was not specifically reduced. Therefore, the antisense 
mechanism was not responsible for cell death induced by these antisense molecules. The BCR-ABL 
antisense oligonucleotides specifically induced cell death in CML cells since they appeared to be more 
sensitive to antisense BCR-ABL oligonucleotides than normal CD34+ cells or AML blasts.
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More cases of sequence dependent non-antisense effects on cells treated with antisense 
oligonucleotides have been described in the literature. We therefore evaluated (chapter 6) whether 
certain short sequence stretches appeared significantly more - or less often than expected in effective 
antisense oligonucleotides targeted to a large number of different mRNA's. These sequences could be 
identified. In antisense oligonucleotides the distribution of sequences is not completely the same as in 
the mRNA's to which they are targeted to. This indicates that other sequence dependent mechanisms 
contribute to the effectivity of antisense oligonucleotides.
In conclusion, we showed that antisense BCR-ABL oligonucleotides can induce cell death in CML 
cells in a sequence dependent way. The effect depends on the length and composition of the 
oligonucleotides. Non-CML cells are consistently less sensitive or not sensitive at all. An antisense 
mechanism did not appear to be the cause of the cell death. Other mechanisms may play a role in the 
effectivity of antisense oligonucleotides.
It was not possible to determine the function of the bcr-abl gene using these antisense molecules 
since the effects that are observed are not a result of a reduction of expression of the protein. Some 
investigators interpreted the effects of antisense BCR-ABL oligonucleotides as a function of the bcr- 
abl gene. The result of these experiments should be interpreted with caution. The molecules may be 
useful for bone marrow purging because they induce cell death in leukemic cells. Whether they are 
better or more selective than other cytostatic agents like arabinosine cytosine should be a topic for 
further research.
The findings described in this thesis are useful for the design of future antisense molecules. 
Several groups aim to find antisense molecules that are more specific and other groups are optimizing 
molecules that make use of non-antisense mechanisms to kill the leukemic CML cells. Which of the 
two strategies will be the best in the end is not known.
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Samenvatting
Antisense oligonucleotiden worden ontwikkeld om specifiek te binden aan mRNA en hierdoor 
de expressie van een specifiek eiwit te remmen. In dit proefschrift werden antisense oligonucleotiden 
complementair aan het het Bcr-Abl mRNA gebruikt. Het chimere BCR-ABL eiwit komt tot expressie 
in leukemische cellen van patiënten met chronische myeloide leukemie (CML). Het doel van de studie 
was om de functie van het BCR-ABL eiwit te evalueren. Bovendien werd de mogelijkheid voor het 
zuiveren van beenmerg m.b.v. deze antisense oligonucleotiden bestudeerd.
In hoofdstuk 2 werden de eigenschappen van phosphorothioate antisense BCR-ABL 
oligonucleotiden beschreven, wanneer ze aan een leukemische cellijn (BV173) werden toegevoegd. 
Afbraak, opname en het effect van deze moleculen op Bcr-Abl mRNA expressie en celgroei werden 
bestudeerd. Antisense BCR-ABL oligonucleotiden induceerden geprogrammeerde celdood in de 
CML cellijn BV173. Controle oligonucleotiden en een niet-CML cellijn lieten geen of veel minder 
effect zien. De oligonucleotiden waren niet specifiek voor een van beide Bcr-Abl mRNA 
breekpunten. De vermindering van de hoeveelheid Bcr-Abl mRNA was gering.
In hoofdstuk 3 werd het mechanisme en specificiteit van deze oligonucleotiden nader 
geëvalueerd. In detail werd bestudeerd of de geinduceerde geprogrammeerde celdood veroorzaakt 
werd door een antisense mechanisme. Dit bleek niet het geval te zijn. Antisense BCR-ABL 
oligonucleotiden induceerden celdood in CML cellijn BV173, maar een expressievermindering van 
het BCR-ABL eiwit kon niet aangetoond worden. Toch trad er een sequentiespecifiek fenomeen op. 
Antisense oligonucleotiden veroorzaakten immers celdood terwijl controle oligonucleotiden dit niet 
deden. Het effect van de lengte op de sequentiespecificiteit werd bestudeerd. Hieruit bleek dat kortere 
oligonucleotiden (16 nucleotiden) een breekpunt specifiek effect veroorzaakten. Aangezien het effect 
van deze oligonucleotiden niet antisense gemedieerd was, leek een ander mechanisme 
verantwoordelijk voor de gevonden effecten. Een van deze mechanismen zou eiwitbinding kunnen 
zijn. Gemodificeerde negatief geladen phophorothioate oligonucleotiden binden sterk aan eiwitten.
In hoofdstuk 4 en 5 werden daarom andere niet geladen antisense BCR-ABL 
methylphosphonate oligonucleotiden geëvalueerd. De oligonucleotiden vertoonden 
sequentiespecificiteit. Antisense-oligonucleotiden induceerden celdood terwijl controle-moleculen dit 
niet deden. De expressie van het BCR-ABL eiwit werd niet specifiek verlaagd, dus een antisense 
mechanisme was niet de oorzaak van celdood. De inductie van celdood door BCR-ABL antisense 
oligonucleotiden was wel specifiek voor CML cellen. In normale CD34+ cellen of cellen van 
patienten met acute myeloide leukemie (AML) werd namelijk veel minder celdood geinduceerd .
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Behalve deze effecten waren nog meer sequentieafhankelijke effecten op cellen met antisense 
oligonucleotiden bekend. In hoofdstuk 6 werd gekeken naar de frequentie van sequenties in 
effectieve antisense oligonucleotiden. Deze oligonucleotiden waren gericht tegen een groot aantal 
verschillende mRNA's. Sequenties met afwijkende frequentie t.o.v. de normale frequentie werden 
inderdaad aangetoond. In antisense oligonucleotiden is de verdeling van de sequenties niet volledig 
dezelfde als in het mRNA waartegen ze gericht zijn. Dit betekent dat er andere sequentieafhankelijke 
mechanismen meespelen die bijdragen tot de effectiviteit van antisense oligonucleotiden in het 
algemeen.
Samenvattend kunnen we stellen dat we aangetoond hebben dat antisense BCR-ABL 
oligonucleotiden celdood kunnen induceren op een sequentie-afhankelijke manier. Het effect is 
afhankelijk van de lengte en de compositie van de oligonucleotiden. Niet-CML cellen zijn veel 
ongevoeliger voor behandeling.
Het bleek niet mogelijk te zijn om de functie van het bcr-abl gen te bestuderen met deze antisense 
oligonucleotiden omdat de effecten die werden waargenomen niet het resultaat waren van een afname 
van de expressie van het eiwit. Sommige onderzoekers hebben de effecten van antisense BCR-ABL 
oligonucleotiden geinterpreteerd als een functie van het bcr-abl gen. De resultaten van deze 
experimenten moeten met voorzichtigheid geinterpreteerd worden. Oligonucleotiden zouden gebruikt 
kunnen worden voor het zuiveren van beenmerg omdat de oligonucleotiden celdood induceren in 
leukemiecellen. Of deze moleculen beter en meer selectief zijn dan andere cytostatica zoals 
arabinosine- cytosine kan onderwerp zijn van verder onderzoek.
De experimenten in dit proefschrift lijken nuttig zijn voor het ontwerpen van nieuwe antisense 
oligonucleotiden. Op twee manieren wordt verder onderzoek gedaan aan antisense BCR-ABL 
oligonucleotiden. Antisense moleculen worden ontworpen die geen additionele effecten vertonen, 
daardoor specifieker zijn en via een antisense mechanisme werken. Ook worden oligonucleotiden 
getest die gebruik maken van de niet-antisense effecten om leukemische CML cellen te doden. Welke 
van de twee strategieen uiteindelijk de beste zal zijn dat zal de toekomst moeten leren.
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Niet technische samenvatting.
Allereerst de verklaring van een aantal termen:
-DNA (Nucleinezuur, Deoxynucleinezuur): stof waarin de erfelijke 
eigenschappen opgeslagen liggen.
-Gen: een erfelijke eigenschap bestaande uit een stukje DNA, met de 
code om een bepaald eiwit te maken.
-Chromosoom: een lange keten DNA die bij een delende cel onder de 
microskoop gezien kan worden. Een menselijke cel heeft 46 
chromosomen.
-Leukemie: bloedkanker
-Sense: DNA sequentie die de code bevat waarmee een eiwit gemaakt 
kan worden.
-Antisense: Complementaire DNA sequentie (anti-sense) waarmee een 
erfelijke eigenschap onderdrukt kan worden door specifieke blokkade 
van het aflezen van het betrokken gen
Chronische Myeloide Leukemie (CML) is een chronische vorm van bloedkanker. De ziekte wordt 
gekenmerkt door een opeenhoping van zieke cellen in het bloed. In deze cellen wordt een afwijkend 
chromosoom gevonden. Dit chromosoom wordt het Philadelphia-chromosoom genoemd naar de stad 
waar het voor het eerst beschreven is. Het chromosoom blijkt ontstaan te zijn uit een uitwisseling van 
materiaal van twee afzonderlijke chromosomen, de chromosomen 9 en 22. Hierbij is een stukje van 
chromosoom 9 aan het chromosoom 22 gaan zitten en omgekeerd. Precies op de plaats waar deze 
chromosomen aan elkaar verbonden zijn, heeft een koppeling plaatsgevonden tussen twee genen, die 
het bcr en het abl gen genoemd worden. De koppeling van deze twee genen, het bcr-abl gen genoemd 
zet bloedcellen aan tot een afwijkend gedrag en is waarschijnlijk de oorzaak van de leukemie .
Om van een gen een eiwit een eiwit te produceren wordt het allereerst afgelezen tot messenger RNA 
(mRNA). Dit mRNA is een copie van het gen en bevat dezelfde code. Dit mRNA wordt uiteindelijk 
gebruikt in de (bloed)cel om eiwit te maken. Van het bcr-abl gen zal dus eerst een mRNA gemaakt 
worden alvorens het leukemie veroorzakende BCR-ABL eiwit gemaakt kan worden. Het doel van dit 
project is geweest stoffen te ontwikkelen die het aflezen van dit afwijkende mRNA blokkeren.
In dit onderzoek is gebruik gemaakt van de zogenaamde antisense oligonucleotiden. Deze antisense 
oligonucleotiden worden synthetisch gemaakt. Ze bestaan uit DNA en bevatten precies de
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complementaire code (anti-sense) van het Bcr-Abl mRNA op de breukplaats. Antisense 
oligonucleotiden zouden in staat moeten zijn om aan het Bcr-Abl mRNA te binden en hierdoor de 
vorming van het gevaarlijke BCR-ABL eiwit te voorkomen. Hiermee kan dan exact de functie van het 
BCR-ABL eiwit bestudeerd worden of het kan gebruikt worden als medicijn tegen de leukemie.
Het effect van deze antisense molekulen werd uitgetest op een aantal verschillende soorten 
leukemiecellen. Hierbij zijn een aantal eigenschappen van deze antisense molekulen tot in detail 
bestudeerd. Dit is gedaan om te zien hoe antisense oligonucleotiden precies werken. Sommige 
leukemiecellen bleken dood te gaan als ze behandeld werden met deze antisense BCR-ABL 
oligonucleotiden.
Behandeling met deze antisense-molekulen leek de vorming van het BCR-ABL te voorkomen en de 
productie van het eiwit te blokkeren. Leukemie-cellen bleken na een nauwkeuriger onderzoek wel 
dood te gaan na behandeling met antisense BCR-ABL maar toch kwam dit niet door een blokkade 
van het BCR-ABL eiwit. Men tast echter nog steeds in het duister over wat dan wel de oorzaak is van 
de gevonden effecten.
Het is nog niet duidelijk wat deze antisense molekulen precies doen, maar wel staat vast dat 
chronische myeloide leukemiecellen gevoeliger zijn voor behandeling met antisense BCR-ABL dan 
normale cellen. Men zoekt nu verder naar molekulen die zoals de antisense oligonucleotiden hier 
beschreven nog beter in staat zijn om op een of andere manier selectief leukemiecellen te doden. 
Daarnaast is men op zoek naar antisense molekulen die wel in staat zijn via binding aan mRNA een 
eigenschap te blokkeren.
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Antisense oligonucleotides used for determination of sequence 
______________________________ frequency.__________________________
Author/AccessFullsequence Sequence - Kozak sequences
ion nr
1) GAGC AGAC GGGC TGCCAT GAGCAGACGGGCTG
2 ) GCCGGGTCCGCCATCTTTCTGGCAG GCCGGGTCCG
3) GCAGCGCGTCCGCCGAGA GCAGCGCGTCCGCCGAGA
3) CAGCTCATCCAGATCCTC CAGCTCATCCAGATCCTC
3) CTCGGGCCTGATGTCGTC C TC GGGC C TGATGTC GTC
4 ) CTCGCATTATAAAGG CTCGCATTATAAAGG
4) GCACAGCTCGGGGGT GCACAGC TC GGGGGT
4) CCGGCGGTGGCGGCC CCGGCGGTGGCGGCC
4) GCCCCCGAAAACCGGC GCCCCCGAAAACCGGC
4) CGCCCGGCTCTTCCA CGCCCGGCTCTTCCA
4) TGGGCCAGAGGCGAA TGGGCCAGAGGCGAA
4) GTGTTGTAAGTTCCA GTGTTGTAAGTTCCA
4) GAGGCTGCTGGTTTT GAGGCTGCTGGTTTT
4) GGGGCATCGTCGCGG GGGGCATCGTCGCGG
4) CCTGTTGGTGAAGCT CCTGTTGGTGAAGCT
5 ) GATCCTCTGCCACCCACACC GATCCTCTGCCACCCACACC
6) CCCTGCTCCCCCCTGGCTCC CCCTGCTCCCCCCTGGCTCC
7) TAGC TTGATGTGAGG TAGCTTGATGTGAGG
7) ACATTTAGAAGCCAG ACATTTAGAAGCCAG
8, 9) ACAGGATCTCTCAGGTGGGT ACAGGATCTCTCAGGTGGGT
8, 9) TTCCCCAGATGCACCTGTTT TTCCCCAGATGCACCTGTTT
8, 9) CTGTGTCTCCTGTCTCCGCT C TGTGTC TC C TGTC TCC GC T
8, 9) AACCCAGTGCTCCCTTTGCT AACCCAGTGCTCCCTTTGCT
8, 9) AAACATCTCCGTACCATGCCA AAACATCTCCGTACCATGCCA
10 ) GTCCACCATGGCGCGGCCGGC GTCCA
11) GTTTTGTGCTTCAGAAATGT GTTTTGTGCTTCAGAAATGT
11) GGGGTCTCCGGGCCAT GGGGTCTCCGGG
12 ) AC TGC TATATATGC TGTG AC TGC TATATATGC TGTG
12 ) GGGTC T TC GGGCCATGGC GGGTCTTCGGG
13 ) GAAGCCCACCGGGTCCAC GAAGCCCACCGGGTCCAC
14 ) CCACGCGGACTATTA CCACGCGGACTATTA
15 ) ACTGTCTTCGTCTTGGCCCT ACTGTCTTCGTCTTGGCCCT
16 ) GCCCCACCTGCCAAG GCCCCACCTGCCAAG
17 ) GGCGGTGAGGGAAAA GGCGGTGAGGGAAAA
17 ) ATGTAGGAAACCTGGTGA ATGTAGGAAACCTGGTGA
18 ) AC TTGATGGC C TGCAT ACTTGATGGCCT
19 ) GTCGTAGTAGGTGGCTTTCTGCATC GTC GTAGTAGGTGGCTTTCT
19 ) TCTAAGAAGGAGTTCATCCTATTATAGTCCATGCG TCTAAGAAGGAGTTCATCCTATTATAGT
20 ) CAGCTCGGAAGAGAAGCC C AGC TC GGAAGAGAAGC C
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21) ATCTTCCATAGTTAGTCA ATCTT
21) AACGTTGAGGGGCAT AACGTTGAGGG
21) GAC TCGGAGC GC CATGGC GAC TC GGAGC GC C ATGGC
22) CAGCTGCAACCCAGC CAGCTGCAACCCAGC
23) GGTTTTGGGCGGCAT GGTTTTGGGCG
24) C C C GGAGGGC GGCATGGGGGA C C C GGAGGGC G
24) GTGAAC GACATC TCATC TAGG GTGAACGACATCTCATCTAGG
24) C TGC GGC TCC TCCATGGCAGT CTGCGGCTCCT
25) TAC TGGC C GC TGAAGGGC TAC TGGC C GC TGAAGGGC
26) GGC TGCCATGGTCCC GGCTG
26) AGCCAAGGTCCTCAT AGCCAAGGTCC
27) GAAGGGCTTTGAACTCT GAAGGGCTTTGAACTCT
28) TCTTCTTGCTGATTTACCGCTGCCCCCTGAGCTACC TCTTCTTGCTGATTTACCGCTGCCCCCTGAGCTACCAGGA 
AGGA
28) CGGCTTGTTGTAGC CGGCTTGTTGTAGC 
2 9) TGAGGGGCATCGTCGTGGCTGTCT TGAGGG
29) GCAGCTGGGCATGGGCTTGCCTCT GCAGCTGG
30) TC C TGGGGGTAC TGG TCCTGGGGGTACTGG
31) GC CAC GGAGC GAGACATCTC GC C AC GGAGC GAG
32) TTTGGCCATCTTGACTTC TTTGG
33) ATCCCAGAGCAGCCT ATCCCAGAGCAGCCT
34) GCCCACCGGGTCCACCAT GCCCACCGGGTCCA
35) GGC TGC TGGAGC GGGGCACAC GGC TGC TGGAGCGGGGCACAC
36) GGC C CAGGAGGGCATCTT GGC C C AGGAGG
36) TGCTGTCAGAGCTGAAGC TGC TGTCAGAGC TGAAGC
37) CTTGCAGATCATGCCCGG CTTGCAGATCATGCCCG
38) GAGGGGGAACAGTTCGTCCATGGC GAGGGGGAACAGT TC GT 
38) TC TAAGAC TATTC TCCATATT TCTAAGACTATTCT 
38) AGAC ATGT TGGTAT TGC ACATTG AGACATGTTGGTATTGC 
38) AGGGGC C C C GGC CAAGGCCATGAC AGGGGC C C C GGC C AAGG 
38) TC CAGC CGAGGGGACCATTTT TCCAGCCGAGGGGA
38) AAGGAC TC TGAGAGCCATGGC AAGGAC TC TGAGAG
39) GATCATGCCCGGCAT GATCATGCCCG
40) CTTCAGGCAGATCTCCAA CTTCAGGCAGATCTCCA
40) TTTTCCAGGCTGCTGCCC TTTTCCAGGCTGCTGCC
41) GTCTACGGCTGCGTCTGACAT GTCTACGGCTGCGTCTG 
41) GGTGTCTACGGCTGCG GGTGTCTACGGCTGCG 
41) CATCATCTTCAGCTGC CATCATCTTCAGCTGC
41) CCAACTACTTATAGTACAG CCAACTACTTATAGTACAG
42) CAGGCTCTGCAGCCACAT CAGGCTCTGCAGCC
42) GGTGGCAGGTCCAGCCAT GGTGGCAGGTCCAG
43) GGCCTCGGCCGCCATCAT GGCCTCGGCCGCCA
44) TATGCTCTGCCGGGGTCTTCGGGC TATGCTCTGCCGGGGTCTTCGGG 
44) CAGCTTATATTCCGTCAT CAGCTTATATTCCG
44) AAGCTTTATATTCAGTCAT AAGCTTTATATTCAG
44) CAGTTTGTACTCAGTCAT CAGTTTGTACTCAG
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(45 TTTTCCAGAGGCGACCTCTGCAT TTTTCCAGAGGCGACCTCT
(46 AGCATTTCTGCGGGG AGCATTTCTGCGGGG
(47 GGTTTTGGGCGGCATGAC GGTTTTGGGCG
(47 CTCAGTAAAGTGAACGA CTCAGTAAAGTGAACGA
(48 GTGCCGGGGTCTTGGGGC GTGCCGGGGTCTTGGGGC
(49 CGGGTCCACCATGGCGCG CGGGTCCA
o\ 
o 
4
5
CTTCCACGCCTCCGCGAAGCC
CATGGTGGTGAATCT
CTTCCACGCCTCCGCGAAGCC
(51 AAGATCCACCCGAC AAGATCCACCCGAC
(51 GAGTGACATAAGAAA GAGTGACATAAGAAA
(52 GAAGGGCATCTACGTTAT GAAGGGCATCTACGTTAT
(52 GGCTGAAGGGCTTTGAACTC GGCTGAAGGGCTTTGAACTC
(53 CGCCGGGATCTCGATGCTCAT CGCCGGGATCTCGATGC
(53 CGGGATCTGGATGTGGCTCAT CGGGATCTGGATGTGGC
(54 GAAGCTAACGTTGAGGGG GAAGCTAACGTTGAGGG
(55 CTCCATGGTGCCCAT CTCCATGGTGC
AC Q11593; tctccctcttagctggtcctctgc tctccctcttagctggtcctctgc
AC Q11594; catgctttcagtgctcatggtgtcctttc catgctttcagtgc
AC Q11595 ; gatcaggaaggagaagaggctgaggaacaa gatcaggaaggagaagaggctgaggaacaa
AC Q11596; ctcagcttgagggtttgc ctcagcttgagggtttgc
AC Q11597; ttcgtcctcctcacagggc ttcgtcctcctcacagggc
AC Q12625; ctggggtatgtcccgcag ctggggtatgtcccgcag
AC Q14267; tacctattctgggctcga tacctattctgggctcga
AC Q14268; ttgggtcgatacgggtgt ttgggtcgatacgggtgt
AC Q14269; caccacaccaaatttcta caccacaccaaatttcta
AC Q14270; atggagaagggtcctgta atggagaagggtcctgta
AC Q20905; tctgagtaacacttcat tctgagtaacacttcat
AC Q22343; tgaagcaatcatgacttcaag tgaagcaa
AC Q22344 ; tataggagttttgatgtgaa tataggagttttgatgtgaa
AC Q22345; acaatgagggggtaatctaca acaatgagggggtaatctaca
AC Q22346; gacaatatacaaaccttccat gacaatatacaaaccttccat
AC Q22629; tgggagccatagcgaggc tgggag
AC Q22630; gaggagctcagcgtcgactg gaggagctcagcgtcgactg
AC Q22631; gacactcaataaatagctggt gacactcaataaatagctggt
AC Q22632 ; gaggctgaggtgggagga gaggctgaggtgggagga
AC Q22633; cgatgggcagtgggaaag cgatgggcagtgggaaag
AC Q22634; gggcgcgtgatccttatagc gggcgcgtgatccttatagc
AC Q22635; catagcgaggctgaggttgc
AC Q22636; cgggggctgctgggagccat cgggggctgctgggag
AC Q22637; agagccccgagcaggaccag agagccccgagcaggaccag
AC Q22638; tgcccatcagggcagtttga tgcccatcagggcagtttga
AC Q22639; ggtcacactgactgaggcct ggtcacactgactgaggcct
AC Q22640; ctcgcgggtgacctcccctt ctcgcgggtgacctcccctt
AC Q22641; tcagggaggcgtggcttgtg tcagggaggcgtggcttgtg
AC Q22642 ; cctgtcccgggataggttca cctgtcccgggataggttca
AC Q22643; cccccaccacttcccctctc cccccaccacttcccctctc
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AC Q22644 ttgagaaagctttattaact ttgagaaagctttattaact
AC Q22650 gcccaagctggcatccgtca gcccaagctggcatccgtca
AC Q22651 tctgtaagtctgtgggcctc tctgtaagtctgtgggcctc
AC Q22652 agtcttgctccttcctcttg agtcttgctccttcctcttg
AC Q22653 ctcatcaggctagactttaa ctcatcaggctagactttaa
AC Q22654 tgtcctcatggtggggctat tgtcctcatggtggggctat
AC Q22655 tctgagtagcagaggagctcga tctgagtagcagaggagctcga
AC Q22656 caatcatgacttcaagagttct caa
AC Q22657 accacactggtatttcacac accacactggtatttcacac
AC Q22658 gtatggaagattataatatat gtatggaagattataatatat
AC Q22659 cacaatccttaagaactcttt cacaatccttaagaactcttt
AC Q22660 acctctgctgttctgatcct acctctgctgttctgatcct
AC Q22661 ctgctgcctctgtctcaggt ctgctgcctctgtctcaggt
AC Q22662 ggtatttgacacagc ggtatttgacacagc
AC Q23741 tacggcgggttttgg tacggcgggttttgg
AC Q23742 ggggctttttgccgg ggggctttttgccgg
AC Q25389 ggcggtactgccagactccat ggcggtactgccagactccat
AC Q25390 gcgtgcctcctcactggc gcgtgcctcctcactggc
AC Q25391 gagctcacattctcgaaggct gagctcacattctcgaaggct
AC Q25392 gatagcacctcgtcgcctcct gatagcacctcgtcgcctcct
AC Q30862 gaacgcagagaaaatcccaggcgccgcgagcgcctc
tcat
gaacgcagagaaaatcccaggcgccgcgagcgcctc
AC Q30863 tcccaggcgccgcgagcgcctctcat tcccaggcgccgcgagcgcctc
AC Q34626 gaacggcatctacgttat gaacggcatctacgttat
AC Q34629 gaagtgctgttgaactct gaagtgctgttgaactct
AC Q34632 gcagggcttctacgtctc gcagggcttctacgtctc
AC Q34639 caacagtccttcgacagcagca caacagtccttcgacagcagca
AC Q34653 cgctgaagggcttcttccttattgat cgctgaagggcttcttccttattgat
AC Q34655 cgctgaagggcttttgaactctgctt cgctgaagggcttttgaactctgctt
AC Q34657 cgctgaagggcttctgcgtctccatg cgctgaagggcttctgcgtctccatg
AC Q34659 cttatattccgtcatcgctc cttatattccg
AC Q34660 tccgtcatcgctcctcaggg tccg
AC Q34664 tgcccacaccgacggcgcccacc tgcccacaccgacggcgcccacc
AC Q34766 gtgtcggggtctccgggc gtgtcggggtctccgggc
AC Q34767 catgtcctccaccttgga catgtcctccaccttgga
AC Q35158; acccagaaagaaaatcccaag acccagaaagaaaatcccaag
AC Q35159; gtgccggggtcttcgggc gtgccggggtcttcggg
AC Q35160; gatcaggcgtgcctcaaa gatcaggcgtgcctcaaa
AC Q36601 gaaaaggatggtcatcac gaaaaggatgg
AC Q36602 ggcagggtcagagtggcg ggcagggtcagagtggcg
AC Q36603 ctatccccttttaatggt ctatccccttttaatggt
AC Q36911; cttcagctcagtcatgac cttcagctcagtcatgac
AC Q36912 cggaccggctcatgagc cggaccggctcatgagc
AC Q37636 aacgttgagggcat aacgttgagggcat
AC Q38442 ccggaggtccacaaagctgaacat ccggaggtccacaaagctga
AC Q40911 cacaaggccgccagctc cacaaggccgccagctc
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AC
AC
Q45731
Q45732
gccaaaccgggcagcatcgc
agcatcgcgaccctgcgcgg
gccaaaccgggcagcatcgc
AC Q45733 aaaccgggcagcatcgcgac aaaccgggca
AC Q45737 aaggtgatgatgatcactgtc aaggtgatgatgatcactgtc
AC Q47766 ggagaaggtggcgtcgcgcg ggagaaggtggcgtcgcgcg
AC Q47767 ccttcctcccgctgagcccc ccttcctcccgctgagcccc
AC Q47769 tcccagtcccacctcccatc tcccagtcccacctcccatc
AC Q47770 aagcggcaaaggcagcaccc aagcggcaaaggcagcaccc
AC Q47771 cggtcaaagccccccaccac cggtcaaagccccccaccac
AC Q47772; cacccgccttggcctcccac cacccgccttggcctcccac
AC Q47773 gggattcacaggcatgagcc gggattcacaggcatgagcc
AC Q47774; cgccaccacacccggctgat cgccaccacacccggctgat
AC Q47775; tctcgaacacctgacctcag tctcgaacacctgacctcag
AC Q47776 caaaaatactcagtggccag caaaaatactcagtggccag
AC Q47777 cacccgccttggcctcccag cacccgccttggcctcccag
AC Q48457 cgcccagtgggtcatcttccccagaagag cgcccagtgggtcatcttccccagaagag
AC Q48458 ggaatcctcctgcatccgg ggaatcctcctgcatccgg
AC Q49816 cccagcgtgcgccatccttccc cccagcgtgcgccatccttccc
AC Q51196 ggtataatcttccat ggtataatctt
AC Q51197 ctgcgggggcctcat ctgcgggggcc
AC Q51198 gactttgctatgcat gactttgctat
AC Q51199 ttttccccagtcaat ttttccccagtcaat
AC Q52701 acaaagttgatgccatc acaaagttgatgccatc
AC Q52702; ttgattccatgnacatt ttgattccatgnacatt
AC Q52703 ccaaatgcctgggcata ccaaatgcctgggcata
AC Q52708 gcatcattcatnccnccata gcatcattcatnccnccata
AC Q52709 ttcaaaggcaactgccatggg ttcaaaggcaactgccatggg
AC Q52710 ctacaatttaggaatcggtatggc ctacaatttaggaatcggtatggc
AC Q54785; atacccagggtgggtgac atacccagggtgggtgac
AC Q55043 gggtcgcctccatttcgg gggtcgcctccatttcgg
AC Q55044 gccaaatggaggcgaccc gccaaatggaggcgaccc
AC Q58460 ctctctgggtacagctctct ctctctgggtacagctctct
AC Q58461; tttccttgaggcccaaggcc tttccttgaggcccaaggcc
AC Q62602; ggtcctgctgggcat ggtcctgctgg
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A 25 .35 0. 82 24 .61 0. 94 23 .05 22 .52 -2 .79 -3 .44 A 24 .61 0. 94 56 1 -AA 6.. 90 0. 55 6. 89 0. 63 5. 01 5. 19 -3 .44 -3 .11 AA 6. 89 0. 63 -3.00
AAA 2 . 04 0. 33 2 .24 0. 41 1. 47 1. 57 -1. 72 -1. 44 AAA 2. 24 0. 41 -1.87
AAAA 0. 63 0. 19 0. 81 0. 25 0. 21 0. 24 -2 .20 -2 .02 AAAA 0. 81 0. 25 -2.36
AAAC 0. 39 0. 10 0. 43 0. 14 0. 18 0. 21 -2 .04 -1. 76 AAAC 0. 43 0. 14 -1.85
AAAG 0..57 0. 15 0. 57 0. 14 0. 32 0. 38 -1. 69 -1. 32 AAAG 0. 57 0. 14 -1.76
AAAT 0. 45 0. 13 0. 44 0. 14 0. 24 0. 27 -1. 66 -1. 37 AAAT 0. 44 0. 14 -1.49
AAC 1. 40 0. 21 1. 34 0. 22 0. 81 0. 83 -2 .82 -2 .70 AAC 1. 34 0. 22 -2.40
AACA 0. 47 0. 12 0. 44 0. 14 0. 21 0. 21 -2 .10 -2 .11 AACA 0. 44 0. 14 -1.69
AACC 0. 40 0. 11 0. 38 0. 12 0. 21 0. 24 -1. 70 -1. 40 AACC 0. 38 0. 12 -1.45
AACG 0.. 18 0. 08 0. 15 0. 07 0. 21 0. 24 0. 34 0. 75 AACG 0. 15 0. 07 0. 86
AACT 0. 35 0. 13 0. 37 0. 12 0. 24 0. 27 -0 .95 -0 .64 AACT 0. 37 0. 12 -1.13
AAG 2. 19 0. 28 2. 02 0. 30 1. 94 1. 98 -0 .89 -0 .74 AAG 2. 02 0. 30 520-
AAGA 0. 78 0. 18 0. 69 0. 17 0. 32 0. 34 -2 .58 -2 .48 AAGA 0. 69 0. 17 -2.07
AAGC 0. 47 0. 13 0. 47 0. 15 0. 41 0. 48 -0 .49 0. 04 AAGC 0. 47 0. 15 - o 4 o
AAGG 0. 55 0. 15 0. 56 0. 15 0. 65 0. 75 0. 63 1. 32 AAGG 0. 56 0. 15 260
AAGT 0. 37 0. 11 0. 30 0. 10 0. 15 0. 17 -1. 99 -1. 78 AAGT 0. 30 0. 10 -1.50
AAT 1. 28 0. 20 1. 28 0. 24 0. 78 0. 80 -2 .50 -2 .39 AAT 1. 28 0. 24 512-
AATA 0. 25 0. 09 0. 26 0. 09 0. 15 0. 17 -1. 16 -0 .90 AATA 0. 26 0. 09 621-
AATC 0. 26 0. 09 0. 22 0. 10 0. 29 0. 24 0. 37 -0 .23 AATC 0. 22 0. 10 0 8 o
AATG 0. 47 0. 12 0. 46 0. 13 0. 15 0. 17 -2 .63 -2 .43 AATG 0. 46 0. 13 -2.29
AATT 0. 30 0. 10 0. 34 0. 12 0. 06 0. 07 -2 .30 -2 .21 AATT 0. 34 0. 12 532-
AC 5. 61 0. 39 5. 38 0. 43 4. 67 4. 77 -2 .39 -2 .14 AC 5. 38 0. 43 761-
ACA 1. 74 0. 24 1. 63 0. 28 1. 05 1. 15 -2 .83 -2 .43 ACA 1. 63 0. 28 602-
ACAA 0. 47 0. 12 0. 40 0. 14 0. 27 0. 31 -1. 65 -1. 30 ACAA 0. 40 0. 14 -0.98
ACAC 0. 35 0. 11 0. 38 0. 15 0. 35 0. 41 0. 08 0. 59 AC AC 0. 38 0. 15 610-
ACAG 0. 54 0. 13 0. 51 0. 15 0. 29 0. 34 -1. 98 -1. 60 AC AG 0. 51 0. 15 -1.47
ACAT 0. 39 0. 11 0. 34 0. 14 0. 35 0. 24 -0 .31 -1. 32 ACAT 0. 34 0. 14 0. 09
ACC 1. 79 0. 23 1. 68 0. 24 1. 83 1. 92 0. 20 0. 59 ACC 1. 68 0. 24 0. 62
ACCA 0. 61 0. 16 0. 48 0. 15 0. 38 0. 31 -1. 40 -1. 87 ACCA 0. 48 0. 15 -0.62
ACCC 0. 44 0. 12 0. 48 0. 15 0. 35 0. 38 -0 .75 -0 .56 ACCC 0. 48 0. 15 480-
ACCG 0. 25 0. 09 0. 21 0. 09 0. 24 0. 27 -0 .11 0. 31 ACCG 0. 21 0. 09 130
ACCT 0. 49 0. 13 0. 53 0. 13 0. 38 0. 45 -0 .81 -0 .34 ACCT 0. 53 0. 13 701-
ACG 0. 78 0. 18 0. 69 0. 18 0. 83 0. 80 0. 29 0. 11 ACG 0. 69 0. 18 0. 81
ACGA 0. 20 0. 09 0. 18 0. 10 0. 06 0. 07 -1. 61 -1. 50 ACGA 0. 18 0. 10 -1.27
ACGC 0. 18 0. 08 0. 19 0. 09 0. 09 0. 10 -1. 12 -0 .95 ACGC 0. 19 0. 09 -1.07
ACGG 0. 23 0. 10 0. 20 0. 09 0. 24 0. 27 0. 05 0. 45 ACGG 0. 20 0. 09 0. 42
ACGT 0. 17 0. 07 0. 13 0. 08 0. 18 0. 21 0. 10 0. 49 ACGT 0. 13 0. 08 0. 64
ACT 1. 28 0. 20 1. 38 0. 21 0. 94 0. 90 -1. 72 -1. 96 ACT 1. 38 0. 21 -2 .02
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RNA Freq ±SD Freq ±SD as + ko as - ko 9 as+ko 9 as-ko__________ freq ± SD /target
ACTA 0. 21 0. 09 0. 18 0. 08 0. 09 0. 10 -1. 36 -1. 19 ACTA 0. 18 0. 08 211-
ACTC 0..29 0. 10 0. 32 0. 11 0. 32 0. 38 0. 33 0. 86 ACTC 0. 32 0. 11 -0.00
ACTG 0..45 0. 12 0. 47 0. 13 0. 35 0. 41 -0. 76 -0. 30 ACTG 0. 47 0. 13 -0.85
ACTT 0.. 34 0. 11 0. 40 0. 12 0. 27 0. 21 -0. 68 -1. 23 ACTT 0. 40 0. 12 -1.10
AG 7. 61 0. 42 7. 49 0. 43 8. 08 8. 40 1. 10 1. 85 AG 7. 49 0. 43 1.36
AGA 2. 37 0. 30 2. 17 0. 29 2. 30 2. 30 -0. 21 -0. 21 AGA 2. 17 0. 29 0.45
AGAA 0.. 84 0. 16 0. 72 0. 17 0. 41 0. 48 -2. 74 -2. 31 AGAA 0. 72 0. 17 -1.79
AGAC 0. 43 0. 12 0. 42 0. 13 0. 18 0. 17 -2. 16 -2. 20 AGAC 0. 42 0. 13 -1.94
AGAG 0. 59 0. 16 0. 58 0. 16 0. 38 0. 41 -1. 34 -1. 17 AGAG 0. 58 0. 16 -1.21
AGAT 0. 48 0. 11 0. 45 0. 13 0. 18 0. 21 -2. 66 -2. 41 AGAT 0. 45 0. 13 -2.03
AGC 2. 04 0. 21 2. 03 0. 28 2. 55 2. 69 2. 41 3. 03 AGC 2. 03 0. 28 1.88
AGCA 0. 63 0. 17 0. 55 0. 17 0. 38 0. 38 -1. 42 -1. 46 AGCA 0. 55 0. 17 -0.96
AGCC 0. 58 0. 14 0. 60 0. 15 0. 47 0. 41 -0. 78 -1. 22 AGCC 0. 60 0. 15 -0.84
AGCG 0. 27 0. 08 0. 28 0. 11 0. 32 0. 31 0. 70 0. 51 AGCG 0. 28 0. 11 0.36
AGCT 0. 56 0. 12 0. 61 0. 14 0. 74 0. 86 1. 43 2. 39 AGCT 0. 61 0. 14 0.93
AGG 1. 95 0. 23 2. 04 0. 27 2. 14 2. 27 0. 79 1. 36 AGG 2. 04 0. 27 0.34
AGGA 0. 79 0. 17 0. 70 0. 16 0. 47 0. 55 -1. 88 -1. 42 AGGA 0. 70 0. 16 -1.42
AGGC 0. 46 0. 13 0. 47 0. 13 0. 74 0. 75 2. 09 2. 21 AGGC 0. 47 0. 13 2.07
AGGG 0. 39 0. 12 0. 51 0. 16 0. 80 0. 86 3. 34 3. 83 AGGG 0. 51 0. 16 1.78
AGGT 0. 31 0. 10 0. 36 0. 12 0. 32 0. 34 0. 16 0. 34 AGGT 0. 36 0. 12 -0.30
AGT 1. 25 0. 20 1. 24 0. 20 1. 00 1. 06 -1. 28 -1. 00 AGT 1. 24 0. 20 -1.21
AGTA 0. 23 0. 08 0. 21 0. 09 0. 15 0. 17 -0. 93 -0. 64 AGTA 0. 21 0. 09 -0.67
AGTC 0. 28 0. 09 0. 27 0. 10 0. 29 0. 21 0. 20 -0. 76 AGTC 0. 27 0. 10 0.21
AGTG 0. 44 0. 14 0. 44 0. 14 0. 27 0. 31 -1. 25 -0. 95 AGTG 0. 44 0. 14 -1.28
AGTT 0. 31 0. 11 0. 31 0. 11 0. 27 0. 24 -0. 42 -0. 66 AGTT 0. 31 0. 11 -0.44
AT 5. 23 0. 36 4. 84 0. 43 5. 56 4. 41 0. 93 -2. 30 AT 4. 84 0. 43 1.67
ATA 0. 77 0. 16 0. 85 0. 19 1. 05 1. 18 1. 82 2. 64 ATA 0. 85 0. 19 1.10
ATAA 0. 22 0. 08 0. 25 0. 10 0. 15 0. 17 -0. 81 -0. 53 ATAA 0. 25 0. 10 -1.04
ATAC 0. 19 0. 08 0. 20 0. 08 0. 12 0. 14 -0. 87 -0. 62 ATAC 0. 20 0. 08 -0.96
ATAG 0. 12 0. 07 0. 15 0. 09 0. 29 0. 24 2. 49 1. 70 ATAG 0. 15 0. 09 1.70
ATAT 0. 24 0. 10 0. 25 0. 11 0. 27 0. 27 0. 22 0. 31 ATAT 0. 25 0. 11 0.10
ATC 1. 43 0. 19 1. 11 0. 18 0. 97 1. 12 -2. 38 -1. 61 ATC 1. 11 0. 18 -0.75
ATCA 0. 46 0. 14 0. 35 0. 11 0. 38 0. 31 -0. 57 -1. 12 ATCA 0. 35 0. 11 0.27
ATCC 0. 41 0. 10 0. 31 0. 11 0. 47 0. 55 0. 61 1. 41 ATCC 0. 31 0. 11 1.51
ATCG 0. 18 0. 08 0. 10 0. 06 0. 24 0. 10 0. 80 -0. 97 ATCG 0. 10 0. 06 2.25
ATCT 0. 38 0. 11 0. 35 0. 11 0. 56 0. 48 1. 69 0. 94 ATCT 0. 35 0. 11 1.94
ATG 1. 92 0. 24 1. 65 0. 25 3. 08 1. 60 4. 83 -1. 33 ATG 1. 65 0. 25 5.77
ATGA 0. 63 0. 13 0. 47 0. 15 0. 29 0. 21 -2. 59 -3. 29 ATGA 0. 47 0. 15 -1.20
ATGC 0. 39 0. 11 0. 35 0. 11 0. 35 0. 34 -0. 36 -0. 46 ATGC 0. 35 0. 11 0.07
ATGG 0. 54 0. 16 0. 44 0. 13 0. 68 0. 41 0. 88 -0. 82 ATGG 0. 44 0. 13 1.78
ATGT 0. 36 0. 12 0. 40 0. 13 0. 27 0. 31 -0. 79 -0. 43 ATGT 0. 40 0. 13 -1.06
ATT 1. 12 0. 19 1. 23 0. 23 0. 64 0. 64 -2. 50 -2. 49 ATT 1. 23 0. 23 -2.60
ATTA 0. 20 0. 09 0. 21 0. 10 0. 15 0. 17 -0. 60 -0. 32 ATTA 0. 21 0. 10 -0.61
ATTC 0. 29 0. 09 0. 25 0. 10 0. 27 0. 31 -0. 22 0. 25 ATTC 0. 25 0. 10 0.14
ATTG 0. 31 0. 10 0. 29 0. 10 0. 09 0. 07 -2. 23 -2. 42 ATTG 0. 29 0. 10 -1.96
ATTT 0. 31 0. 10 0. 47 0. 14 0. 27 0. 27 -0. 47 -0. 38 ATTT 0. 47 0. 14 -1.47
C 26. 35 0. 99 26. 70 0. 93 27. 74 28. 64 1. 41 2. 31 C 26. 70 0. 93 1.13
CA 7. 85 0. 46 7. 31 0. 54 6. 74 6. 75 -2. 44 -2. 42 CA 7. 31 0. 54 -1.06
CAA 1. 91 0. 22 1. 71 0. 25 1. 36 1. 44 -2. 48 -2. 13 CAA 1. 71 0. 25 -1.38
CAAA 0. 50 0. 13 0. 47 0. 14 0. 35 0. 41 -1. 08 -0. 64 CAAA 0. 47 0. 14 -0.85
CAAC 0. 47 0. 13 0. 40 0. 13 0. 12 0. 14 -2. 66 -2. 52 CAAC 0. 40 0. 13 -2.24
CAAG 0. 65 0. 13 0. 58 0. 14 0. 27 0. 24 -2. 96 -3. 15 CAAG 0. 58 0. 14 -2.23
CAAT 0. 29 0. 10 0. 26 0. 10 0. 24 0. 21 -0. 56 -0. 85 CAAT 0. 26 0. 10 -0.27
CAC 1. 64 0. 27 1. 67 0. 29 1. 33 1. 41 -1. 13 -0. 85 CAC 1. 67 0. 29 -1.16
CACA 0. 44 0. 13 0. 45 0. 16 0. 53 0. 55 0. 67 0. 81 CACA 0. 45 0. 16 0.48
CACC 0. 63 0. 17 0. 59 0. 15 0. 74 0. 75 0. 66 0. 76 CACC 0. 59 0. 15 0.97
CACG 0. 24 0. 10 0. 18 0. 09 0. 09 0. 10 -1. 52 -1. 37 CACG 0. 18 0. 09 -0.98
CACT 0. 33 0. 11 0. 45 0. 14 0. 21 0. 24 -1. 11 -0. 82 CACT 0. 45 0. 14 -1.83
CAG 2. 69 0. 26 2. 63 0. 29 2. 67 2. 85 -0. 10 0. 60 CAG 2. 63 0. 29 0.12
CAGA 0. 74 0. 17 0. 69 0. 16 0. 47 0. 55 -1. 59 -1. 14 CAGA 0. 69 0. 16 -1.31
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RNA Freq ±SD Freq ±SD as + ko as - ko 9 as+ko 9 as-ko__________ freq ± SD /target
CAGC o. ss o. 17 o. s4 o. 2o o. 74 o. 79 -0. s4 -0. 45 CAGC o. s4 o. 2o -0.52
CAGG o. 64 o. 14 o. 64 o. 14 o. 6s o. 75 o. 3o o. s2 CAGG o. 64 o. 14 0.30
CAGT o. 44 o. 13 o. 47 o. 13 o. 47 o. 45 o. 26 o. o7 CAGT o. 47 o. 13 0.02
CAT 1. 62 o. 23 1. 3o o. 25 1. 55 1. 25 -0. 2s -1. 6o CAT 1. 3o o. 25 1.03
CATA o. 15 o. os o. 1s o. os o. 21 o. 1o o. 72 -0. 5s CATA o. 1s o. os 0.34
CATC o. 6o o. 15 o. 42 o. 13 o. 94 o. 69 2. 2s o. 55 CATC o. 42 o. 13 4.15
CATG o. 53 o. 14 o. 39 o. 14 o. 91 o. 51 2. s5 -0. 1o CATG o. 39 o. 14 3.71
CATT o. 34 o. 11 o. 31 o. 11 o. 27 o. 24 -0. 71 -0. 95 CATT o. 31 o. 11 -0.40
CC 7. s7 o. 5s s. 61 o. 65 9. 65 9. 93 3. o7 3. 54 CC s. 61 o. 65 1.59
CCA 2. 49 o. 2s 2. 36 o. 2s 2. os 1. 95 -1. 47 -1. 94 CCA 2. 36 o. 2s -1.01
CCAA o. 55 o. 15 o. 51 o. 13 o. 35 o. 3s -1. 3o -1. 15 CCAA o. 51 o. 13 -1.23
CCAC o. 55 o. 15 o. 54 o. 17 o. s3 o. s2 1. s2 1. so CCAC o. 54 o. 17 1.74
CCAG o. 91 o. 17 o. 91 o. 17 o. so o. 93 -0. 65 o. 1o CCAG o. 91 o. 17 -0.6s
CCAT o. 49 o. 13 o. 4o o. 15 1. o9 o. 4s 4. 63 -0. o7 CCAT o. 4o o. 15 4.47
CCC 2. o6 o. 37 2. 71 o. 42 3. 2s 3. 42 3. 3o 3. 7o CCC 2. 71 o. 42 1.35
CCCA o. 61 o. 17 o. 73 o. 15 o. 91 1. o3 1. s5 2. 53 CCCA o. 73 o. 15 1.23
CCCC o. 59 o. 1s o. s6 o. 24 o. 65 o. 75 o. 33 o. 92 CCCC o. s6 o. 24 -0.91
CCCG o. 33 o. 11 o. 49 o. 14 o. 41 o. 4s o. 77 1. 41 CCCG o. 49 o. 14 -0.50
CCCT o. 54 o. 15 o. 64 o. 16 o. 29 o. 31 -1. 6s -1. 59 CCCT o. 64 o. 16 -2.13
CCG 1. 1s o. 2o 1. 26 o. 23 1. s9 1. 92 3. 56 3. 72 CCG 1. 26 o. 23 2.74
CCGA o. 27 o. 1o o. 26 o. 1o o. 1s o. 21 -0. 93 -0. 63 CCGA o. 26 o. 1o -0.s3
CCGC o. 39 o. 14 o. 43 o. 15 o. 41 o. 45 o. 14 o. 3s CCGC o. 43 o. 15 -0.10
CCGG o. 35 o. 1o o. 3s o. 13 o. 74 o. 75 3. 71 3. s6 CCGG o. 3s o. 13 2.s4
CCGT o. 17 o. os o. 19 o. o9 o. 15 o. o7 -0. 27 -1. 24 CCGT o. 19 o. o9 -0.46
CCT 2. 16 o. 24 2. 29 o. 29 2. 2s 2. 5o o. 4s 1. 37 CCT 2. 29 o. 29 -0.06
CCTA o. 24 o. o9 o. 27 o. 11 o. o6 o. o7 -2. o9 -1. 9s CCTA o. 27 o. 11 -2.01
CCTC o. 5s o. 13 o. 69 o. 1s 1. o6 1. o6 3. 56 3. 56 CCTC o. 69 o. 1s 2.04
CCTG o. 91 o. 17 o. s6 o. 1s o. 53 o. 55 -2. 29 -2. 1s CCTG o. s6 o. 1s -1.s4
CCTT o. 42 o. 11 o. 45 o. 15 o. 47 o. 51 o. 46 o. s3 CCTT o. 45 o. 15 0.12
CG 3. 63 o. 39 3. 62 o. 39 4. 69 4. s3 2. 73 3. os CG 3. 62 o. 39 2.79
CGA o. s2 o. 16 o. 76 o. 2o 1. os 1. o6 1. 64 1. 4s CGA o. 76 o. 2o 1.65
CGAA o. 15 o. os o. 15 o. o9 o. 15 o. 17 -0. oo o. 3o CGAA o. 15 o. o9 -0.04
CGAC o. 21 o. os o. 2o o. o9 o. 27 o. 24 o. 6s o. 37 CGAC o. 2o o. o9 0.74
CGAG o. 35 o. o9 o. 31 o. 12 o. 24 o. 21 -1. 16 -1. 4s CGAG o. 31 o. 12 -0.66
CGAT o. 11 o. o7 o. 1o o. o7 o. o9 o. 1o -0. 37 -0. 16 CGAT o. 1o o. o7 -0.23
CGC 1. o4 o. 23 1. 1o o. 25 1. 5s 1. 47 2. 37 1. s9 CGC 1. 1o o. 25 1.96
CGCA o. 22 o. os o. 21 o. os o. o9 o. 1o -1. 55 -1. 3s CGCA o. 21 o. os -1.49
CGCC o. 3s o. 13 o. 41 o. 15 o. 59 o. 65 1. 6o 2. o7 CGCC o. 41 o. 15 l.ls
CGCG o. 1s o. os o. 22 o. 1o o. 44 o. 34 3. 32 2. o4 CGCG o. 22 o. 1o 2.22
CGCT o. 25 o. o9 o. 25 o. 1o o. 27 o. 24 o. 1s -0. 1o CGCT o. 25 o. 1o 0.17
CGG 1. 13 o. 21 1. 17 o. 21 1. 39 1. 57 1. 25 2. 12 CGG 1. 17 o. 21 1.05
CGGA o. 25 o. o9 o. 24 o. 11 o. 21 o. 24 -0. 49 -0. 14 CGGA o. 24 o. 11 -0.34
CGGC o. 41 o. 13 o. 39 o. 13 o. 65 o. 55 1. s4 1. o6 CGGC o. 39 o. 13 1.99
CGGG o. 32 o. 11 o. 3s o. 11 o. s3 o. 96 4. 73 5. 9s CGGG o. 3s o. 11 4.15
CGGT o. 15 o. os o. 15 o. os o. 15 o. 17 -0. o2 o. 3o CGGT o. 15 o. os 0.03
CGT o. 63 o. 13 o. 59 o. 14 o. 53 o. 61 -0. s1 -0. 2o CGT o. 59 o. 14 -0.47
CGTA o. o6 o. o4 o. o7 o. o5 o. o6 o. o7 -0. 1o o. 13 CGTA o. o7 o. o5 -0.12
CGTC o. 17 o. o7 o. 17 o. o9 o. 5o o. 41 4. 42 3. 21 CGTC o. 17 o. o9 3.90
CGTG o. 29 o. 1o o. 26 o. 1o o. 1s o. 17 -1. 15 -1. 2o CGTG o. 26 o. 1o -o.so
CGTT o. 1o o. o6 o. 1o o. o6 o. 15 o. 17 o. 74 1. 13 CGTT o. 1o o. o6 0.s5
CT 7. o2 o. 45 7. 2o o. 46 6. 29 6. 75 -1. 6o -0. 6o CT 7. 2o o. 46 -1.9s
CTA o. 93 o. 17 o. s9 o. 17 o. 61 o. 5s -1. 92 -2. 13 CTA o. s9 o. 17 -1.61
CTAA o. 16 o. os o. 19 o. os o. o9 o. 1o -0. 94 -0. 76 CTAA o. 19 o. os -1.22
CTAC o. 39 o. 1o o. 32 o. 11 o. 27 o. 31 -1. 2o -0. 79 CTAC o. 32 o. 11 -0.50
CTAG o. 13 o. o7 o. 13 o. o7 o. o6 o. o7 -0. 94 -0. so CTAG o. 13 o. o7 -0.94
CTAT o. 26 o. o9 o. 25 o. 1o o. 24 o. 27 -0. 25 o. 1s CTAT o. 25 o. 1o -0.14
CTC 1. 71 o. 25 2. oo o. 31 1. s6 2. o2 o. 61 1. 24 CTC 2. oo o. 31 -0.45
CTCA o. 46 o. 12 o. 44 o. 13 o. so o. 65 2. 71 1. 53 CTCA o. 44 o. 13 2.72
CTCC o. 61 o. 14 o. 75 o. 1s o. ss o. 93 1. 95 2. 23 CTCC o. 75 o. 1s 0.76
CTCG o. 19 o. os o. 3o o. 11 o. 3s o. 45 2. 2s 3. o2 CTCG o. 3o o. 11 0.75
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CTCT 0..45 0. 15 0. 52 0. 15 0. 71 0. 72 1. 71 1. 8 O CTCT 0. 52 0. 15 1.25
CTG 2.. 87 0. 28 2. 69 0. 27 2. 44 2. 69 -1. 51 -0. 64 CTG 2. 69 0. 27 -0.89
CTGA 0. 57 0. 14 0. 54 0. 15 0. 68 0. 72 0. 78 1. 08 CTGA 0. 54 0. 15 0.96
CTGC 0. 84 0. 18 0. 81 0. 17 1. 03 0. 99 1. 08 0. 87 CTGC 0. 81 0. 17 1.31
CTGG 0.. 94 0. 18 0. 84 0. 17 0. 62 0. 69 -1. 74 -1. 39 CTGG 0. 84 0. 17 -1.28
CTGT 0. 51 0. 14 0. 50 0. 14 0. 47 0. 51 -0. 27 0. 04 CTGT 0. 50 0. 14 -0.20
CTT 1. 50 0. 21 1. 61 0. 25 1. 55 1. 73 0. 24 1. 05 CTT 1. 61 0. 25 -0.20
CTTA 0. 17 0. 08 0. 20 0. 10 0. 21 0. 24 0. 43 0. 86 CTTA 0. 20 0. 10 0.11
CTTC 0. 61 0. 16 0. 59 0. 16 0. 83 0. 79 1. 41 1. 17 CTTC 0. 59 0. 16 1.48
CTTG 0.. 34 0. 10 0. 42 0. 15 0. 50 0. 51 1. 59 1. 71 CTTG 0. 42 0. 15 0.53
CTTT 0. 40 0. 12 0. 40 0. 11 0. 44 0. 45 0. 39 0. 42 CTTT 0. 40 0. 11 0.36
G 26. 57 0. 90 26. 02 0. 90 29. 51 29. 15 3. 25 2. 85 G 26. 02 0. 90 3.87
GA 7. 54 0. 47 6. 95 0. 48 7. 92 7. 56 0. 81 0. 03 GA 6. 95 0. 48 2.04
GAA 2. 23 0. 23 2. 03 0. 28 1. 61 1. 60 -2. 73 -2. 77 GAA 2. 03 0. 28 -1.47
GAAA 0. 65 0. 16 0. 58 0. 17 0. 32 0. 38 -2. 06 -1. 73 GAAA 0. 58 0. 17 -1.56
GAAC 0. 41 0. 11 0. 36 0. 11 0. 38 0. 41 -0. 20 0. 05 GAAC 0. 36 0. 11 0.18
GAAG 0. 81 0. 19 0. 73 0. 18 0. 74 0. 86 -0. 40 0. 25 GAAG 0. 73 0. 18 0.05
GAAT 0. 36 0. 09 0. 35 0. 13 0. 09 0. 07 -2. 91 -3. 13 GAAT 0. 35 0. 13 -1.97
GAC 1. 59 0. 23 1. 47 0. 22 1. 92 1. 79 1. 42 0. 89 GAC 1. 47 0. 22 1.98
GACA 0. 48 0. 12 0. 41 0. 14 0. 27 0. 24 -1. 83 -2. 05 GACA 0. 41 0. 14 -1.01
GACC 0. 49 0. 13 0. 44 0. 13 0. 24 0. 21 -1. 99 -2. 23 GACC 0. 44 0. 13 -1.58
GACG 0. 25 0. 09 0. 27 0. 11 0. 06 0. 07 -2. 10 -1. 99 GACG 0. 27 0. 11 -1.84
GACT 0. 36 0. 10 0. 35 0. 11 0. 35 0. 31 -0. 04 -0. 48 GACT 0. 35 0. 11 0.06
GAG 2. 28 0. 29 2. 20 0. 28 2. 83 2. 82 1. 91 1. 85 GAG 2. 20 0. 28 2.23
GAGA 0. 67 0. 15 0. 59 0. 16 0. 27 0. 27 -2. 81 -2. 75 GAGA 0. 59 0. 16 -1.99
GAGC 0. 58 0. 14 0. 53 0. 14 0. 59 0. 58 0. 06 0. 00 GAGC 0. 53 0. 14 0.43
GAGG 0. 68 0. 15 0. 73 0. 18 0. 88 0. 93 1. 35 1. 63 GAGG 0. 73 0. 18 0.86
GAGT 0. 35 0. 11 0. 35 0. 11 0. 21 0. 21 -1. 30 -1. 31 GAGT 0. 35 0. 11 -1.28
GAT 1. 43 0. 20 1. 23 0. 20 1. 64 1. 41 1. 02 -0. 12 GAT 1. 23 0. 20 2.02
GATA 0. 21 0. 08 0. 20 0. 08 0. 09 0. 10 -1. 54 -1. 36 GATA 0. 20 0. 08 -1.33
GATC 0. 36 0. 11 0. 33 0. 13 0. 41 0. 48 0. 49 1. 12 GATC 0. 33 0. 13 0.66
GATG 0. 60 0. 14 0. 48 0. 15 0. 35 0. 41 -1. 73 -1. 33 GATG 0. 48 0. 15 -0.82
GATT 0. 26 0. 11 0. 23 0. 09 0. 12 0. 14 -1. 32 -1. 15 GATT 0. 23 0. 09 -1.26
GC 7. 11 0. 44 6. 97 0. 43 8. 60 8. 22 3. 41 2. 53 GC 6. 97 0. 43 3.76
GCA 1. 90 0. 24 1. 77 0. 28 1. 94 1. 92 0. 19 0. 09 GCA 1. 77 0. 28 0.64
GCAA 0. 45 0. 12 0. 37 0. 11 0. 12 0. 14 -2. 69 -2. 54 GCAA 0. 37 0. 11 -2.33
GCAC 0. 36 0. 11 0. 40 0. 12 0. 18 0. 17 -1. 71 -1. 76 GCAC 0. 40 0. 12 -1.82
GCAG 0. 75 0. 15 0. 72 0. 19 0. 65 0. 65 -0. 64 -0. 63 GCAG 0. 72 0. 19 -0.39
GCAT 0. 34 0. 11 0. 27 0. 10 0. 80 0. 41 3. 99 0. 63 GCAT 0. 27 0. 10 5.29
GCC 2. 21 0. 26 2. 30 0. 28 3. 47 3. 10 4. 77 3. 38 GCC 2. 30 0. 28 4.14
GCCA 0. 68 0. 13 0. 62 0. 16 0. 91 0. 65 1. 79 -0. 18 GCCA 0. 62 0. 16 1.80
GCCC 0. 62 0. 16 0. 83 0. 21 0. 65 0. 69 0. 19 0. 41 GCCC 0. 83 0. 21 -0.85
GCCG 0. 37 0. 12 0. 35 0. 13 0. 41 0. 45 0. 31 0. 58 GCCG 0. 35 0. 13 0.48
GCCT 0. 55 0. 13 0. 49 0. 14 0. 62 0. 65 0. 50 0. 73 GCCT 0. 49 0. 14 0.96
GCG 1. 01 0. 20 1. 05 0. 20 1. 33 1. 28 1. 66 1. 39 GCG 1. 05 0. 20 1.37
GCGA 0. 19 0. 09 0. 17 0. 08 0. 32 0. 24 1. 49 0. 52 GCGA 0. 17 0. 08 1.88
GCGC 0. 30 0. 11 0. 32 0. 12 0. 38 0. 34 0. 75 0. 39 GCGC 0. 32 0. 12 0.55
GCGG 0. 36 0. 13 0. 40 0. 14 0. 53 0. 45 1. 30 0. 65 GCGG 0. 40 0. 14 0.98
GCGT 0. 15 0. 07 0. 17 0. 08 0. 29 0. 34 2. 07 2. 75 GCGT 0. 17 0. 08 1.66
GCT 2. 00 0. 23 1. 87 0. 28 1. 97 2. 02 -0. 12 0. 07 GCT 1. 87 0. 28 0.37
GCTA 0. 25 0. 09 0. 21 0. 08 0. 18 0. 21 -0. 80 -0. 48 GCTA 0. 21 0. 08 -0.47
GCTC 0. 46 0. 13 0. 49 0. 15 0. 71 0. 65 1. 87 1. 45 GCTC 0. 49 0. 15 1.44
GCTG 0. 93 0. 19 0. 81 0. 18 1. 15 1. 27 1. 14 1. 77 GCTG 0. 81 0. 18 1.90
GCTT 0. 35 0. 10 0. 35 0. 12 0. 56 0. 62 2. 19 2. 77 GCTT 0. 35 0. 12 1.72
GG 7. 34 0. 55 7. 35 0. 62 8. 70 9. 00 2. 48 3. 01 GG 7. 35 0. 62 2.19
GGA 2. 36 0. 26 2. 19 0. 27 2. 61 2. 72 0. 95 1. 36 GGA 2. 19 0. 27 1.53
GGAA 0. 59 0. 12 0. 57 0. 15 0. 29 0. 34 -2. 45 -2. 06 GGAA 0. 57 0. 15 -1.80
GGAC 0. 51 0. 13 0. 51 0. 17 0. 15 0. 14 -2. 72 -2. 80 GGAC 0. 51 0. 17 -2.17
GGAG 0. 86 0. 18 0. 81 0. 17 0. 53 0. 62 -1. 80 -1. 33 GGAG 0. 81 0. 17 -1.62
GGAT 0. 39 0. 11 0. 31 0. 11 0. 21 0. 24 -1. 65 -1. 35 GGAT 0. 31 0. 11 -0.89
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GGC 2.. 06 0. 29 2. 00 0. 28 2. 58 2. 53 1. 80 1. 61 GGC 2. 00 0. 28 2.11
GGCA 0. 52 0. 11 0. 51 0. 13 0. 86 0. 62 2. 89 0. 81 GGCA 0. 51 0. 13 2.56
GGCC 0. 66 0. 16 0. 71 0. 18 0. 74 0. 69 0. 50 0. 17 GGCC 0. 71 0. 18 0.18
GGCG 0. 33 0. 12 0. 34 0. 14 0. 62 0. 65 2. 51 2. 79 GGCG 0. 34 0. 14 1.99
GGCT 0. 55 0. 14 0. 45 0. 12 1. 03 1. 06 3. 40 3. 61 GGCT 0. 45 0. 12 4.77
GGG 1.. 73 0. 29 1. 92 0. 37 2. 30 2. 53 1. 94 2. 70 GGG 1. 92 0. 37 1.03
GGGA 0..49 0. 13 0. 56 0. 15 0. 38 0. 41 -0. 81 -0. 60 GGGA 0. 56 0. 15 -1.17
GGGC 0. 55 0. 14 0. 60 0. 16 1. 27 1. 13 5. 02 4. 06 GGGC 0. 60 0. 16 4.22
GGGG 0. 45 0. 16 0. 53 0. 19 0. 91 0. 89 2. 84 2. 69 GGGG 0. 53 0. 19 2.02
GGGT 0. 24 0. 10 0. 23 0. 10 0. 80 0. 93 5. 44 6. 71 GGGT 0. 23 0. 10 5.64
GGT 1. 17 0. 18 1. 23 0. 26 1. 33 1. 38 0. 88 1. 12 GGT 1. 23 0. 26 0.40
GGTA 0. 14 0. 07 0. 16 0. 10 0. 29 0. 34 2. 18 2. 87 GGTA 0. 16 0. 10 1.39
GGTC 0. 27 0. 08 0. 32 0. 12 0. 71 0. 75 5. 40 5. 98 GGTC 0. 32 0. 12 3.28
GGTG 0. 54 0. 14 0. 47 0. 17 0. 59 0. 58 0. 34 0. 29 GGTG 0. 47 0. 17 0.68
GGTT 0. 20 0. 08 0. 27 0. 11 0. 21 0. 21 0. 02 0. 00 GGTT 0. 27 0. 11 -0.62
GT 4. 56 0. 35 4. 76 0. 45 4. 17 4. 26 -1. 14 -0. 88 GT 4. 76 0. 45 -1.31
GTA 0. 64 0. 14 0. 76 0. 20 0. 64 0. 74 -0. 01 0. 66 GTA 0. 76 0. 20 -0.63
GTAA 0. 14 0. 07 0. 17 0. 09 0. 15 0. 17 0. 12 0. 48 GTAA 0. 17 0. 09 -0.27
GTAC 0. 21 0. 08 0. 19 0. 09 0. 18 0. 21 -0. 36 -0. 02 GTAC 0. 19 0. 09 -0.15
GTAG 0. 11 0. 07 0. 21 0. 09 0. 15 0. 17 0. 56 0. 93 GTAG 0. 21 0. 09 -0.66
GTAT 0.. 18 0. 08 0. 19 0. 09 0. 21 0. 24 0. 31 0. 71 GTAT 0. 19 0. 09 0.15
GTC 1.. 08 0. 19 1. 13 0. 19 1. 03 0. 86 -0. 30 -1. 18 GTC 1. 13 0. 19 -0.55
GTCA 0. 34 0. 10 0. 36 0. 11 0. 44 0. 27 0. 99 -0. 62 GTCA 0. 36 0. 11 0.78
GTCC 0. 34 0. 10 0. 37 0. 13 0. 68 0. 65 3. 34 3. 07 GTCC 0. 37 0. 13 2.39
GTCG 0. 12 0. 06 0. 09 0. 06 0. 29 0. 31 2. 68 2. 89 GTCG 0. 09 0. 06 3.57
GTCT 0. 29 0. 09 0. 31 0. 11 0. 56 0. 62 2. 92 3. 53 GTCT 0. 31 0. 11 2.40
GTG 1. 87 0. 26 1. 76 0. 34 1. 64 1. 70 -0. 90 -0. 67 GTG 1. 76 0. 34 -0.35
GTGA 0. 43 0. 11 0. 43 0. 13 0. 38 0. 41 -0. 40 -0. 15 GTGA 0. 43 0. 13 -0.36
GTGC 0. 43 0. 12 0. 40 0. 14 0. 29 0. 34 -1. 14 -0. 74 GTGC 0. 40 0. 14 -0.73
GTGG 0. 66 0. 15 0. 55 0. 16 0. 50 0. 51 -1. 00 -0. 92 GTGG 0. 55 0. 16 -0.33
GTGT 0. 36 0. 12 0. 37 0. 17 0. 18 0. 17 -1. 54 -1. 59 GTGT 0. 37 0. 17 -1.10
GTT 0. 96 0. 18 1. 09 0. 20 0. 81 0. 90 -0. 84 -0. 34 GTT 1. 09 0. 20 -1.43
GTTA 0. 14 0. 06 0. 19 0. 10 0. 09 0. 07 -0. 92 -1. 25 GTTA 0. 19 0. 10 -1.03
GTTC 0. 29 0. 11 0. 27 0. 11 0. 18 0. 17 -1. 09 -1. 14 GTTC 0. 27 0. 11 -0.86
GTTG 0. 26 0. 10 0. 31 0. 12 0. 29 0. 31 0. 39 0. 53 GTTG 0. 31 0. 12 -0.09
GTTT 0. 28 0. 09 0. 33 0. 11 0. 29 0. 34 0. 21 0. 71 GTTT 0. 33 0. 11 -0.32
T 21. 72 0. 79 22. 66 0. 95 19. 70 19. 70 -2. 56 -2. 56 T 22. 66 0. 95 -3.12
TA 3. 10 0. 29 3. 42 0. 33 2. 75 3. 00 -1. 19 -0. 34 TA 3. 42 0. 33 -2.05
TAA 0. 72 0. 14 0. 88 0. 17 0. 61 0. 67 -0. 76 -0. 34 TAA 0. 88 0. 17 -1.58
TAAA 0. 25 0. 09 0. 36 0. 13 0. 09 0. 10 -1. 85 -1. 68 TAAA 0. 36 0. 13 -2.08
TAAC 0. 14 0. 08 0. 14 0. 07 0. 09 0. 10 -0. 66 -0. 48 TAAC 0. 14 0. 07 -0.71
TAAG 0. 17 0. 07 0. 15 0. 09 0. 18 0. 21 0. 15 0. 57 TAAG 0. 15 0. 09 0.33
TAAT 0. 17 0. 08 0. 22 0. 10 0. 12 0. 14 -0. 58 -0. 35 TAAT 0. 22 0. 10 -1.04
TAC 1. 00 0. 17 0. 90 0. 19 0. 67 0. 77 -1. 89 -1. 31 TAC 0. 90 0. 19 -1.27
TACA 0. 36 0. 12 0. 33 0. 10 0. 15 0. 17 -1. 78 -1. 58 TACA 0. 33 0. 10 -1.79
TACC 0. 27 0. 10 0. 27 0. 11 0. 15 0. 17 -1. 31 -1. 06 TACC 0. 27 0. 11 -1.18
TACG 0. 12 0. 06 0. 10 0. 06 0. 21 0. 24 1. 47 2. 02 TACG 0. 10 0. 06 1.74
TACT 0. 24 0. 10 0. 20 0. 10 0. 18 0. 21 -0. 66 -0. 36 TACT 0. 20 0. 10 -0.27
TAG 0. 46 0. 13 0. 61 0. 16 0. 64 0. 74 1. 41 2. 17 TAG 0. 61 0. 16 0.16
TAGA 0. 17 0. 08 0. 21 0. 10 0. 06 0. 07 -1. 44 -1. 32 TAGA 0. 21 0. 10 -1.50
TAGC 0. 11 0. 06 0. 18 0. 08 0. 27 0. 24 2. 46 2. 06 TAGC 0. 18 0. 08 1.13
TAGG 0. 08 0. 05 0. 11 0. 07 0. 18 0. 21 1. 95 2. 54 TAGG 0. 11 0. 07 0.98
TAGT 0. 10 0. 06 0. 12 0. 07 0. 15 0. 10 0. 90 0. 13 TAGT 0. 12 0. 07 0.36
TAT 0. 92 0. 16 1. 03 0. 19 0. 83 0. 83 -0. 56 -0. 57 TAT 1. 03 0. 19 -1.03
TATA 0. 16 0. 08 0. 20 0. 12 0. 41 0. 48 3. 22 4. 07 TATA 0. 20 0. 12 1.75
TATC 0. 21 0. 08 0. 15 0. 08 0. 03 0. 03 -2. 26 -2. 20 TATC 0. 15 0. 08 -1.51
TATG 0. 33 0. 11 0. 32 0. 09 0. 18 0. 17 -1. 43 -1. 48 TATG 0. 32 0. 09 -1.65
TATT 0. 22 0. 08 0. 36 0. 13 0. 38 0. 41 1. 93 2. 26 TATT 0. 36 0. 13 0.16
TC 5. 74 0. 44 5. 75 0. 47 5. 32 5. 64 -0. 94 -0. 22 TC 5. 75 0. 47 -0.90
TCA 1. 72 0. 23 1. 54 0. 23 1. 86 1. 89 0. 61 0. 73 TCA 1. 54 0. 23 1.40
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Appendix
Seq CDS mRNA Target mRNA Freq as SD as /targ mRNA /as 9 as+k 
RNA Freq ±SD Freq ±SD as + ko as - ko 9 as+ko 9 as-ko__________ freq ± SD /target
TCAA 0. 44 0. 12 0. 42 0. 14 0. 21 0. 17 -1. 90 -2. 91 TCAA 0. 42 0. 14 -1.51
TCAC 0.. 37 0. 12 0. 36 0. 12 0. 24 0. 24 -1. 15 -1. 11 TCAC 0. 36 0. 12 -1.02
TCAG 0..51 0. 12 0. 48 0. 14 0. 68 0. 75 1. 42 2. 06 TCAG 0. 48 0. 14 1.45
TCAT 0. 40 0. 11 0. 28 0. 12 0. 88 0. 48 4. 28 0. 73 TCAT 0. 28 0. 12 4.93
TCC 1.. 80 0. 23 1. 94 0. 29 1. 22 1. 38 -2. 55 -1. 87 TCC 1. 94 0. 29 -2.48
TCCA 0.. 60 0. 12 0. 53 0. 16 0. 83 0. 75 1. 81 1. 23 TCCA 0. 53 0. 16 1.79
TCCC 0. 41 0. 12 0. 55 0. 15 0. 68 0. 75 2. 25 2. 87 TCCC 0. 55 0. 15 0.83
TCCG 0. 23 0. 09 0. 22 0. 10 0. 35 0. 41 1. 39 2. 04 TCCG 0. 22 0. 10 1.38
TCCT 0. 57 0. 14 0. 64 0. 17 0. 88 0. 93 2. 14 2. 42 TCCT 0. 64 0. 17 1.45
TCG 0. 67 0. 15 0. 61 0. 15 0. 78 0. 77 0. 74 0. 67 TCG 0. 61 0. 15 1.13
TCGA 0. 16 0. 07 0. 14 0. 08 0. 24 0. 27 1. 03 1. 56 TCGA 0. 14 0. 08 1.26
TCGC 0. 17 0. 08 0. 16 0. 09 0. 32 0. 24 2. 01 0. 91 TCGC 0. 16 0. 09 1.92
TCGG 0.. 19 0. 07 0. 20 0. 10 0. 32 0. 38 1. 86 2. 61 TCGG 0. 20 0. 10 1.32
TCGT 0. 14 0. 07 0. 11 0. 07 0. 27 0. 24 1. 81 1. 43 TCGT 0. 11 0. 07 2.27
TCT 1. 55 0. 23 1. 67 0. 26 1. 11 1. 22 -1. 92 -1. 46 TCT 1. 67 0. 26 -2.17
TCTA 0. 23 0. 09 0. 22 0. 10 0. 29 0. 34 0. 70 1. 25 TCTA 0. 22 0. 10 0.72
TCTC 0. 37 0. 13 0. 49 0. 15 0. 68 0. 65 2. 38 2. 17 TCTC 0. 49 0. 15 1.32
TCTG 0. 55 0. 13 0. 55 0. 14 0. 65 0. 65 0. 77 0. 78 TCTG 0. 55 0. 14 0.71
TCTT 0. 39 0. 12 0. 42 0. 15 0. 62 0. 62 1. 90 1. 88 TCTT 0. 42 0. 15 1.39
TG 7. 98 0. 40 7. 60 0. 54 7. 89 6. 96 -0. 23 -2. 55 TG 7. 60 0. 54 0.55
TGA 1. 99 0. 24 1. 82 0. 24 1. 97 1. 60 -0. 09 -1. 63 TGA 1. 82 0. 24 0.63
TGAA 0. 65 0. 14 0. 59 0. 16 0. 50 0. 51 -1. 06 -0. 97 TGAA 0. 59 0. 16 -0.59
TGAC 0. 43 0. 12 0. 36 0. 11 0. 38 0. 24 -0. 35 -1. 52 TGAC 0. 36 0. 11 0.25
TGAG 0. 48 0. 13 0. 49 0. 13 0. 62 0. 69 1. 07 1. 57 TGAG 0. 49 0. 13 1.05
TGAT 0. 44 0. 11 0. 38 0. 12 0. 41 0. 48 -0. 28 0. 31 TGAT 0. 38 0. 12 0.32
TGC 1. 96 0. 25 1. 85 0. 27 1. 67 1. 34 -1. 21 -2. 53 TGC 1. 85 0. 27 -0.68
TGCA 0. 53 0. 13 0. 50 0. 16 0. 29 0. 17 -1. 79 -2. 72 TGCA 0. 50 0. 16 -1.27
TGCC 0. 59 0. 12 0. 59 0. 16 0. 71 0. 69 0. 97 0. 79 TGCC 0. 59 0. 16 0.76
TGCG 0. 23 0. 10 0. 21 0. 09 0. 27 0. 24 0. 40 0. 14 TGCG 0. 21 0. 09 0.66
TGCT 0. 63 0. 14 0. 56 0. 18 0. 68 0. 72 0. 36 0. 65 TGCT 0. 56 0. 18 0.68
TGG 2. 52 0. 27 2. 22 0. 30 2. 97 2. 69 1. 66 0. 61 TGG 2. 22 0. 30 2.51
TGGA 0. 83 0. 16 0. 69 0. 15 0. 18 0. 21 -4. 18 -3. 99 TGGA 0. 69 0. 15 -3.28
TGGC 0. 64 0. 15 0. 56 0. 15 0. 80 0. 62 1. 10 -0. 13 TGGC 0. 56 0. 15 1.57
TGGG 0. 57 0. 14 0. 50 0. 14 0. 74 0. 72 1. 13 1. 01 TGGG 0. 50 0. 14 1.73
TGGT 0. 48 0. 13 0. 49 0. 17 0. 44 0. 34 -0. 26 -1. 03 TGGT 0. 49 0. 17 -0.29
TGT 1. 50 0. 21 1. 70 0. 30 1. 22 1. 25 -1. 33 -1. 21 TGT 1. 70 0. 30 -1.59
TGTA 0. 20 0. 08 0. 33 0. 12 0. 18 0. 21 -0. 34 0. 02 TGTA 0. 33 0. 12 -1.25
TGTC 0. 37 0. 11 0. 38 0. 12 0. 44 0. 45 0. 68 0. 70 TGTC 0. 38 0. 12 0.55
TGTG 0. 59 0. 13 0. 58 0. 20 0. 24 0. 27 -2. 68 -2. 39 TGTG 0. 58 0. 20 -1.72
TGTT 0. 34 0. 11 0. 41 0. 13 0. 21 0. 24 -1. 20 -0. 89 TGTT 0. 41 0. 13 -1.55
TT 4. 91 0. 49 5. 87 0. 61 3. 96 4. 38 -1. 94 -1. 08 TT 5. 87 0. 61 -3.10
TTA 0. 76 0. 14 0. 93 0. 18 0. 47 0. 54 -2. 05 -1. 55 TTA 0. 93 0. 18 -2.59
TTAA 0. 20 0. 08 0. 28 0. 11 0. 12 0. 14 -1. 12 -0. 87 TTAA 0. 28 0. 11 -1.42
TTAC 0. 21 0. 09 0. 19 0. 09 0. 03 0. 03 -2. 08 -2. 02 TTAC 0. 19 0. 09 -1.88
TTAG 0. 11 0. 06 0. 13 0. 07 0. 12 0. 10 0. 20 -0. 06 TTAG 0. 13 0. 07 -0.15
TTAT 0. 25 0. 09 0. 33 0. 12 0. 35 0. 41 1. 17 1. 81 TTAT 0. 33 0. 12 0.21
TTC 1. 50 0. 24 1. 51 0. 23 1. 50 1. 66 -0. 02 0. 68 TTC 1. 51 0. 23 -0.04
TTCA 0. 46 0. 14 0. 38 0. 13 0. 44 0. 45 -0. 10 -0. 08 TTCA 0. 38 0. 13 0.50
TTCC 0. 44 0. 14 0. 50 0. 16 0. 59 0. 62 1. 10 1. 30 TTCC 0. 50 0. 16 0.56
TTCG 0. 17 0. 08 0. 13 0. 07 0. 24 0. 27 0. 85 1. 35 TTCG 0. 13 0. 07 1.46
TTCT 0. 43 0. 13 0. 49 0. 14 0. 38 0. 38 -0. 39 -0. 44 TTCT 0. 49 0. 14 -0.81
TTG 1. 32 0. 22 1. 51 0. 24 0. 97 1. 02 -1. 63 -1. 39 TTG 1. 51 0. 24 -2.29
TTGA 0. 36 0. 11 0. 39 0. 11 0. 56 0. 62 1. 81 2. 32 TTGA 0. 39 0. 11 1.53
TTGC 0. 30 0. 09 0. 30 0. 11 0. 29 0. 27 -0. 02 -0. 24 TTGC 0. 30 0. 11 -0.09
TTGG 0. 39 0. 11 0. 39 0. 12 0. 35 0. 41 -0. 37 0. 17 TTGG 0. 39 0. 12 -0.27
TTGT 0. 28 0. 11 0. 44 0. 14 0. 18 0. 21 -0. 96 -0. 69 TTGT 0. 44 0. 14 -1.85
TTT 1. 34 0. 28 1. 92 0. 41 0. 97 1. 12 -1. 31 -0. 78 TTT 1. 92 0. 41 -2.33
TTTA 0. 25 0. 08 0. 34 0. 12 0. 21 0. 24 -0. 58 -0. 18 TTTA 0. 34 0. 12 -1.06
TTTC 0. 32 0. 10 0. 39 0. 12 0. 35 0. 34 0. 31 0. 20 TTTC 0. 39 0. 12 -0.34
TTTG 0. 42 0. 12 0. 48 0. 14 0. 47 0. 55 0. 44 1. 08 TTTG 0. 48 0. 14 -0.07
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Antisense BCR-ABL oligonucleotides in CML.
Seq CDS mRNA Target mRNA Freq as SD as /targ mRNA /as 9 as+ko
RNA Freq ±SD Freq ±SD as + ko as - ko 9 as+ko 9 as-ko__________ freq ± SD /target
TTTT 0.35 0.15 0.v2 0.30 0.41 0.45 0.42 0.65 TTTT 0.v2 0.30 -1.02
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